AHNS 2013 Annual Meeting - American Head and Neck Society

Table of Contents6 General Information7 JW Marriott Grande LakesOrlando Floorplan9 About The American Head &Neck Society10 Audience Response Instructions12 AHNS President13 2013 Program Chair14 2013 Poster Chair15 Hayes Martin Lecture17 John J. Conley Lecture19 Jatin P. Shah Symposium20 Guest of Honor21 Distinguished Service Award22 Presidential Citations25 Best Paper Awards26 AHNS Leadership30 Past-Presidents31 Robert Maxwell Byers Biography32 Alando J. Ballantyne ResidentResearch Pilot Grant33 AHNS Education and ResearchFoundation35 AHNS Accreditation36 Commercial Bias Reporting Form37 Scientific Program47 Faculty Listing48 Faculty & Presenter Disclosures49 Oral Papers67 Poster Papers80 AHNS Certificate ofIncorporation82 AHNS Constitution & BylawsThe programs and lectures presented at the AHNS 2013 Annual Meeting arecopyrighted products of the American Head & Neck Society.Any reproduction or broadcasting without the express consentof the AHNS is strictly prohibited.AHNS 2013 ANNUAL MEETINGCORPORATE SUPPORTERSThanks to our Corporate Supporters!The American Head & Neck Society gratefully acknowledges generousunrestricted educational grants in support of the AHNS 2013 Annual Meetingby the following companies:Platinum LevelCelSci CorporationOmni Guide, Inc.PfizerGOLD LevelDePuy Synthes CMFStrykerSilver LevelMedtronic Surgical TechnologiesBronze LevelCook Medical IncorporatedKarl Storz Endoscopy-America Inc.PENTAX MedicalAdditional SupportOlympus Corporation of the AmericasApril 10 - 11, 2013 · www.ahns.info 5

General InformationThe American Head and Neck Society’s 2013Annual MeetingApril 10 - 11, 2013JW Marriott Grande Lakes4040 Central Florida Parkway, Orlando, FL 32837COSM Registration Hours Mediterranean Foyer, Lobby LevelWednesday, April 10Thursday, April 11Friday, April 12Saturday, April 13Sunday, April 14COSM Exhibit Hall HoursThursday, April 11Friday, April 12Saturday, April 136:30 AM - 5:00 PM7:00 AM - 5:00 PM7:00 AM - 5:00 PM7:00 AM - 3:00 PM7:00 AM - 10:00 AMCoquina Ballroom, Lobby Level9:00 AM - 4:00 PM9:00 AM - 4:00 PM9:00 AM - 4:00 PMCOSM Speaker Ready Room HoursTuesday, April 9Wednesday, April 10Thursday, April 11Friday, April 12Saturday, April 13Sunday, April 14COSM Spouse Lounge HoursWednesday, April 10Thursday, April 11Friday, April 12Saturday, April 13Sunday, April 14COSM Shuttle Buses4:00 PM - 8:00 PM6:00 AM - 6:00 PM6:00 AM - 6:00 PM6:00 AM - 6:00 PM7:00 AM - 6:00 PM7:00 AM - 10:00 AM8:00 AM - 2:00 PM8:00 AM - 2:00 PM8:00 AM - 2:00 PM8:00 AM - 2:00 PM8:00 AM - 12:00 PMCordova 4, Lower LevelSegura 5, Lower LevelShuttle buses between the JW Marriott Grande Lakes and theRenaissance SeaWorld Resort will be provided on an hourly anddaily basis. The shuttles will pick up and drop off attendees at theMediterranean Ballroom Entrance.Wednesday, April 10 6:30 AM - 10:00 PMThursday, April 11 6:30 AM - 10:00 PMFriday, April 12 6:30 AM - 10:00 PMSaturday, April 13 6:30 AM - 11:00 PMSunday, April 14 6:30 AM - 1:00 PMOfficial LanguageThe official language of the conference is English. Simultaneoustranslation will not be offered.6 AHNS 2013 Annual Meeting

JW Marriott Grande Lakes FloorplanSAVE THE DATE!AHNS FUTURE MEETING SCHEDULE5 th World Congress of the International Federation of Head & NeckOncologic Societies (IFHNOS) combined with 2014 AHNS Annual MeetingJuly 26 - 30, 2014 • New York Marriott Marquis • New York, New YorkAHNS 2015 Research WorkshopFall 2015 • Location TBDAHNS 2015 Annual MeetingDuring the Combined Otolaryngology Society MeetingsApril 22 - 26, 2015 • Sheraton Boston • Boston, MassachusettsAHNS 9 th International Conference on Head and Neck CancerJuly 16 - 20, 2016 • Washington State Convention Center • Seattle, WashingtonAHNS 2017 Annual MeetingDuring the Combined Otolaryngology Society MeetingsApril 26 - 30, 2017 • Manchester Grand Hyatt • San Diego, CaliforniaApril 10 - 11, 2013 · www.ahns.info 7

General InformationAHNS 2013 Annual Meeting Educational ObjectivesThe conference is designed to facilitate discussion regarding theapproaches used in the diagnosis, treatment, and rehabilitation ofhead and neck neoplasms throughout the world. Participants shouldaccomplish the following at the conclusion of this event:• Understand the clinical uses of new novel molecular agents in themanagement of head and neck cancer;• Understand the role of surgery, radiation therapy, chemoradiation,and combined modality therapy in the treatment of head and neckcancer as defined by results from randomized control trials;• Understand the appropriate use of transoral approaches to removetumors of the oropharynx;• Understand the impact of treatment on functional outcome of headand neck cancer patients;• Understand novel approaches to head and neck reconstruction.AHNS 2013 CME Credit Claim ProcessPlease use the worksheet on page 34 to track the number of CME hoursyou attend for each activity. After the meeting, an email will be sent toattendees with a link to the on-line survey and claim form.To Receive Your CME Credit:AHNS has instituted a process for claiming CME credits and printingcertificates. All attendees wishing to receive a CME certificate foractivities attended at the AHNS 2013 Annual Meeting must first completean on-line meeting evaluation form. Attendees will have access to theon-line form via link on the AHNS website after the meeting.Please allow 4-6 weeks for processing before your certificate arrives.Attendance CertificatesAttendees in need of an attendance certificate instead of a certificate withyour CME hours may ask for one at the AHNS Desk.AHNS Foundation/Centurion Club Lounge Amarante 1Wednesday, April 10 9:00 AM - 5:00 PMThursday, April 11 9:00 AM - 5:30 PM8 AHNS 2013 Annual Meeting

About the American Head and Neck SocietyMission StatementThe purpose of this societyis to promote and advancethe knowledge of prevention,diagnosis, treatment andrehabilitation of neoplasms andother diseases of the head andneck, to promote and advanceresearch in diseases of the headand neck, and to promote andadvance the highest professionaland ethical standards.Why Join the AHNS?The American Head and Neck Society isan organization of physicians, scientistsand allied health professionalsdedicated to improving theunderstanding of Head and Neck Cancerand the care of patients afflicted withthat disease. Membership is open to awide variety of interested individualsin several categories that differ bothin terms of responsibility and level ofinvolvement in the society.For more information aboutAHNS membership andto apply on-line, please visitwww.ahns.info/membercentral,call +1-310-437-0559, ext. 110or ask at the AHNS desk foradditional information.The Benefits ofAHNS Membership:• Interaction with colleagues dedicatedto promoting and advancing theknowledge of prevention, diagnosis,treatment, and rehabilitation ofneoplasms and other diseases of thehead and neck• Member rates on all meetingregistration fees• The honor of being a part of ourworldwide network of surgeons,physicians and health careprofessionals dedicated to theprevention and treatment of head andneck cancer• Opportunities to partake ineducational offerings, including thoseplanned by the society and those cosponsoredby the society• Opportunity to post regional meetingsand courses on the AHNS “RelatedMeetings” web page• Access to the AHNS member contactinformation in the “Members Only”section of our web site• E-newsletter with updates about thesociety and head & neck surgery• Ability to apply for research grantawards offered yearly• Opportunity to participate oncommittees and to vote at the annualbusiness meetingQualifications for ActiveFellowship:Surgical Applicants must beDiplomats of the American Board ofOtolaryngology, Plastic Surgery, orSurgery or OTHER EQUIVALENTCERTIFICATION BOARD. Additionally,all applicants must be Fellows of theAmerican College of Surgeons, Fellowsin the Royal College of Surgeons (FRCS)or equivalent non-surgical organization.Qualifications for AssociateFellowship:An applicant for Associate Fellowshipmust be a physician, dentist, or scientistwho has special interest contributionsin the field of neoplastic or traumaticdiseases of the head and neck.Qualifications for CandidateFellowship:The trainee currently enrolled inan approved residency program inOtolaryngology, Plastic Surgery, orGeneral Surgery or in a Fellowshipprogram approved by the AdvancedTraining Council may become aCandidate Fellow.Qualifications forCorresponding Fellowship:An Applicant for CorrespondingFellowship must be a physician whospecializes in the treatment of head andneck cancer, who by their professionalassociations and publications, wouldappear in the judgment of Council to bequalified to treat head and neck cancer.Corresponding Fellows must reside ina country other than the United Statesor Canada.Deadline for the 2014 cycle is October 31, 2013April 10 - 11, 2013 · www.ahns.info 9

AHNS Audience Response Instructions**NEW** Audience response system for 2013.Use your phone, tablet or laptop to text, tweetor post to pollev.com/ahnsYour privacy is protected! AHNS will not collect your cell phone number.You will NOT receive any text messages after the meeting.Standard texting rates apply: it may be free if you have a text plan, or upto US$0.20 on some carriers if you do not have a text messaging plan.Reminder to keep cell phones on silent! Thank you.INSTRUCTIONS10 AHNS 2013 Annual Meeting

AHNS Audience Response InstructionsApril 10 - 11, 2013 · www.ahns.info 11

AHNS PresidentMark K. Wax, MDDr. Mark K. Wax received his undergraduate degree fromthe University of Toronto. Following his Otolaryngologytraining he pursued private practice in Canada. Desiringto get more advanced training, he left private practice andcompleted a fellowship in Advanced Head and NeckOncologic Reconstructive Surgery at the University ofToronto. He then moved to the University of West Virginiawhere he established a busy Head and Neck Oncologicreconstructive practice. He continued to develop hisinterests in the field of Head and Neck Surgery. He was recruited to developand lead the Head and Neck program at SUNY Buffalo. After a few years hemoved to become a full professor and Director of the MicrovascularReconstructive Program at OHSU. While at OHSU he developed theMicrovascular and Reconstructive Fellowship Program that has graduated 13fellows, with the majority going on to academic careers.Dr. Wax has been intimately interested in academic medicine since reenteringthe academic world. He is a well renowned educator, visiting morethan 20 institutions as a visiting professor. He has published over 180 articlesin the peer reviewed literature with contributions to more than 8 textbooks.Dr. Wax has focused his career on reconstructive surgery and developedmany innovative reconstructive techniques while critically evaluating manyaspects of reconstructive surgery.His interest in the American Head and Neck Society goes back more thantwo decades. While always an active member of the society he joined theleadership by participating in the audit and finance committee. This wasfollowed by a six-year term as treasurer. This was an exciting time as itsaw the expansion of the society and the formalization of many budgetaryprocesses. He was elected Vice President in 2009 and is now the Presidentof the American Head and Neck Society. Education and the advancement ofHead and Neck Oncologic and Reconstructive Surgery remains his focus.Dr. Wax is married to Roberta Guild-Wax and has two wonderful children,Blair and Stephanie, who both attend college in Washington D.C.About the American Head and Neck SocietyHistory of the SocietyOn May 13, 1998, The American Head and Neck Society (AHNS) became thesingle largest organization in North America for the advancement of research andeducation in head and neck oncology. The merger of two societies, the AmericanSociety for Head and Neck Surgery and the Society of Head and Neck Surgeons,formed the American Head and Neck Society.The contributions made by the two societies forming the AHNS are significantin the history of surgery in the United States. Dr. Hayes Martin conceived theSociety of Head and Neck Surgeons in 1954, a surgeon considered by many to bethe “father of modern head and neck tumor surgery.” The purpose of the societywas to exchange and advance the scientific knowledge relevant to the surgery ofhead and neck tumors (exclusive of brain surgery) with an emphasis on cancerof the head and neck. Two years later, The American Society for Head and NeckSurgery was organized with the goal to “facilitate and advance knowledge relevantto surgical treatment of diseases of the head and neck, including reconstructionand rehabilitation; promote advancement of the highest professional and ethicalstandards as they pertain to the practice of major head and neck surgery; and tohonor those who have made major contributions in the field of head and necksurgery, or have aided in its advancement”.The new Society remains dedicated to the common goals of its parentalorganizations.12 AHNS 2013 Annual Meeting

2013 Program ChairEben L. Rosenthal, MDDr. Eben L. Rosenthal received his undergraduatedegree from Haverford College in 1988 and graduatedwith honors from University of Michigan MedicalSchool, where he also completed his residency inOtolaryngology. After completing a fellowship in facialand plastic and reconstructive surgery at OregonHealth Sciences University, Dr. Rosenthal joined theDivision of Otolaryngology at UAB. Dr. Rosenthal iscertified by the American Board of Otolaryngology and is a Diplomate ofthe American Board of Facial Plastic and Reconstructive Surgery. Hisclinical interest is in the reconstruction of head and neck defects usinglocal, regional and microvacular free flap techniques.In 2012, Dr. Rosenthal became Division Director of Otolaryngology –Head and Neck Surgery and the holder of the John S. Odess EndowedChair at the University of Alabama at Birmingham. He serves as anAssociate Editor for Head & Neck and is a founding member of the NIHDevelopmental Therapeutics Study Section. He has published over 100peer-reviewed scientific and clinical manuscripts and co-authored manybook chapters.He has focused his career on translational research in head and neckcancer. He has received grant funding from the American CancerSociety, NIH/NCI and NIH/NIDCR to study the role of optical imagingin surgical resections. Translating this technology to treat a variety ofcancers has become a major focus of his laboratory. His laboratory alsofocuses on tumor stromal interactions in the promotion of head andneck cancer and the role of targeted therapy in head and neck cancer. Hehas received R01 funding from the NIH/NCI to study the role of CD147targeted therapy alone and in combination with conventional therapyto treat head and neck cancer. To facilitate clinical translation of targetedtherapy, he is principal investigator on multiple investigator-initiated andindustry sponsored clinical trials.He is married to Mary T. Hawn, MD, MPH, Professor of Surgery at UAB,with whom he has two children, Sarah and Walker.April 10 - 11, 2013 · www.ahns.info 13

2013 Poster ChairKaren T. Pitman, MDKaren T. Pitman MD FACS is a native of the Marylandsuburbs of Washington DC and a graduate of theUniversity of Maryland where she received a BS inZoology. She then worked at the NIH as a researchassistant in the Section on Neurotoxicology. Time afterwork was spent as a volunteer at a local firedepartment where she obtained certification as aparamedic. The sum of these experiences sparked akeen interest in medicine and the US Navy provided the means to fulfillher dream of becoming a physician. She is a graduate of the UniformedServices University of the Health Sciences in Bethesda, MD and servedon active duty in the US Navy for 17 years. She completed herOtolaryngology residency at Naval Medical Center Portsmouth VA,followed by fellowship training in Head and Neck Surgery at theUniversity of Pittsburgh School of Medicine. Her commitment to the USNavy was fulfilled aboard the USS Emory S. Land as a general medicalofficer before residency, and later as an otolaryngologist at NMCPortsmouth VA. In addition to her busy clinical practice, she was activelyinvolved with otolaryngology resident training and research while onactive duty. She was honorably discharged from the Navy and therecipient of several awards, including 2 commendation medals.The next phase of her career took her to the Department ofOtolaryngology at the University of Mississippi Medical School,advancing to Professor of Otolaryngology. There, she initiated themultidisciplinary head and neck treatment team and oversaw its’ growthand development for over 10 years. In that role she recruited all themembers of a dynamic and energetic treatment team, chaired a vibranthead and neck tumor conference, and oversaw the research efforts ofthe group serving as PI or Co-PI on numerous institutional and multiinstitutionalstudies carried out during her tenure. As the only tertiarycare facility and the sole location for comprehensive head and neckcancer care in Mississippi, her clinical practice was busy and varied,focusing on all aspects of head and neck surgery. All along she wasactively involved in resident education and she was the medical studentdirector, overseeing the department’s educational activities for all levelsof medical student otolaryngology exposure.Research interests focus on evaluation and management of the clinicallynegative neck and institutional reviews, studying treatment outcomes atthe University of Mississippi. Academic service includes leadership rolesin both the American Head and Neck Society and American Academyof Otolaryngology, Head and Neck Surgery Foundation. She serveson the editorial board of the Laryngoscope and American Journal ofOtolaryngology, is an Associate Editor for Head and Neck and a memberof the Triological Society, completing her thesis in 2001. She served aspresident of the Mississippi Society of Otolaryngology. Recent awardsand honors are the AAO-HNSF Distinguished Service award in 2012,Castle Connolly America’s Top Doctors Award for 5 consecutive yearsand Castle Connolly America’s Top Doctors for Cancer. A new careerphase recently started at Banner-MDACC in Phoenix, Arizona as oneof 2 surgeons spearheading the development of the Head and NeckTreatment program.14 AHNS 2013 Annual Meeting

Hayes Martin LecturerJonas T. Johnson, MDJonas T. Johnson is Professor and Chairman of theDepartment of Otolaryngology at the University ofPittsburgh School of Medicine where he holds a jointappointment as professor of Radiation Oncology. Heis also professor of oral maxillofacial surgery in theSchool of Dental Medicine. Dr. Johnson limits hisclinical practice to the treatment of patients withtumors of the head and neck as well as the diagnosisand therapy of snoring and obstructive sleep apnea.Dr. Johnson was an undergraduate at Dartmouth College. He earned hismedical degree at SUNY Update Medical Center. He later completed hisresidency at the same institution.Dr. Johnson has developed his research around the care of patients withcancer of the head and neck. He has special interest and expertise in themanagement of patients with carcinoma of the upper aerodigestive tractas well as neoplasia of the salivary apparatus and thyroid surgery. Hehas a major interest in the management of cervical metastasis, surgicaltherapy for early laryngeal cancer, and adjuvant therapy for advancedhead and cancer. In 1980, a prospective database of all patients treatedfor head and neck cancer was established at the University of Pittsburgh.This allowed for an extended period of practice-based learning,which resulted in the publications of over 500 manuscripts in thepeer-reviewed literature. Dr. Johnson has contributed 175 chapters totextbooks and edited or co-edited 21 texts.Dr. Johnson is a past president of the American Academy ofOtolaryngology- Head & Neck Surgery (2003) and the American Head& Neck Society (2004). He is the past editor of the Laryngoscope (2004-2011) and President Elect of the Triologic Society.Past Hayes Martin LecturersGregory T. Wolf, MD (2012)Randal S. Weber, MD (2011)Adel El-Naggar, MD (2010)Charles W. Cummings, MD (2009)Waun Ki Hong, MD (2008)Jesus E. Medina, MD (2007)Keith S. Heller, MD (2006)Richard K. Reznick, MD, MEd (2005)Christopher J. O’Brien, MD (2004)Michael Johns, MD (2003)Eugene Myers, MD (2002)William Wei, MS (2001)Robert M. Byers, MD (2000)Jean-Louis H. LeFebvre, MD (1999)Jatin P. Shah, MD (1998)Blake Cady, MD (1997)Joseph N. Attie, MD (1996)Helmuth Goepfert, MD (1995)John G. Batsakis, MD (1994)Ronald H. Spiro, MD (1993)John M. Lore, MD (1992)Ian Thomas Jackson, MD (1991)Alando J. Ballantyne, MD (1990)George A. Sisson, MD (1989)M.J. Jurkiewicz, MD (1988)Elliot W. Strong, MD (1987)Donald P. Shedd, MD (1986)Alfred S. Ketcham, MD (1985)William A. Maddox, MD (1984)John J. Conley, MD (1983)Milton Edgerton, MD (1982)Richard H. Jesse, MD (1981)Condict Moore, MD (1980)Edward F. Scanlon, MD (1979)Harvey W. Baker, MD (1978)Harry W. Southwick, MD (1977)Edgar L. Frazell, MD (1976)Charles C. Harrold, MD (1975)Arthur G. James, MD (1974)Oliver H. Beahrs, MD (1973)William S. MacComb, MD (1972)April 10 - 11, 2013 · www.ahns.info 15

Hayes Martin BiographyHayes Martin, MDHayes Martin was born in Dayton, a small town in northcentral Iowa. He attended the University of Iowa at IowaFalls before being accepted to the medical school in 1913on the same campus, finishing 4 years later in a class of20.World War I began in April 1917 while Hayes was in hisfinal year of medical school. Many of his classmates at themedical school were in the Army ROTC units; however,Dr. Martin opted for the Navy, which he joined on the dayAmerica entered the war. He traveled to Europe on the USS Arkansas andwas assigned to his permanent duty station at the U.S. Navy Air Station, LaTrinite Sur Mer, France – a small seaside village on the southern coast ofBrittany. The purpose of this base was antisubmarine warfare using blimpsand kite balloons. Dr. Martin was made commanding officer of the air stationfor a brief period of time when the line officer in charge had become ill; it wasa unique position for a medical officer in the Navy to take command duringwartime.After the war, Dr. Martin returned to the U.S and sought out an internship atthe old Poly Clinic Hospital in New York City, which was temporarily madeinto a Veteran’s Administration hospital. Part of his internship was spent atBellevue in the fourth surgical division, where he felt he would have thebest possible training in general surgery. The chief of the second divisionwas John A. Hartwell, MD, the distinguished surgeon memorialized bythe Fellow’s Room in the library of the New York Academy of Medicine. Dr.Hartwell suggested that Dr. Martin go to Memorial Hospital to learn aboutcancer.Dr. Martin received an internship at Memorial in the summer of 1922 andstayed on as a resident until 1923. He then had two years at the secondsurgical service at Bellevue, where he operated to his heart’s content and gotthe surgical education he so strongly desired. Once he finished his residency,Dr. Martin returned to Memorial where he joined as clinical assistant surgeonon the staff.Dr. Martin made the use of aspiration biopsy on all solid tumors popularthroughout Memorial. Now, this procedure is done throughout the world.Dr. Martin co-authored the first report on the subject published in the Annalsof Surgery. Numerous other articles followed, including Dr. Martin’s twomost famous publications, “Cancer of the Head and Neck,” published intwo issues of the Journal of the American Medical Association in 1948, and“Neck Dissection,” appearing in Cancer in 1951. These two papers were soextensively requested that the American Cancer Society made reprints by thethousands available to those who requested them as many as 20 years afterpublication. Dr. Martin’s bibliography encompasses more than 160 articles.In 1934, Dr. Martin was appointed Chief of the Head and Neck Service atMemorial Hospital. It wasn’t until 1940 that surgery began to take over asthe treatment of choice for the majority of cancers of the head and neck.In that year, the beginnings of improved anesthesia permitted advances insurgery. Later, during World War II, antibiotics became available and surgerybegan to dominate much of head and neck cancer management. Dr. Martinwrote extensively on many subjects, most within the realm of head and necksurgery. His ideal was to be the complete head and neck surgeon and hetreated a wide variety of head and neck abnormalities. His book, Surgery ofthe Head and Neck Tumors, was published in 1957.Dr. Martin retired from active practice in 1957 at the age of 65. He performedhis last operation at Memorial Hospital, assisted by Dr. Elliot Strong, inOctober 1959, but continued to see patients in his office until he passed awayin 1977.16 AHNS 2013 Annual Meeting

John J. Conley LecturerPatrick J. Gullane, CM, MB, FRCSC, FACS, FRACS(Hon), FRCS (Hon), FRCSI (Hon)Professor Patrick Gullane was born in Ireland andreceived his medical degree from Galway University,Ireland in 1970. He is a Fellow of the Royal College ofSurgeons of Canada and certified by the AmericanBoard of Otolaryngology-Head and Neck Surgery. In1975 he was selected as the McLaughlin Fellow andthen pursued advanced training in Head and NeckOncology in Pittsburgh, and New York.In 1978 Dr. Gullane was appointed to the Department of Otolaryngology-Head and Neck Surgery at the University of Western Ontario. He wassubsequently recruited to the Department of Otolaryngology-Headand Neck Surgery at the University of Toronto in 1983. In 1989 hewas appointed as Otolaryngologist-in-Chief within the UniversityHealth Network and in 2002 appointed as Professor and Chair of theDepartment of Otolaryngology-Head and Neck Surgery, University ofToronto. He concluded his second and final term as Chair in June 2012.Dr. Gullane is a member of numerous Surgical Societies, nationally andinternationally, and has been invited as a Visiting Professor to over 65countries lecturing on all aspects of Head and Neck Oncology. He hasdelivered over 770 presentations nationally/internationally and serves onthe Editorial Board of 10 Journals. Dr. Gullane has published 281 papersin peer-reviewed journals and 73 chapters in textbooks. In addition hehas published 9 books on various aspects of Head and Neck Surgery.Dr. Gullane has been a PI or collaborator on numerous research grants(10 ongoing) receiving funding from various Agencies, including NCICand NIH.Honours/Awards2012 Recipient of the Royal College of Surgeons in Ireland Honorary Fellowship(RCSI), Ireland Feb 20122011 Election to Fellowship in the Canadian Academy of Health Sciences(CAHS) Induction- Ottawa Sept 20112011 Recipient of the “Teacher of the Year Award” - Department ofOtolaryngology-Head and Neck Surgery - University of Toronto- June 20112011-12 Vice-President Elect - Canadian Society of Otolaryngology-Head and NeckSurgery (CSO-HNS)2011 Guest of Honour - 65th Annual CSO-HNS Meeting, Victoria BC May 20112010 Appointed as a Member to the Order of Canada by the GovernorGeneral of Canada: Cited for his inspiration of young surgeons and hiscontributions to the field of Head and Neck Surgery2010 Recipient of Royal College of Surgeons of England Honorary Fellowship(FRCS), London England2008 Invited Faculty - 1st Educational World Tour (11 countries) - InternationalFederation of Head and Neck Oncologic Societies - Current Concepts inHead and Neck Surgery and Oncology2006 Recipient of the Royal Australasian College of Surgeons HonoraryFellowship (FRACS), Sydney Australia2005-06 Served as Vice-President, Triological Society (Eastern Section)2004-05 Served as President, the North American Skull Base Society2004-05 Served as President, the American Head and Neck Society1998 Facilitated the establishment of four University-Hospital Chairs: Head &Neck Surgery, Reconstruction, Radiation Oncology, and Basic Science,from private funding donations in excess of $14.5 M. - with continualfunding up to the present timeApril 10 - 11, 2013 · www.ahns.info 17

John J. Conley BiographyJohn J. Conley, MDAlthough he looked and sounded like an English nobleman,Dr. John Conley was born in Carnegie, Pennsylvania, a smallsteel mill town just outside of Pittsburgh. He graduated fromthe University of Pittsburgh and later its school of medicine.He interned at Mercy Hospital in Pittsburgh. During that year,the nuns who ran the hospital suggested that Dr. Conley takea residency in cardiology and come back to Mercy as theircardiologist.He went to Kings County Hospital in Brooklyn, a very busycity hospital with a huge patient population. Shortly after he began his training, hehad an arrhythmia diagnosed as paroxysmal atrial tachycardia. Little was knownabout this benign condition at that time. Dr. Conley was told that cardiology wastoo stressful and that he should go into an easier, less-stressful field with betterworking hours, like ENT. He did an otolaryngology residency at Kings CountyHospital. This was followed by four years of military service during World War II,which included experience in otolaryngology and plastic and reconstructive andmaxillofacial surgery in the U.S. Army Medical Corps, both in this country and inthe South Pacific theater. Exposure to the construction of war wounds would proveinvaluable to him later on in applying these principles to reconstruction followingablative head and neck surgery.Dr. Conley returned to New York City after the war. He became an assistant andthen an associate of Dr. George T. Pack, a technically superb general oncologicsurgeon at Memorial Hospital who taught Dr. Conley major ablative surgery ofthe head and neck. They worked day and night catching up with the backlog ofsurgery that was neglected during the war years. The combination of his training inotolaryngology, the exposure to ablative surgery, and the World War II experiencein reconstructive surgery set the stage for Dr. Conley to evolve his uniqueapproach to head and neck surgery.Ironically, despite the admonition of the cardiologists about hard work, Dr.Conley did a prodigious amount of major head and neck reconstructive surgery.This proved to be more than ample to provide training to many fellows. Hiscommitment to education is further attested to by the position he held for manyyears as Clinical Professor of Otolaryngology at the College of Physicians andSurgeons at Columbia University. He loved his appointment at Columbia andparticularly his involvement in teaching the residents.Dr. Conley’s vast surgical experience, together with active research interests, ledto the authorship of almost 300 contributions to the scientific literature, and eightbooks. As a result of his productivity and rhetorical eloquence, he was very muchin demand as a speaker in this country and abroad. He gave many prestigiouseponymous lectures in our field and received many awards for his work, includingthe Philip H. Hench Award as the Distinguished Alumnus of the University ofPittsburgh School of Medicine, and the DeRoaldes and Newcomb Awards of theAmerican Laryngological Association.Dr. Conley’s contributions to the scientific literature, many technical innovationsand surgical experience placed him in the position to receive many honors andimportant leadership positions, such as President of the American Academy ofOtolaryngology and Ophthalmology, member of the Board of Governors of theAmerican College of Surgeons, founding member of the Society of Head and NeckSurgeons, and founding member and first President of the American Society forHead and Neck Surgery. During those years, Dr. Conley used, to the great benefitof us all, his wisdom and diplomacy in carrying out such high-level responsibilities.Past John J. Conley LecturersJulie A. Freischlag, MD (2012)Benjamin S. Carson, Sr., MD (2011)Robert L. Comis, MD (2010)James D. Smith, MD (2009)Carolyn Dresler, MD (2008)Kenneth I. Shine, MD (2007)John Stone, MD, MACP (2006)James F. Battey Jr., MD (2005)David C. Leach, MD (2004)Jonathan D. Moreno, MD (2003)Rabbi David Saperstein (2002)Edward Hughes, MD (2001)18 AHNS 2013 Annual Meeting

Jatin P. Shah Symposium & BiographyProfessor Jatin P. Shah graduated from the MedicalCollege of MS University in Baroda, India, and receivedhis training in Surgical Oncology and Head and NeckSurgery at Memorial Sloan Kettering Cancer Center. Heis Professor of Surgery, at the Weil Medical College ofCornell University, and Chief of the Head and NeckService, Leader of the Head and Neck DiseaseManagement Team, and holds The Elliott W. StrongChair in Head and Neck Oncology at Memorial Sloan-Kettering CancerCenter in New York City.Dr. Shah is a national and international leader in the field of head and necksurgery, having served as President of The New York Cancer Society, TheNew York Head and Neck Society, The Society of Head and Neck Surgeons,The North American Skull Base Society and the International Academy ofOral Oncology. He is Founder of The International Federation of Head andNeck Oncologic Societies, in 1986. He currently serves as Chairman of theAJCC task force on Head and Neck. He was Chairman of the Joint Councilfor advanced training in head and neck oncologic surgery in the USA. Hewas also Chairman of the 4th International Conference on Head and NeckCancer in Toronto in 1996. He has served in varying capacities for TheAmerican Board of Surgery, and the American College of Surgeons.Professor Shah has been the recipient of numerous awards from variousparts of the world, and is the recipient of honorary fellowships fromThe Royal College of Surgeons of Edinburgh, London and Australia. Heholds Honorary PhD, degrees from the Catholic University of Louvain,in Belgium and the University of Athens, in Greece. He is recipient ofthe Blokhin Gold medal, the highest Honor in Oncology in Russia. Hehas been elected as an honorary member of several head and necksocieties in Europe, Asia, Australia, Africa and Latin America. He hasbeen continuously listed in the “Best Doctors in America” directoriesfor several years. He serves on the Editorial and Review Boards of 18scientific journals and has published over 300 peerreviewed articles, 50book chapters and 7 books. His textbook of Head and Neck Surgery andOncology won First Prize from The British Medical Association and TheRoyal Society of Medicine and was awarded the George Davey HowellsPrize from the University of London, for the best published book inotolaryngology in the preceding five years.He is a much sought after speaker who has delivered over 1,000 scientificpresentations including, 59 eponymous lectures and keynote addresses,and visiting professorships in the United States, Canada, United Kingdom,Scotland, Sweden, Belgium, Germany, Italy, Spain, Poland, Russia,Croatia, Turkey, Egypt, South Africa, India, China, Korea, Japan, HongKong, Taiwan, Singapore, Phillipines, Australia, Argentina, Brazil, Chile,Peru, Equador, Venezula, Panama, and Mexico.In recognition of his outstanding contributions, and World Leadershipin Head and Neck Surgery, Memorial Sloan Kettering Cancer Center,has established The “Jatin Shah Chair in Head and Neck Surgery andOncology”, The International Federation of Head and Neck OncologicSocieties has established “The Jatin Shah Lecture”, at its worldcongresses, and the American Head and Neck Society has established the“Jatin Shah Symposium” at its annual meeting.April 10 - 11, 2013 · www.ahns.info 19

Guest of HonorT. David R. Briant, FRCS(C), FACSDr. Briant was born in Toronto Ontario Canada. He waseducated at Ridley College and later at the Universityof Toronto. He graduated as an M.D. in 1955 passinghis Canadian examinations and his National StateBoard examinations. He did a post graduate course inGeneral Surgery under Dr Professor. F.G. Kergin andworked with Dr. Robert Mustard and Dr. John Palmernoted general surgeons specializing in head and necksurgery and often scrubbed with Dr.Harold Wookey of the WookeyProcedure. This was followed by a postgraduate course inOtolaryngology Head and Neck Surgery under Percy Ireland. Hecompleted the examinations of the Royal College of Surgeons of Canadain Otolarngology in 1961. He then did a Fellowship at the MiddlesexHospital in London England under Mr.C.P Wilson and spent time withMr. Angel James learning Trans –Sphenoidal Hypophosectomy.He became a staff member of the Toronto General Hospital (now part ofthe University of Toronto Network) for ten years. In 1964 he became aConsultant at the Ontario Cancer Institute, Princess Margaret Hospitaland Sunnybrook Hospital. He then transferred to St. Michaels Hospitalbecoming Chief of the Department of Otolarngology of the hospital.In 1966, he became a Fellow of the American college of Surgeons.In 1986, he became Head of the Division of Head and Neck SurgicalOncology of the Department of Otolarngology at the University ofToronto.He has published 76 learned papers and written two chapters in booksas well as doing an award winning movie. He also took a keen interest infacial plastic surgery and was an early adopter of the external approachrhinoplasty.He was a member of Council of the American Society of Head andNeck Surgery from 1986- 89 and was involved in many other societiespertaining to the region. He mentored 13 fellows practically allrecognized by the program of the American Society of Head and NeckSurgery; your present president being one of them and perhaps themost productive of the group.His hobbies included painting and flying, owning a number of planes.Since retirement he spends the winters in Costa Rica and his summersat his cottage on Lake of Bays in the Muskoka region of Ontario andthe opera season spring and fall in Toronto at the newish Four SeasonsOpera House. He is married to a college professor of economics andsinger for better than 55 years and has three children who all livenearby. There are four grand children, two boys and two girls, one ofwho graduated with Honours from University and hopes to go intomedicine.20 AHNS 2013 Annual Meeting

Distinguished Service AwardDennis H. Kraus, MDDr. Dennis Kraus is the Director of the Center for Headand Neck Oncology within the New York Head andNeck Institute and the North Shore-LIJ CancerInstitute. He has served in a number of administrativepositions within otolaryngology and head and necksurgery. He has served in multiple positions within theAHNS including program chair of the annual meetingand secretary. He serves as a member of the Board ofGovernors for the American College of Surgeons and theOtolaryngology Advisory Council. He is the past president of the NorthAmerican Skull Base Society, the New York Head and Neck Society andthe New York Laryngological Society. He is currently the co-editor inchief of the Skull Base Journal and associate editor of Head and NeckSurgery. He is a member of the Subspecialty Advisory Council for theAmerican Association of Otolaryngology-Head and Neck Surgery and ispast chair of the Head and Neck Educational Committee. His clinicalinterest focus on all aspects of head and neck oncology and his researchefforts have parallel his clinical initiatives. He has been fortunate tolecture across both the USA and around the world in a number ofvenues.He is very honored to be the recipient of this prestigious award. On apersonal level, he is married to his wife of 25 years, Daryl, and all 3 ofhis children are currently attending college. He continues to enjoy golf,skiing and travel.Past Distinguished Service Award RecipientsJatin P. Shah, MD 1989Stephan Ariyan, MD 1990Ashok R. Shaha, MD 1991Elliot W. Strong, MD 1995John J. Coleman, III MD 1999David L. Larson, MD 1999Harold J. Wanebo, MD 1999Jonas T. Johnson, MD 2001Helmuth Goepfert, MD 2003Marc D. Coltrera, MD 2004Wayne Koch, MD 2005John A. Ridge, MD, PhD 2006Ernest A. Weymuller, Jr., MD 2007Helmuth Goepfert, MD 2008Keith S. Heller, MD 2009Mark K. Wax, MD 2010Randal S. Weber, 2011Ashok R. Shaha, MD 2012Past Special Recognition Award RecipientsPaul B. Chyetien, MD 1984John M. Lore, Jr., MD 1985William S. MacComb, MD 1986Calvin T. Klopp, MD 1987Edgar L. Fazell, MD 1988Harvey W. Baker, MD 1989Vahram Y. Bakamjian, MD 1991Jean-Louis Lefevbre, MD 1995April 10 - 11, 2013 · www.ahns.info 21

Presidential CitationsBrian B. Burkey, MDBrian B. Burkey MD FACS is currently Vice-chairman andSection Head of the Section of Head and Neck Surgeryand Oncology at the Cleveland Clinic Head and NeckInstitute. He also serves as Medical Director of the Centerfor Consumer Health Information within the EducationInstitute at the Cleveland Clinic, which is a group of 30people dedicated to the production of multimedia patienthealth information for all medical needs of patients andtheir families. Dr. Burkey came to the Cleveland Clinic after almost twentyyears at Vanderbilt University Medical Center, rising to Professor ofOtolaryngology and Vice-chairman within that department.Dr. Burkey finished undergraduate studies at Johns Hopkins University,before obtaining his medical degree at the University of Virginia School ofMedicine in 1986. He completed otolaryngology residency training at theUniversity of Michigan Department of Otolaryngology and a fellowshipin microvascular and facial plastic and reconstructive surgery at the OhioState University, before launching his career at Vanderbilt. He has beenan American Board of Otolaryngology diplomate since 1992, and hispractice has an emphasis on head and neck oncologic and microvascularreconstructive surgery. He began co-directing the Vanderbilt fellowshipin Head and Neck Oncologic and Microvascular Reconstructive Surgerystarting in 1992, one of the early fellowships in microvascular surgery, andhas trained 30 fellows over his career, almost all of whom have positionsin academic otolaryngology both nationally and internationally. He hascontinued this fellowship at the Cleveland Clinic.At Vanderbilt, Dr. Burkey served as residency Program Director for 15 years,which spanned three successful site visits. Dr. Burkey recently completed aseven-year tenure on the Otolaryngology Residency Review Committee ofthe ACGME, serving two years as Vice-chairman and two years as Chairmanof that body. He then served as a consultant with ACGME-Internationaland helped three programs in Singapore gain initial accreditation. He wason the steering committee which founded the Otolaryngology ProgramDirectors Organization (OPDO), and served on the Executive Council and asPresident of the Society of University Otolaryngologists (SUO). He has alsoserved as a guest examiner and senior examiner of the American Boardof Otolaryngology and has been a member of the Board of Governors andnumerous educational committees of the American College of Surgeons.Dr. Burkey has been an active member of the American Head and NeckSociety, serving on the Educational and Website committees, and justcompleted his second term on the Council, comprising over twelveyears of service. He currently is the chair of the Constitution and Bylawscommittee. He serves on the editorial board of multiple journals in thefield of otolaryngology, and has lectured extensively on educational andclinical subjects both nationally and internationally. He has authored over15 book chapters and 75 peer-reviewed articles on head and neck andreconstructive surgery topics. He has been a leader on several cooperativegroup studies and currently is a co-principal investigator of NIH-fundedresearch. He continues to mentor residents and fellows and is hoping tocontinue innovation within all areas of medical education. He will completehis Masters degree in Education with an emphasis on the health professionsin 2014. Dr. Burkey is married to Maureen, his wife of over 30 years, and theirdaughter Rachel Burkey lives and teaches in Nashville, TN.22 AHNS 2013 Annual Meeting

Presidential CitationsNeal D. Futran, MD, DMDNeal D. Futran, MD, DMD joined the University of Washingtonfaculty in 1995. He is currently the Allison T. WanamakerProfessor and Chair of the Department of Otolaryngology –Head and Neck Surgery. He is also the Director of Head andNeck Surgery as well as an adjunct professor in thedepartments of Plastic Surgery and Neurology Surgery. Dr.Futran earned his dentistry degree at the University ofPennsylvania and completed training in oral and maxillofacialsurgery as well as an MD degree at the Health Science Centerat Brooklyn, New York. He then trained in Otolaryngology – Head and Neck Surgeryat the University of Rochester followed by a Head and Neck Oncology andMicrovascular Surgery fellowship at Mount Sinai Hospital in New York with Dr.Mark Urken. Dr. Futran became an assistant professor in the Department ofOtolaryngology at the University of South Florida in 1993 specializing in head andneck oncologic and reconstructive surgery and subsequently relocated to Seattle.Dr. Futran is board certified in Otolaryngology and has outstanding expertise andan active practice in head and neck oncology and microvascular reconstructionand rehabilitation of complex, oncology and trauma cases. He also specializesin skull base surgery utilizing both endoscopic and open approaches. His majorresearch activites center on microvascular reconstruction of the head and neck andhe also participates in grants studying molecular profiles and gene analysis in oralcarcinogenesis. He enjoys teaching on the topics of head and neck reconstruction,craniofacial trauma, skull base surgery, and head and neck oncology worldwide.He is on the board of trustees of the AO Foundation, UW Physicians, and theVirginia Bloedel Hearing Research Institute. Dr. Futran is on the editorial boards ofseveral scientific journals and holds the position of associate editor of both Headand Neck, and Oral Oncology. He is listed in the Best Doctor’s in America.Paul A. Levine, MDBorn in Brooklyn, New York on November 4, 1947, Paul A. Levine,MD received a Bachelor of Science degree in Biology fromRensselaer Polytechnic Institute in 1969, his M.D. from AlbanyMedical College in 1973, and completed his internship andotolaryngology-head and neck surgery surgical residency atYale in 1977. After a year fellowship at Stanford in head andneck, maxillofacial, and facial plastic and reconstructive surgerycompleted in 1978, Dr. Levine remained on the Stanford facultyas an assistant professor in the Division of Otolaryngology-Headand Neck Surgery as well as the associate chief for the Division at Santa Clara ValleyMedical Center. In 1984, he joined the Department of Otolaryngology-Head and NeckSurgery at the University of Virginia as an associate professor and vice chair, becamea tenured professor in 1987, and was named chairman of the department at UVA in1997, a position he stills holds.Dr. Levine has contributed over 140 publications to the specialty during hiscareer and has been very active in institutional and national committees, in andoutside the specialty throughout his career. He was an early proponent of platefixation for mandible fractures, and he has become recognized for his expertise intreating sinonasal malignancies, especially esthesioneuroblastoma and sinonasalundifferentiated carcinoma, as well as experience in performing craniofacialresections and sparing of the eye when treating these malignancies. A nationallyand internationally recognized academic head and neck cancer surgeon, Dr. Levinehas served as a member of all the major societies in the field and as a leader ofmany. He has served as the past president of the American Broncho-EsophagologicalAssociation, chairman of the Advanced Training Council of the American Head andNeck Society as well as the President of the American Head and Neck Society. He hasbeen a director of the American Board of Otolaryngology, completing his 12 yearterm in 2010 and also served as its treasurer for four years. He completed his term asSouthern Section Vice President of the Triological Society in 2007 and currently servesas the editor of JAMA Otolaryngology-Head and Neck Surgery (formerly known asArchives of Otolaryngology-Head and Neck Surgery) as well as an editorial boardmember of JAMA. Dr. Levine most recently was the Guest of Honor at the TriologicalSociety Combined Otolaryngology Sections Meeting in April 2012 and has been namedthe Guest of Honor for the Triological Society Southern Sections Meeting in 2013.April 10 - 11, 2013 · www.ahns.info 23

Presidential CitationsJeffrey N. Myers, MDDr. Jeffrey N. Myers received his medical (MD) and doctoral(PhD) degrees from the University of Pennsylvania School ofMedicine, and he then completed his residency training inOtolaryngology-Head and Neck Surgery at the University ofPittsburgh. He subsequently completed fellowship training inHead and Neck Surgical Oncology at the University of TexasM.D. Anderson Cancer Center, where he has been on thefaculty ever since. Dr. Myers leads a basic and translationalresearch program and his primary research interests are inthe role of p53 mutation in oral cancer progression, metastasis and response totreatment.Dr. Myers and his wife Lisa have enjoyed 22 years of marriage and are the proudparents of three boys, Keith 21, Brett 17 and Blake 12.Stephen Wetmore, MD, MBA, FACSDr. Wetmore grew up in northern Indiana and attendedcollege and medical school at the University of Michiganwhere he graduated with distinction in 1971. He did hisinternship and a year of general surgery training in LosAngeles and then completed four years of specialty training inOtolaryngology Head and Neck Surgery at the University ofIowa. For the next eleven years, he was on staff at theUniversity of Arkansas School of Medicine where he was apioneer in laser surgery. From 1979 to 1982 he was anAmerican Cancer Society Junior Faculty Clinical Fellow under the guidance of Dr.James Suen. In 1985 he did a fellowship in neurotology and skull base surgery inZurich, Switzerland, under the guidance of Dr. Ugo Fisch.Dr. Wetmore came to West Virigina University in the summer of 1988 as Professorand Chairman of the Otolaryngology- Head and Neck Surgery Department. Hismain area of interest is in diseases of the ear including hearing loss, dizziness,tinnitus, facial paralysis, and surgery of the ear and skull base.Dr. Wetmore has published over seventy articles and book chapters in the medicalliterature on subjects ranging from laser surgery to sleep apnea to approachesto skull base surgery. He is also a member of numerous professional medicalsocieties. In 1999 he received the degree of Masters in Business Administration “toenable me to become a better leader of my department and the medical center.” In2004, he received the Distinguished Service Award from the American Academy ofOtolaryngology/Head and Neck Surgery.On a personal level, Dr. Wetmore is married and has four children all of whom aremarried. For relaxation, he enjoys reading, using his personal computer, and skiing.24 AHNS 2013 Annual Meeting

Congratulations to theAHNS 2013 Award Winners!Presented during the AHNS Awards CeremonyThursday, April 11, 20139:45AM - 10:00AMRobert Maxwell Byers AwardSteven M. Sperry, MDUniversity of Pennsylvania“Supracricoid Partial Laryngectomy for Primary andRecurrent Laryngeal Cancer”Best Resident Basic Science PaperChi T. Viet, DDS, PhDNew York University, Bluestone Center for Clinical Research“Decitabine and Cisplatin Combination Therapy forHead and Neck Squamous Cell Carcinoma”Best Resident Clinical PaperGretchen M. Oakley, MDUniversity of Utah Health Sciences Center“Significant Familial Risk in Multiple Generations ofPapillary Thyroid Carcinoma Probands”April 10 - 11, 2013 · www.ahns.info 25

AHNS LeadershipOfficers of the AHNSPresident: Mark K. Wax, MDPresident-Elect: Terry A. Day, MDVice-President: Douglas A. Girod, MDSecretary: Dennis H. Kraus, MDTreasurer: Ehab Y. Hanna, MDPast Presidents: Carol R. Bradford, MDDavid W. Eisele, MDJohn A. Ridge, MD, PhDFellows-At-Large:Jeffrey Bumpous, MDDaniel G. Deschler, MDRalph W. Gilbert, MDCherie-Ann O. Nathan, MDLisa A. Orloff, MDKerstin A. Stenson, MDErich M. Stugis, MDRalph P. Tufano, MDMarilene B. Wang, MDCommittees of the AHNSAd Hoc ATC Advanced Technologies Task ForceRandal S. Weber, MD (Chair) 2011-2013Jeffrey M. Bumpous, MD 2011-2013Terry A. Day, MD 2011-2013Ramon Esclamado, MD 2011-2013Ad Hoc CME Measurement Task ForceGreg A. Krempl (Chair) 2012-2014Karen T. Pitman, MD 2010-2013Eben L. Rosenthal, MD 2010-2013Paul L. Friedlander, MD 2012-2014Samir Khariwala, MD 2012-2014Advanced Training Council (ATC)William M. Lydiatt, MD (Chair) 2012-2014Jeffrey M. Bumpous, MD 2008-2013Ramon Esclamado, MD 2008-2013Kerstin M. Stenson, MD 2009-2014Neal Topham, MD 2009-2014Jeffrey Scott Magnuson, MD, FACS2011-2013Bert W. O’Malley, Jr., MD 2011-2013Ashok R. Shaha, MD 2011-2013Stuart Charles Coffey, MD 2012-2015Jan L. Kasperbauer, MD 2012-2015Rohan Ramchandra Walvekar, MD2012-2015Danny Enepekides, MD, FRCS 2010-2015Erich M. Sturgis, MD 2010-2015Douglas A. Girod, MD 2012-2017David A. Terris, MD, FACS 2012-2017Donald T. Weed, MD 2012-2017Awards CommitteeD. Gregory Farwell, MD (Chair) 2010-2013William R. Carroll, MD 2010-2013Daniel G. Deschler, MD 2010-2013Jason Hwa Yound Kim, MD 2010-2013CME Compliance CommitteePaul L. Friedlanders, MD (Chair)2011-2013Dennis H. Kraus, MD (Ex Officio)2007-2013Jeffrey N. Myers, MD, PhD 2011-2013John H. Yoo, MD, FACS 2010-2013Miriam Lango, MD 2011-2014John H. Lee, MD, FACS 2012-2015Yelizaveta Lisa Shnayder, MD 2012-2015Samir Khariwala, MD 2012-2014Greg A. Krempl, MD 2012-2014Oleg Militsakh, MD 2012-2014Joseph Scharpf, MD, FACS 2012-2014Marrilene B. Wang, MD 2012-201426 AHNS 2013 Annual Meeting

AHNS LeadershipConstitution and By-Laws CommitteeBrian B. Burkey, MD (Chair) 2010-2013Dennis H. Kraus, MD (Ex Officio)2007-2013Brandon G. Bentz, MD 2007-2013Paul L. Friedlander, MD 2007-2013Ellie Maghami, MD 2010-2013Gerry F. Funk, MD 2012-2015M. Boyd Gillespie, MD, MS 2012-2015Credentials CommitteeMark K. Wax, MD (Chair) 2012-2015Dennis H. Kraus, MD (Ex Officio)2007-2013David W. Eisele, MD 2010-2013Education CommitteeDavid Goldenberg, MD (Chair) 2010-2013David I. Rosenthal, MD 2007-2013Stephen W. Bayles, MD 2010-2013R. Bryan Bell, MD, DDS 2010-2013Robert W. Dolan, MD 2010-2013Miriam Lango, MD 2010-2013Neil Dwayne Gross, MD 2011-2014Eric Lentsch, MD 2011-2014Ellie Maghami, MD 2011-2014Endocrine CommitteeDavid J. Terris, MD (Chair) 2010-2013Gary L. Clayman, MD, DDS 2007-2013Gregory L. Randolph, MD 2007-2013Maisie Shindo, MD 2007-2013Ralph P. Tufano, MD 2007-2013Salvatore M. Caruana, MD 2010-2013Amy Y. Chen, MD 2010-2013Lisa A. Orloff, MD 2010-2013Joseph C. Sniezek, MD 2010-2013Carol R. Bradford, MD 2012-2014Daniel G. Deschler, MD 2012-2015Kavita Pattani, MD, MS 2011-2014Stuart C. Coffey, MD 2012-2015Tamer Ghanem, MD, PhD 2012-2015Jeffrey Chang-Jen Liu, MD 2012-2015Luc G.T. Morris, MD 2012-2015Nitin A. Pagedar, MD 2012-2015Theodoros N. Teknos, MD 2012-2015Terance T. Tsue, MD 2012-2015Brendan C. Stack, Jr., MD 2010-2013David Steward, MD 2010-2013Eric Lentsch, MD 2011-2014Glenn E. Peters, MD 2011-2014Kevin T. Brumund, MD 2012-2015Maria Evasovich, MD 2012-2015Neal D. Gross, MD 2012-2015Russell B., Smith, MD 2012-2015Ethics and Professionalism CommitteeWilliam M. Lydiatt, MD (Chair) 2010-2013Jeffrey M. Bumpous, MD 2010-2013Daniel G. Deschler, MD 2010-2013M. Boyd Gillespie, MD, MS 2010-2013Douglas A. Girod, MD 2010-2013Wayne M. Koch, MD 2010-2013Susan Dixon McCammon, MD 2010-2013Pierre Lavertu, MD 2012-2015Mark E.P. Prince, MD 2012-2015Finance CommitteeCherie-Ann O. Nathan, MD (Chair)2011-2014Ehab Y. Hanna, MD (Ex Officio) 2010-2013Robert L. Ferris, MD, PhD 2011-2013Shawn D. Newlands, MD, PhD 2012-2015Head and Neck Reconstructive CommitteeMark K. Wax, MD (Chair) 2012-2015Derrick Lin, MD (Co-Chair) 2012-2015Matthew M. Hanasono, MD 2010-2013Oleg Militsakh, MD 2010-2013Urjeet A. Patel, MD 2011-2014Jeremy Richmon, MD 2011-2014Yelizaveta Lisa Shnayder, MD 2012-2015History CommitteeGreg A. Krempl, MD (Chair) 2012-2014Keith S. Heller, MD 2010-2014Jonas T. Johnson, MD 2010-2014Randal S. Weber, MD 2011-2013David S. Eisele, MD 2012-2014Daniel D. Lydiatt, MD, DDS 2012-2014Alan T. Richards, MD 2012-2014Ralph P. Tufano, MD 2012-2014April 10 - 11, 2013 · www.ahns.info 27

AHNS LeadershipHumanitarian CommitteeWayne M. Koch, MD (Chair) 2009-2015James L. Netterville, MD 2009-2015K. Thomas Robbins, MD 2009-2015Robert W. Dolan, MD 2010-2013Robert A. Frankenthaler, MD 2010-2013Gady Har-El, MD 2010-2013Shawn Newlands, MD, PhD 2010-2013Nominating CommitteeCarol R. Bradford, MD (Chair) 2012-2013John A. Ridge, MD, PhD 2010-2013David W. Eisele, MD 2011-2014Francisco J. Civantos, MD 2011-2013Gregory L. Randolph, MD 2011-2013Merry E. Sebelik, MD 2011-2013M. Boyd Gillespie, MD, MS 2012-2015Joshua Hornig, MD 2012-2015Scharukh Jalisi, MD 2012-2015Randal A. Otto, MD 2012-2015Paul L. Friedlander, MD 2012-2013Bhuvanesh Singh, MD, PhD 2012-2013Prevention and Early Detection CommitteeElizabeth A. Blair, MD (Chair) 2010-2013Ann M. Gillenwater, MD 2007-2013Daniel D. Lydiatt, MD, DDS 2007-2013Jay O. Boyle, MD 2010-2013Samir Khariwala, MD 2010-2013Karen T. Pitman, MD 2010-2013Eben L. Rosenthal, MD 2010-2013Hadi Seikaly, MD 2010-2013Uttam K. Sinha, MD 2010-2013Derrick Wallace, MD 2010-2013Joseph A. Califano, MD 2011-2014Michael G. Moore, MD 2011-2014Cherie-Ann O. Nathan, MD 2011-2014Joseph Scharpf, MD 2012-2015Program CommitteeEben L. Rosenthal, MD (Chair) 2012-2013Amit Agrawal, MD 2012-2013Stephen W. Bayles, MD 2012-2013Brandon G. Bentz, MD 2012-2013Jeffrey M. Bumpous, MD 2012-2013Brian B. Burkey, MD 2012-2013William R. Carroll, MD 2012-2013Marion E. Couch, MD 2012-2013Danny Enepekides, MD, FRCS 2012-2013Ramon Esclamado, MD 2012-2013Thomas Gal, MD, MPH 2012-2013Tamer Ghanem, MD, PhD 2012-2013M. Boyd Gillespie, MD, MS 2012-2013Neil D. Gross, MD 2012-2013Patrick K. Ha, MD 2012-2013Matthew M. Hanasono, MD 2012-2013Michael L. Hinni, MD 2012-2013Joshua Hornig, MD 2012-2013Ellie Maghami, MD 2012-2013Publications CommitteeWilliam M. Lydiatt, MD (Chair) 2010-2013Robert L. Ferris, MD, PhD (Co-Chair)2011-2013Dennis H. Kraus, MD (Ex Officio)2012-2013Mark K. Wax, MD (Ex Officio) 2012-2013Brian B. Burkey, MD 2011-2013Jennifer R. Grandis, MD 2011-2013Ehab Y. Hanna, MD 2011-2013Brian Nussenmaum, MD 2011-2013Cecelia Schmalbach, MD, MS 2011-2013Theodoros N. Teknos, MD 2011-2013Marita Shan-Shan Teng, MD 2011-2013Ralph P. Tufano, MD 2011-2013Marilene B. Wang, MD 2011-2013Kelly M. Malloy, MD 2012-2013Susan D. McCammon, MD 2012-2013Eduardo Mendez, MD 2012-2013Oleg Militaskh, MD 2012-2013Brian A. Moore, MD 2012-2013Cherie-Ann O. Nathan, MD 2012-2013Jason G. Newman, MD 2012-2013Brian Nussenbaum, MD 2012-2013Vicente Resto, MD, PhD 2012-2013Jeremy Richmon, MD 2012-2013James Rocco, MD, PhD 2012-2013Hadi Seikaly, MD, FRCSC 2012-2013Yelizaveta Lisa Shnayder, MD 2012-2013Uttam K. Sinha, MD 2012-2013Marita Shan-Shan Teng, MD 2012-2013Teraance T. Tsue, MD 2012-2013Mark A.S. Varvares, MD 2012-2013J. Trad Wadsworth, MD 2012-2013Wendell G. Yarbrough, MD 2011-2013Peter E. Andersen, MD 2012-2014Joseph A. Califano, MD 2012-2014Bruce Campbell, MD 2012-2014Bruce J. Davidson, MD 2012-2014Michael L. Hinni, MD 2012-2014Joshua Hornig, MD 2012-2014Scharukh Jalisi, MD 2012-2014Eduardo Mendez, MD 2012-2014Shawn D. Newlands, MD, PhD 2012-2014Yelizaveta Lisa Shnayder, MD 2012-2014Russell B. Smith, MD 2012-2014Robert A. Weisman, MD 2012-2014Gregory S. Weinstein, MD 2012-201428 AHNS 2013 Annual Meeting

AHNS LeadershipQuality of Care CommitteeAmy C. Hessel, MD (Chair) 2012-2015Elizabeth A. Blair, MD 2010-2013Christopher Klem, MD 2010-2013Jeremy Richmon, MD 2010-2013Stanley H. Chia, MD 2012-2015Bruce J. Davidson, MD 2012-2015Ramon Esclamado, MD 2012-2015Ralph W. Gilbert, MD 2012-2015Christine G. Gourin, MD 2012-2015Relative Value and CPT Advisory CommitteeBrendan C. Stack (Chair) 2012-2015Dennis H. Kraus, MD (Ex Officio)2007-2013Michael L. Hinni, MD 2010-2013Joshua Hornig, MD 2010-2013Neils Kokot, MD 2010-2013Amy-Anne Donatelli Lassig, MD2010-2013Eric J. Moore, MD 2010-2013Peter M. Hunt, MD 2012-2015Michael Kupferman, MD 2012-2015Stephen Y. Lai, MD, PhD 2012-2015Amy-Anne Donatelli Lassig, MD2012-2015Carol Lewis, MD, MPH 2012-2015Brian Nussenbaum, MD 2012-2015Nitin Pagedar, MD 2012-2015Robert L. Witt, MD 2012-2015Peter E. Andersen, MD 2012-2015William R. Carroll, MD 2012-2015Ramon Esclamado, MD 2012-2015Michael J. Kaplan, MD 2012-2015J. Scott Magnuson, MD 2012-2015Randal A Otto, MD 2012-2015Alfred A. Simental, MD 2012-2015David J. Terris, MD 2012-2015Terance T. Tsue, MD 2012-2015Research CommitteeWendell G. Yarbrough (Chair) 2012-2015Nishant Agrawal, MD 2010-2013Christine G. Gourin, MD 2010-2013Walter T. Lee, MD 2010-2013Eben L. Rosenthal, MD 2010-2013John Sunwoo, MD 2010-2013M. Boyd Gillespie, MD 2011-2014Website CommitteeKaren T. Pitman, MD (Chair) 2009-2015Dennis H. Kraus, MD (Ex Officio)2007-2013Brian Nussenbaum, MD 2009-2015Mark A.S. Varvares, MD 2009-2015Marc D. Coltrera, MD 2010-2013Miriam Lango, MD 2010-2013RepresentativesAmerican College of SurgeonsBoard of GovernorsJohn A. Ridge, MD, PhD 2009-2015American Board of OtolaryngologyLiaisonMark K. Wax, MD 2010-2013American Board of OtolaryngolodyMOU InitiativeAmy Y. Chen, MD, MPH 2011-2014American College of SurgeonsCommission on CancerDaniel G. Deschler, MD 2012-2014American College of SurgeonsBoard of Governers AdvisoryCouncil for Otolaryngology- Headand Neck SurgeryTheodoros N. Teknos, MD 2012-2015American Joint Committee onCancerJames Rocco, MD, PhD 2010-2013Dieter C. Gruenert, PhD 2011-2014Louise Davies, MD, MS 2012-2015Ian Ganly, MD, PhD 2012-2015Neil D. Gross, MD 2012-2015Patrick K. Ha, MD 2012-2015Hisham Mehanna, PhD 2012-2015Eduardo Mendez, MD 2012-2015Jeffrey S. Moyer, MD 2010-2013Joshua Hornig, MD 2011-2014Elizabeth A. Blair, MD 2012-2015Emiro E. Caicedo-Granados, MD2012-2015Emad Kandil, MBBCh 2012-2015Young Kim, MD, PhD 2012-2015AAO-HNSF Board of GovernorsD. Gregory Farwell, MD 2012-2014AAO-HNSF Legislative LiaisonJ. Scott Magnuson, MD 2012-2018AAO-HNSF Specialty AdvisoryCouncilDennis H. Kraus, MD 2008-2013Gregory T. Wolf, MD 2011-2014Archives of OtolaryngologyAssociate Co-EditorsWilliam M. Lydiatt, MD 2010-2013Archives of Otolaryngology NewsEditorM. Boyd Gillespie, MD 2010-2013Sisson Lecture Course DirectorsPeter Andersen, MD 2010-2013Karen T. Pitman, MD 2012-2015Thyroid Robotics GroupRepresentativeGregory L. Randolph, MD 2010-2013April 10 - 11, 2013 · www.ahns.info 29

AHNS LeadershipPast PresidentsThe American Head and Neck Society:Carol R. Bradford, MD (2012)David W. Eisele, MD (2011)John A. Ridge, MD (2010)Wayne M. Koch, MD (2009)Gregory T. Wolf, MD (2008)Randal S. Weber, MD (2007)John J. Coleman, III, MD (2006)Patrick J. Gullane, MD (2005)The Society of Head and Neck Surgeons:Jonas T. Johnson, MD (2004)Paul A. Levine, MD (2003)Keith S. Heller, MD (2002)Ernest A. Weymuller, Jr., MD (2001)Jesus E. Medina, MD (2000)Ashok R. Shaha, MD (1999)K. Thomas Robbins, MD (1999)The American Society for Head and Neck Surgery:Dale H. Rice, MD (1997-98)Nicholas J. Cassisi, MD (1996-97)Charles W. Cummings, MD (1995-96)Gary L. Schechter, MD (1994-95)James Y. Suen, MD (1993-94)Bryon J. Bailey, MD (1992-93)Michael E. Johns, MD (1991-92)Helmuth Goepfert, MD (1990-91)Willard N. Fee, Jr., MD (1989-90)Eugene N. Myers, MD (1988-89)Charles J. Krause, MD (1987-88)John M. Lore, Jr., MD* (1986-87)Robert W. Cantrell, MD (1985-86)Hugh F. Biller, MD (1984-85)Paul H. Ward, MD (1983-84)Jerome C. Goldstein, MD (1982-83)Douglas B. Bryce, MD* (1981-82)Ronald H. Spiro, MD (1998)John R. Saunders, Jr., MD (1997)Robert M. Byers, MD (1996)Michael B. Flynn, MD (1995)J. Edward M. Young, MD (1994)Stephen Ariyan, MD (1993)Oscar Guillamondegui, MD (1992)Jatin P. Shah, MD (1991)M.J. Jurkiewicz, MD (1990)James T. Helsper, MD* (1989)Robert D. Harwick, MD (1988)William R. Nelson, MD* (1987)Frank C. Marchetta, MD* (1986)Alando J. Ballantyne, MD* (1985)Darrell A. Jaques, MD (1984)Alvin L. Watne, MD (1983)John M. Moore, MD (1982)Elliot W. Strong, MD (1981)Robert G. Chambers, M.D.* (1980)John C. Gaisford, MD (1979)William A. Maddox, MD (1978)J. Ryan Chandler, MD* (1980-81)Loring W. Pratt, MD (1979-80)William M. Trible, MD* (1978-79)John A. Kirchner, MD (1977-78)George F. Reed, MD* (1976-77)Emanuel M. Skolnick, MD* (1975-76)Daniel Miller, MD* (1974-75)Charles M. Norris, MD* (1973-74)Edwin W. Cocke, Jr., MD* (1972-73)Burton J. Soboroff, MD* (1971-72)John S. Lewis, MD* (1970-71)George A. Sisson, MD* (1969-70)W. Franklin Keim, MD* (1967-69)John F. Daly, MD* (1965-67)Joseph H. Ogura, MD* (1963-65)Paul H. Holinger, MD* (1961-63)John J. Conley, MD* (1959-61)Donald P. Shedd, MD (1977)Condict Moore, MD (1976)Richard H. Jesse, MD* (1975)Alfred Ketcham, MD (1974)Robin Anderson, MD* (1973)Charles C. Harrold, MD* (1972)Harvey W. Baker, MD* (1971)Ralph R. Braund, MD* (1970)William S. MacComb, MD* (1969)Arthur G. James, MD* (1968)Oilver H. Beahrs, MD* (1967)Edgar L. Frazell, MD* (1966)Harry W. Southwick, MD* (1965)Calvin T. Kloop, MD* (1964)H. Mason Morfit, MD* (1962-63)Arnold J. Kremen, MD (1960-61)Danely P. Slaughter, MD* (1959)Grant Ward, MD * (1958)Hayes Martin, MD* (1954-1957)*Deceased30 AHNS 2013 Annual Meeting

Robert Maxwell Byers BiographyRobert Maxwell ByersThe Robert Maxwell Byers Award, in the amount of$1000, is awarded for the best clinical or basic scienceresearch paper submitted for presentation at the annualmeeting of the American Head and Society.Robert Maxwell Byers, M.D. was born in Union Hospital,Baltimore, Maryland on September 24, 1937. He grewup on the Eastern Shore of Maryland in the small townof Elkton. Very active in the varsity sports of baseball,basketball and track during his high school years, hecontinued his athletic participation at Duke University along with his premedstudies. He entered the University of Maryland Medical School inBaltimore in 1959 where he excelled in his medical studies and receivedmembership in AOA and the Rush Honor Medical Society. The highlight ofhis sophomore year was his 1961 marriage to Marcia Davis, his high schoolsweetheart. During his junior year, he was commissioned an Ensign in theUnited States Naval Reserve and later rose to the rank of Captain in 1986.In 1963, Dr. Byers begin his general surgical residency with Dr. RobertBuxton at the University Hospital in Baltimore. Five years later, as a fullytrained general surgeon, he went to the Republic of Vietnam with the1st Marine Division where he received a unit commendation medal anda combat action ribbon. On return to the United States, he spent a yearat Quonset Point, Rhode Island Naval Hospital as Chief of Surgery. In1969, he was certified by the American Board of Surgery. After dischargefrom the Navy in 1970, Dr. Byers and his family moved to Houston, Texaswhere he began a fellowship in Surgical Oncology at the University ofTexas M.D. Anderson Cancer Center under the guidance of Drs. R. LeeClark, Richard Martin, Ed White, William MacComb, Richard Jesse andAlando J. Ballantyne. This move proved to be a decisive event, as he neverleft. His career in Head and Neck Surgical Oncology was born, nurtured,and matured during the 31 years of his academic/clinical practice at theUniversity of Texas M.D. Anderson Cancer Center.During his tenure at M.D. Anderson Cancer Center he rose through theranks from Assistant Professor in 1972 to Associate Professor in 1976 and,finally, Professor and Surgeon in 1981.In 1998, he was honored with the Distinguished Alando J. BallantyneChair of Head and Neck Surgery. He is the author or co-author of over 200published papers, book chapter and monographs. He has given invitedlectures all over the world. Most recently (1999), he was selected to givethe Hayes Martin Memorial Lecture at the 5th International Conference onHead and Neck Cancer. He has been President of the American RadiumSociety and President of the Society of Head and Neck Surgeons both in1995 - 1996. His research interests and his expertise have been focusedon cancer of the oral cavity, head and neck cancer in young people andtreatment of the neck involved with metastatic cancer with a particularinterest in various neck dissections. Dr. Byers is a member of manyprestigious societies, of which the Southern Surgical Association, the TexasSurgical Society, the American College of Surgeons and the Society ofSurgical Oncologists are but a few. He is a peer reviewer for many medicaljournals and on the Editorial Board of three. During his 31 years at theUniversity of Texas M.D. Anderson Cancer Center, he has participated inthe surgical education of over 300 residents and fellows, many of whohave gone on to become prominent members of the specialty. The youthcommunity of Houston has benefited from his coaching expertise inbaseball and basketball while he has indulged in the hobbies of hunting,travel, and collecting toy soldiers.April 10 - 11, 2013 · www.ahns.info 31

AHNS Education and Research FoundationThe Research and Education Foundation of the AmericanHead and Neck Society extends a special thank you to our2013 Centurion Club* members for their generous donationsof $1,000 or more:Elliot AbemayorCarol Bier-LaningElizabeth BlairJoseph CalifanoBruce CampbellWilliam CarrollPeter CostatinoTerrence DayDavid EiseleRamon EsclamadoRobert FerrisMarvin Boyd GillespieDoug GirodDavid GoldenbergPatrick GullaneEhab HannaJonas JohnsonDennis KrausGreg KremplPierre LavertuDerrick LinBill LydiattEllie MaghamiMatthew MillerEugene MyersBrian NussenbaumJohn O’BrienNitin PagedarLester PetersKaren PitmanJohn RidgeEben RosenthalJohn SaundersJatin ShahUttam SinhaKerstin StensonDavid TerrisMarilene WangMark WaxRandal WeberWilliam WeiGregory WeinsteinMark WeisslerErnest WeymullerWendell YarbroughBevan Yueh*List as of March 12, 2013The Research and Education Foundation of the American Head and Neck Societywould like to thank our supporters who gave $100 or more in 2012:Elliot AbemayorCarol Bier-LaningBryan R. BellElizabeth BlairCarol BradfordJohn BrockenbroughBrian BurkeyMary ByrneJoseph CalifanoBruce CampbellWilliam CarrollChin-Yen ChienHui-Ching ChuangPeter ConstantinoTerrence DayDaniel DeschlerDavid EiseleJoel ErnsterRamon EsclamadoRobert FerrisGerry FunkRalph GilbertMarvin Boyd GillespieDoug GirodDavid GoldenbergPatrick GullaneGary Har-ElAndrew and Jan HaynesKeith HellerHouston Society of OHNSJonas JohnsonLuiz KowalskiDennis KrausGreg KremplPierre LavertuJeffrey Le BengerJohn LeeWilliam LydiattEllie MaghamiMariann MoranEugene MyersBrian NussenbaumJohn O’BrienRobert ParkeLester PetersKaren PitmanJose PoliJohn RidgeThomas RobbinsJames RoccoEben RosenthalJohn SaundersMark SaundersJatin ShahUttam SinhaMichael StadlerKerstin StensonElliot StrongKrishnamurthi SundaramDavid TerrisJose Guilherme VartanianMarilene WangMark WaxJacklin WeberRandal WeberWilliam WeiGregory WeinsteinMark WeisslerErnest WeymullerCheryl WhiteGregory WolfWendell YarbroughBevan YuehApril 10 - 11, 2013 · www.ahns.info 33

CME WorksheetThis is not your CME credit form. Please use the worksheet below totrack the number of CME hours you attend for each activity. Fill in thenumber of hours you attended each activity in the chart below to trackyour CME credits.WEDNESDAY, APRIL 10, 2013TimeActivityCreditsAvailable8:00 AM - 8:15 AM Welcome and Introduction ofGuest of Honor08:15 AM - 9:15 AM Panel: Implementation of Quality inHead & Neck Surgry19:15 AM - 10:00 AM Hayes Martin Lecture:“Dysphagia: A Silent Killer”.7510:30 AM - 11:30 AM Scientific Session #1 111:30 AM - 12:30 PM Panel: Contemporary Managementof Oropharynx11:30 PM - 2:30 PM Scientific Session #2 12:30 PM - 3:30 PM Panel: Current Trends in ManagementNMSC14:00 PM - 5:00 PM Scientific Session #3 15:00 PM - 6:00 PM Panel: Thyroid Controversies InManagement & Diagnosis1Total Credits Available for Wednesday, April 10, 2013: 7.75THURSDAY, APRIL 11, 2013TimeActivityCreditsAvailable8:00 AM - 9:00 AM Scientific Session #4 19:00 AM - 9:45 AM John Conley Lecture:“What Would Dr. Conley Think?”.759:45 AM - 10:00 AM AHNS Awards Ceremony 010:30 AM - 10:35 AM Introduction of the AHNS President 010:35 AM - 11:15 AM AHNS Presidential Address,Distinguished Service Award and .5Presidential Citations11:15 AM - 12:15 PM Jatin P. Shah Symposium onClinical Controversies in Head andNeck Surgery: “Controversies inHead & Neck Cancer Management1& Reconstruction: Debating theCurrent Standard of Care”1:15 PM - 2:15 PM Scientific Session #5 12:15 PM - 3:15 PM Panel: Evidence Based Managementof Oral Cavity Cancer13:45 PM - 5:00 PM Scientific Session #6 1.25Total Credits Available for Thursday, April 11, 2013: 6.5TOTAL CREDITS AVAILABLE 14.2534 AHNS 2013 Annual MeetingHoursAttendedHoursAttendedTo receive your CME credit:AHNS has instituted a process for claiming CME credits and printingcertificates. All attendees wishing to receive a CME certificate foractivities attended at the AHNS 2013 Annual Meeting must first completean on-line meeting evaluation form. Attendees will have access to theon-line form via link on the AHNS website after the meeting. Pleaseallow 4-6 weeks for processing before your certificate arrives.

AHNS AccreditationThe American Head & Neck Society (AHNS) is accredited by theAccreditation Council for Continuing Medical Education (ACCME) tosponsor Continuing Medical Education for physicians.The AHNS designates this activity for a maximum of 14.25 AMAPRA Category 1 Credit(s). Physicians should only claim creditcommensurate with the extent of their participation in the activity.Questions?Comments?Join the conversation behind the scenes …Tweet!#AHNS2013Follow us @AHNSinfoApril 10 - 11, 2013 · www.ahns.info 35

Commercial Bias Reporting FormYou are encouraged to …1) Document (on this form) any concerns about commercially-biasedpresentations/materials during educational sessions,2) Make suggestions about how bias might have been avoided/minimized, and3) Immediately take your completed form to the AHNS staff at theRegistration DeskYour feedback will be shared with a member of the CME ComplianceCommittee, who will make the faculty aware of the concerns and/orsuggestions.Commercial BiasThe AHNS CME Compliance Committee has defined “bias” as anexisting predisposition that may interfere with objectivity in judgment.Bias may be minimized through prior declaration of any source ofconflict of interest, reference to evidence-based literature and expertopinions, and/or an independent peer-review process.If an educational presentation certified for CME includes bias of anycommercial interests*, please provide the following details:(*Commercial interest is defined by the ACCME as an entity producing,marketing, re-selling, or distributing health care goods or servicesconsumed by, or used on, patients.)Presentation: Commercial Bias by: Promotion via:(eg session name, etc) (ie faculty name, company rep) (eg handouts, slides, whatthey said, actions)Commercial Bias about:(check all that apply)Patient treatment/management recommendations were not based on strongestlevels of evidence available.Emphasis was placed on one drug or device versus competing therapies, andno evidence was provided to support its increased safety and/or efficacy.Trade/brand names were used.Trade names versus generics were used for all therapies discussed.The activity was funded by industry and I perceived a bias toward the grantors.The faculty member had a disclosure and I perceived a bias toward thecompanies with which he/she has relationships.Other (please describe): __________________________________________________________________________________________________________________________________________________________________________________________________________Suggestions for avoiding or minimizing bias:______________________________________________________________________________________________________________________________________________________________________________________________________Extra Copies Are Available at the AHNS DeskPlease return this form to the AHNS Membership Boothor the Registration Desk, or mail it to:AHNS CME, 11300 W. Olympic Blvd, Suite 600,Los Angeles, CA 9006436 AHNS 2013 Annual Meeting

Wednesday, April 10, 2013 Thursday, April 11, 2013Scientific Program Wednesday, April 10, 201310:30 - 11:30 AM Scientific Session #1: Mediterranean 5Discussion SessionModerators: Floyd “Chris” Holsinger, MD, Eben L.Rosenthal, MD and David J. Terris, MD10:30 AM S001: TRANSORAL ROBOTIC SURGERY FOR OROPHARYNGEALCANCER: LONG TERM QUALITY OF LIFE AND FUNCTIONALOUTCOMES. Peter T Dziegielewski, MD, FRCSC, K Durmus, MD, TN Teknos, MD, FACS, M Old, MD, FACS, A Agrawal, MD, FACS, KKakarala, MD, FACS, E Ozer, MD; The Ohio State University.10:38 AM COMMENTARY William M. Lydiatt, MD10:44 AM COMMENTARY Bruce H. Haughey, MD10:50 AM S002: THE IMPACT OF PHARYNGEAL CLOSURE TECHNIQUE ONFISTULA AFTER SALVAGE LARYNGECTOMY. Urjeet A Patel, MD,Brian Moore, MD, Mark Wax, MD, Eben Rosenthal, MD, LarissaSweeny, MD, Oleg Militsakh, MD, Joseph A Califano, MD, Alice CLin, MD, Christine P Hasney, MD, R B Butcher, MD, Jamie Flohr, MD,Demetri Arnaoutakis, MD, Matthew Huddle, MD, Jeremy D Richmon,MD; Northwestern University, Chicago, IL; Oschner Health System,New Orleans, LA; Oregon Health Science University, Portland, OR;University of Alabama, Birmingham, AL; University of NebraskaMedical Center, Omaha, NE; Johns Hopkins Hospital, Baltimore, MD.10:58 AM COMMENTARY Matthew M. Hanasono, MD11:04 AM COMMENTARY Eric Genden, MD11:10 AM S003: SO-CALLED TOTAL THYROIDECTOMY: MEASURING THEEXTENT OF THYROID SURGERY WITH RAI. Juntian Lang, MD, PhD,Uma Ramaswamy, Eric Rohren, MD, Naifa L Bussaidy, MD, Maria ECabanillas, MD, Randal S Weber, MD, FACS, Christopher F Holsinger,MD, FACS; The University of Texas MD Anderson Cancer Center.11:18 AM COMMENTARY Ralph P. Tufano, MD11:24 AM COMMENTARY Gregory L. Randolph, MD11:30 - 12:30 PM Panel: Contemporary Mediterranean 5Management Of OropharynxPanel Moderator: Robert L. Ferris, MDA series of short “state of the art” talks on surgicaland non-surgical therapy for oropharynx cancer willbe presented, followed by real-life decision making bynational leaders based on model oropharynx cancer casesfor HPV+ and HPV- disease cases.11:30 AM HPV+: Does adding transoral surgery Robert L. Ferris, MD, PhDeffectively permit de-escalation and improve functional outcome?11:40 AM HPV- Disease: Floyd “Chris” Holsinger, MDCan Transoral Surgery Improve Survival?11:50 AM What is Optimal Nonsurgical Management Ezra E.W. Cohen, MDfor Oropharynx Cancer, Induction Chemotherapyor Concurrent Chemoradiation?12:00 PM Optimal Reconstruction after Salvage Surgery Eben L. Rosenthal, MDfor Recurrent Oropharync Cancer?12:10 PM Cases for Discussion Andrea “Andy” Trotti, MDAt the conclusion of this session, participants will be able to:• Describe the role of up-front transoral surgery to reducethe intensity of adjuvant therapy for HPV+ for goodprognoses HPV+ disease• Discuss the likelihood of survival improvement byadding up-front transoral surgery and adjuvant radiation/chemoradiation38 AHNS 2013 Annual Meeting

Scientific Program Wednesday, April 10, 2013• Understand the current prospectively obtained evidencein support of concurrent chemoradiation versusinduction chemotherapy• Be aware of the reconstructive options for recurrent/salvage surgery for recurrent oropharynx cancerThe AHNS gratefully acknowledges educational grants in supportof this panel from CelSci Corporation and OmniGuide, Inc.12:30 - 1:30 PM AHNS Business Meeting or Mediterranean 5Lunch on Own1:30 - 2:30 PM Scientific Session #2: Mediterranean 5ReconstructionModerators: Oleg Militsakh, MD and Marita S. Teng, MD1:30 PM S004: DONOR SITE MORBIDITY IN ELDERLY PATIENTS AFTERFASCIOCUTANEOUS FREE TISSUE TRANSFER. Jacob L Wester, BS,Amy Pittman, MD, Robert H Lindau, MD, Mark K Wax, MD; OregonHealth and Science University.1:38 PM S005: USE OF THE SUPRACLAVICULAR ARTERY ISLAND FLAP INHEAD AND NECK ONCOLOGIC RECONSTRUCTION: APPLICATIONSAND LIMITATIONS. Niels Kokot, MD, Grace Peng, MD, KashifMazhar, MD, Lindsay Reder, MD, Uttam K Sinha, MD; Keck School ofMedicine, University of Southern California.1:46 PM S006: DISPOSITION OF ELDERLY PATIENTS FOLLOWING HEAD ANDNECK MICROVASCULAR RECONSTRUCTION. Jeanne L Hatcher, MD,Elizabeth B Bell, BS, Joshua D Waltonen, MD; Wake Forest School ofMedicine.1:54 PM Discussion (6 minutes)2:00 PM S007: PATHOLOGICALLY DETERMINED TUMOR VOLUMEOUTPERFORMS T STAGE IN THE PREDICTION OF OUTCOMEFOLLOWING SURGICAL TREATMENT OF OROPHARYNGEALSQUAMOUS CELL CARCINOMA. Frank L Palmer, Dr. Nancy Y Lee, Dr.Ian Ganly, Dr. Iain J Nixon; Memorial Sloan Kettering Cancer Center.2:08 PM S008: USE IT OR LOSE IT: SWALLOWING EXERCISE ANDMAINTENANCE OF ORAL INTAKE DURING RADIOTHERAPY OFCHEMORADIOTHERAPY FOR OROPHARYNGEAL CANCERS.Katherine A Hutcheson, PhD, Mihir K Bhayani, MD, Beth M Beadle,MD, PhD, Kathryn A Gold, MD, Eileen H Shinn, PhD, Stephen Y Lai,MD, PhD, Jan S Lewin, PhD; The University of Texas MD AndersonCancer Center, The University of Chicago Pritzker School of Medicine.2:16 PM S009: A COMPARISON OF OUTCOMES USING IMRT AND 3DCRT INTREATMENT OF OROPHARYNGEAL CANCER. Shivangi Lohia, BA,Mayuri M Rajapurkar, MD, Anand K Sharma, MD, Terry A Day, MD;Medical University of South Carolina.2:24 PM Discussion (6 minutes)The AHNS gratefully acknowledges a generous educational grantin support of this session from Stryker.Wednesday, April 10, 2013 Thursday, April 11, 20132:30 - 3:30 PM Panel: Current Trends Mediterranean 5in Management NMSCPanel Moderator: Cecelia Schmalbach, MD, MSThis panel will review current challenges, and provideevidence based literature, for the management of headand neck non-melanoma skin cancer (NMSC). Casebased presentations with audience participation willhighlight the management of high-risk NMSC, the role ofobservation, elective neck dissection, and sentinel nodebiopsy in the N-zero neck, the therapeutic horizons toinclude adjuvant radiation, chemotherapy and targetedagents and important considerations for successful NMSCreconstruction.April 10 - 11, 2013 · www.ahns.info 39

Wednesday, April 10, 2013 Thursday, April 11, 2013Scientific Program Wednesday, April 10, 20132:30 PM Identifying the High-Risk Patient and William R. Carroll, MDManaging Their Recurrent Disease2:42 PM Management of the N-zero in NMSC: Brian A. Moore, MDObservation, Dissection or Sentinel Node Biopsy2:54 PM Adjuvant Treatment & Michael Kupferman, MDTherapeutic Horizons for NMSC3:06 PM Reconstructive Principles Daniel Alam, MDFollowing NMSC Resection3:18 PM Panel Discussion All PanelistsAt the conclusion of this session, participants will be able to:• Identify and accurately stage high risk NMSC patientsusing the current American Joint Committee on Cancer(AJCC) system• Appropriately utilize sentinel node biopsy, elective neckdissection, and patient observation in the managementof N-zero NMSC patients• Discuss the role of adjuvant treatment to includeradiation, chemotherapy, and targeted agents• Develop a reconstructive algorithm to successfullymanage NMSC patients undergoing surgical extirpation3:30 - 4:00 PM Afternoon Break Coquina Ballroom4:00 - 5:00 PM Scientific Session #3: Mediterranean 5RoboticsModerators: Tamer Ghanem, MD, PhD andJ. Scott Magnuson, MD4:00 PM S010: PROGNOSTIC SIGNIFICANCE OF IMMUNE COMPROMISE ANDHISTOLOGIC RISK FACTORS FOR LOCAL CONTROL AND SURVIVALIN TLM-TRETED ORAL CAVITY SQUAMOUS CELL CARCINOMA.Parul Sinha, MBBS, MS, Mitra Mehrad, MD, Rebecca D Chernock,MD, James S Lewis Jr, MD, Samir K El-Mofty, DMD, PhD, BrianNussenbaum, MD, Bruce H Haughey, MBChB, FACS, FRACS;Washington University School of Medicine.4:08 PM S011: TRANSORAL ROBOTIC SURGERY (TORS): SIMULATION-BASEDSTANDARDIZED TRAINING. Ning Zhang, Baran D Sumer, MD;University of Texas Southwestern Medical Center.4:16 PM S012: ROBOT-ASSISTED COMPREHENSIVE NECK DISSECTION VIAA TRANSAXILLARY AND RETROAURICULAR (“TARA”) APPROACHIN PAPILLARY THYROID CANCER WITH CERVICAL LYMPH NODEMETASTASES: A COMPARATIVE STUDY WITH THE TRANSAXILLARYAPPROACH. Won Shik Kim, MD, Yoon Woo Koh, MD, PhD, Jae WookKim, MD, Hyun Jun Hong, MD, Hyung Kwon Byeon, MD, Young MinPark, MD, Hyo Jin Chung, MD, Sang Chul Park, MD, Michelle J. Suh,MD, Eun Jung Lee, MD, Eun Chang Choi, MD, PhD; 1Department ofOtorhinolaryngology, Yonsei University College of Medicine, Seoul,Korea 2Department of Otolaryngology–Head and Neck Surgery,Soonchunhyang University College of Medicine, Seoul, Korea.4:24 PM Discussion (6 minutes)4:30 PM S013: SURGEON EXPERIENCE AND COMPLICATIONS WITHTRANSORAL ROBOTIC SURGERY (TORS). Stanley H Chia, MD, FACS,Neil D Gross, MD, FACS, Jeremy Richmon, MD, FACS; MedstarWashington Hospital Center, Medstar Georgetown UniversityHospital, Oregon Health Sciences University, Johns Hopkins Hospital.4:38 PM S014: ANALYSIS OF POSTOPERATIVE BLEEDING IN TRANSORALLASER MICROSURGERY OF THE OROPHARYNX. Taylor R Pollei, MD,Michael L Hinni, MD, Eric J Moore, MD, Richard E Hayden, MD, LoganC Walter, BS, Kerry D Olsen, MD; Mayo Clinic Phoenix, Arizona; MayoClinic Rochester, MN.40 AHNS 2013 Annual Meeting

Scientific Program Wednesday, April 10, 20134:46 PM S015: SURGICAL FEASIBILITY AND ONCOLOGIC SAFETY OF ROBOT-ASSISTED NECK DISSECTION FOLLOWED BY TRANSORAL ROBOTICSURGERY (TORS) IN HEAD AND NECK CANCER. Hyung Kwon Byeon,MD, Jae Wook Kim, MD, Eun Sung Kim, MD, Hyo Jin Chung, MD,Eun Jung Lee, MD, Hyun Jun Hong, MD, Won Shik Kim, MD, YoonWoo Koh, MD, PhD, Eun Chang Choi, MD, PhD; 1Department ofOtorhinolaryngology, Yonsei University College of Medicine, Seoul,Korea 2Department of Otolaryngology–Head and Neck Surgery,Soonchunhyang University College of Medicine, Seoul, Korea.4:54 PM Discussion (6 minutes)5:00 - 6:00 PM Panel: Thyroid Controversies Mediterranean 5in Management & DiagnosisPanel Moderators: Cherie-Ann O. Nathan, MD andDavid J. Terris, MD, PhDThis session will discuss the controversies andchallenges in the diagnosis and management ofthyroidectomy to include the work up of a thyroid nodulefocusing on the indeterminate group, determiningthe extent of surgery for thyroid cancers in this ageof personalized medicine with emphasis on ATAguidelines. In addition, controversies in the approach tothyroidectomy and inpatient v/s outpatient stay will beaddressed.5:00 PM Cervical vs. Extra-Cervical Thyroid Surgery Jeremy Richmon, MD5:10 PM Molecular Diagnostics Can Change the Cherie-Ann O. Nathan, MDDiagnosis and Management of Thyroid Cancer5:20 PM Postoperative Management: David J. Terris, MDSame-Day Surgery vs. Overnight Stay5:30 PM Risk Groups Determine Extent of Ashok R. Shaha, MDTreatment for WDTC5:40 PM Panel Discussion All PanelistsAt the conclusion of this session, participants will be able to:• Increase awareness of alternative approaches includingremote access• Incorporate the technique of diagnostic molecular panelsin the diagnosis and management of well differentiatedthyroid cancers• Properly select patients eligible for outpatient careWednesday, April 10, 2013 Thursday, April 11, 20136:00 - 6:45 PM Fellowship Mediterranean 5Information SessionJay O. Boyle, MD and William M. Lydiatt, MDAttend the fellowship information session and learn whatfellowships are available and network with programdirectors.April 10 - 11, 2013 · www.ahns.info 41

Wednesday, April 10, 2013 Thursday, April 11, 2013Scientific Session Thursday, April 11, 2013THURSDAY, APRIL 11, 20137:00 - 7:30 AM NCI-sponsored Clinical Trials Mediterranean 5in Transoral Endoscopic H&NSurgery: Open Forum andInvestigators’ MeetingThis session is not accredited for CMERobert L. Ferris, MDFloyd “Chris” Holsinger, MDObjectives:• To review eligibility criteria and primary objectives forHPV+ (ECOG3311) and HPV- (RTOG1221) clinical trials• To review clinical research infrastructure requirementsto participate in NCI-sponsored clinical trials.• To review requirements for surgeon credentialing andongoing quality assurance8:00 - 9:00 AM Scientific Session #4: Mediterranean 5Thyroid/GeneralModerators: Jeffrey M. Bumpous, MD andEllie Maghami, MD8:00 AM S016: SIGNIFICANT FAMILIAL RISK IN MULTIPLE GENERATIONS OFPAPILLARY THYROID CARCINOMA PROBANDS. Gretchen M Oakley,MD, Karen Curtin, PhD, Luke O Buchmann, MD, Elke Jarboe, MD,Jason P Hunt, MD; University of Utah Health Sciences Center. *BestResident Clinical Paper Award Winner8:08 AM SO17: MALIGNANCY RATE AND SUBSTRATIFICATION EFFICACY INTHYROID NODULES CLASSIFIED AS ATYPIA OF UNDETERMINEDSIGNIFICANCE. Allen S Ho, MD, Evan Sarti, DO, Hangjun Wang, MD,Kunal S Jain, MD, Oscar Lin, MD, Iain J Nixon, MD, Ashok R Shaha,MD, Jatin P Shah, MD, R. Michael Tuttle, MD, Ronald Ghossein, MD,Richard J Wong, MD, Luc G.T. Morris, MD, MSc; Memorial Sloan-Kettering Cancer Center.8:16 AM S018: CAUSES OF EMERGENCY ROOM VISITS FOLLOWING THYROIDAND PARATHYROID SURGERY. William G Young, MD, Linda Hsu, BS,Eric Succar, BS, Gary Talpos, MD, FACS, Tamer A Ghanem, MD, PhD;Henry Ford Hospital.8:24 AM Discussion (6 minutes)8:30 AM S019: COMBINED MODALITY TREATMENT OUTCOMES FOR HEADAND NECK CANCER: COMPARISON OF CARE AT AN ACADEMICCANCER CENTER VERSUS ACADEMIC-TO-COMMUNITY TRANSFER,2002-2012. Jonathan R George, MD, MPH, Sue S Yom, MD, PhD,Steven J Wang, MD; University of California, San Francisco.8:38 AM S020: DESIGNING THE NEXT GENERATION OF BIOREACTORS FORSTEM-CELL TRACHEAL TRANSPLANTATION. Hunter Faircloth, BS,Don Mettenberg, AS, Aaron Cunningham, BS, Matt Jones, MSECE,Madelaine Dubin, Frederick Rueggeberg, DDS, Gregory Postma, MD,Paul Weinberger, MD; Georgia Health Sciences University.8:46 AM S021: RISK FACTORS FOR PLACEMENT OF A PERCUTANEOUSENDOSCOPIC GASTROSTOMY TUBE DURINGCHEMORADIOTHERAPY FOR OROPHARYNGEAL SQUAMOUS CELLCARCINOMA. Tobin Strom, MD, Andy Trotti, MD, Nikhil G Rao, MD,Julie A Kish, MD, Judith C McCaffrey, MD, Tapan Padhya, MD, JimmyJ Caudell, MD, PhD; H. Lee Moffitt Cancer Center.8:54 AM Discussion (6 minutes)42 AHNS 2013 Annual Meeting

Scientific Session Thursday, April 11, 20139:00 - 9:45 AM John J. Conley Lecture Mediterranean 5“What Would Dr. Conley Think?”Patrick J. Gullane, MD, Wharton Chair Head and NeckSurgery, Professor and Former Chair, Department ofOtolaryngology- Head and Neck Surgery, Professor ofSurgery, Faculty of Medicine, University of TorontoIntroduction by Mark K. Wax, MDThe AHNS gratefully acknowledges educational grants in support of this lecturefrom our Platinum Supporters- CelSci Corporation, OmniGuide, Inc. and Pfizer.9:45 - 10:00 AM AHNS Awards Ceremony Mediterranean 5Presented by: D. Gregory Farwell, MD andWendell G. Yarbrough, MD• AHNS Alando J. Ballantyne Resident Research Pilot Grant• AHNS Pilot Research Grant• AHNS/AAO-HNS Young Investigator Award, in Memory ofDuane A. Sewell, MD• AHNS/AAO-HNSF Translational Innovator Combined Award• Robert Maxwell Byers Award• Best Resident Basic Science Research Paper• Best Resident Clinical Paper10:00 - 10:30 AM Morning Break with ExhibitorsWednesday, April 10, 2013 Thursday, April 11, 201310:00 - 10:35 AM Introduction of the Mediterranean 5AHNS PresidentIntroduced by AHNS President-Elect Terry A. Day, MD10:35 - 11:15 AM AHNS Presidential Address, Mediterranean 5Distinguished Service Awardand Presidential Citations“A New Paradigm in Life LongLearning: Removing the Silos”Mark K. Wax, MD, Oregon Health and Science University,Portland, OregonDistinguished Service AwardDennis H. Kraus, MDPresidential CitationsBrian B. Burkey, MDNeal D. Futran, MD, DMDPaul A. Levine, MDJeffrey N. Myers, MD, PhDStephen J. Wetmore, MD, MBAApril 10 - 11, 2013 · www.ahns.info 43

Wednesday, April 10, 2013 Thursday, April 11, 2013Scientific Session Thursday, April 11, 201311:15 AM - 12:15 PM Jatin P. Shah Symposium Mediterranean 5on Clinical Controversies inHead and Neck Surgery“Controversies in Head & Neck CancerManagement & Reconstruction:Debating the Current Standard of Care”Panel Moderator: Gregory D. Farwell, MD11:15 AM Post Therapy Imaging for Brendan C. Stack, Jr. MD & Mike Yao, MDTumor Surveillance11:35 AM Salvage Neck Dissection: Dennis H. Kraus, MD & Kerstin M. Stenson, MDWho and When to Operate11:55 PM 3D Modeling for Head Matthew M. Hanasono, MD & Mark K. Wax, MDand Neck ReconstructionAt the conclusion of this session, participants will be able to:• Identify the role of imaging in the post-treatmentmanagement of head and neck cancer patients• Determine when salvage neck dissection is absolutelynecessary and when observation is acceptable• Describe the role of surgical planning in head and neckcancer reconstruction12:15 - 1:15 PM Lunch with Exhibitors Coquina Ballroom1:15 - 2:15 PM Scientific Session #5: Mediterranean 5Salivary/GeneralModerators: Nishant Agarwal, MD andKaren T. Pitman, MD1:15 PM S022: PROGNOSTIC FACTORS ASSOCIATED WITH DECREASEDSURVIVAL IN ACINIC CELL CARCINOMA. David M Neskey, MD,Jonah D Klein, MS, Adam S Garden, MD, Diana Bell, MD, Adel K El-Naggar, MD, PhD, Merrill S Kies, MD, Randall S Weber, MD, Michael EKupferman, MD; UT MD Anderson Cancer Center.1:23 PM S023: RACIAL AND ETHNIC DISPARITIES IN SALIVARY GLANDCANCER SURVIVAL. Shani J Ortiz, BS, Vicente A Resto, MD, PhD, TravisP Schrank, MD, PhD; The University of Texas Medical Branch.1:31 PM S024: MANAGEMENT OF THE NECK IN CARCINOMA OF THE PAROTIDGLAND. Safina Ali, MD, Frank L Palmer, BA, Monica Whitcher, BA,Jatin P Shah, MD, Snehal G Patel, MD, Ian Ganly, MD, PhD; MemorialSloan-Kettering Cancer Center.1:39 PM Discussion (6 minutes)1:45 PM S025: PROGNOSTIC FACTORS OF LOCALIZED SINONASALMUCOSAL MELANOMA. Adil Benlyazid, MD, Thomas Filleron, PhD;Institut Claudius Regaud.1:53 PM S026: SUPRACRICOID PARTIAL LARYNGECTOMY FOR PRIMARYAND RECURRENT LARYNGEAL CANCER. Steven M Sperry, MD,Christopher H Rassekh, MD, Gregory S Weinstein, MD; University ofPennsylvania. *Robert Maxwell Byers Award Winner2:01 PM S027: IMPACT OF SURGICAL RESECTION ON SURVIVAL IN PATIENTSWITH ADVANCED REGIONAL METASTATIC HEAD AND NECK CANCERINVOLVING CAROTID ARTERY. Nauman Manzoor, MD, JonathonRussell, MD, Shlomo Koyfman, MD, Joseph Scharpf, MD, BrianBurkey, MD, Mumtaz Khan, MD; Head and Neck Institute / ClevelandClinic Foundation, Cleveland, Ohio, USA.2:09 PM Discussion (6 minutes)44 AHNS 2013 Annual Meeting

Scientific Session Thursday, April 11, 20132:15 - 3:15 PM Panel: Evidence Based Mediterranean 5Management of Oral Cavity CancerPanel Moderators: Brian Nussenbaum, MD andHadi Seikaly, MD, FRCSCThis panel will review and discuss current practices in themanagement of oral cavity carcinoma. Using evidencebased medicine and data to support the expert opinions,the current role surgery (including considerationsof biomarkers), role of chemoradiation as definitiveor adjuvant therapy, and the role of reconstruction(particularly focusing on glossectomy and lateralmandibulectomy defects) in the treatment of oral cavitycarcinoma will be highlighted.2:15 PM Evidence for Surgery: Will Management Eduardo Mendez, MDDecisions Change with the Use of Biomarkers in 20132:30 PM Evidence for Definitive or Adjunctive Kerstin M. Stenson, MDUse of Chemoradiation: Standard Therapy in 20132:45 PM Evidence for Reconstruction: Eric Genden, MDReporting Functional Outcomes in 20133:00 PM Panel Discussion All PanelistsAt the conclusion of this session, participants will be able to:• Describe NCCN guidelines for management of oral cavitycancer• Discuss evidence based principles for the appropriate use ofsurgery, radiation, and chemoradiation in the managementof oral cavity patients, and how to incorporate thesetherapies in the most effective manner• Understand how to make treatment decisions regardingreconstruction of oral cavity defects, with the abundance ofexpert opinion and lack of comparative effectiveness studies• Recognize the emerging role of using biomarkers in thispatient population and how these biomarkers may beincorporated into future evidence based medicine treatmentguidelinesThe AHNS acknowledges a generous educational grantin support of this panel from CelSci Corporation.Wednesday, April 10, 2013 Thursday, April 11, 20133:15 - 3:45 PM Afternoon Break Coquina Ballroom3:45 - 4:45 PM Scientific Session #6: Mediterranean 5Basic ScienceModerators: Eduardo Mendez, MD andWendell G. Yarbrough, MD3:45 PM S028: FOLATE RECEPTOR BETA TARGETING FOR INVIVO OPTICALIMAGING OF HEAD AND NECK SQAMOUIS CELL CARCINOMA. JoelY Sun, Joel Thibodeaux, Gang Huang, Yiguang Wang, Jingming Gao,Philip S Low, Baran D Sumer; University of Texas SouthwesternMedical Center; Purdue University.3:53 PM S029: DECITABINE AND CISPLATIN COMBINATION THERAPY FORHEAD AND NECK SQUAMOUS CELL CARCINOMA. Chi T Viet, DDS,PhD, Dongmin Dang, MD, Yi Ye, PhD, Brian L Schmidt, DDS, MD, PhD;New York University, Bluestone Center for Clinical Research.*Best Resident Basic Science Paper Award Winner4:01 PM S030: USE OF RETINOBLASTOMA PROTEIN (PRB)IMMUNOHISTOCHEMICAL STAINING AS A PROGNOSTIC INDICATORIN OROPHARYNGEAL SQUAMOOUS CELL CARCINOMA. Adam LBaker, MD, Joseph Curry, MD, Gao W, BS, Cognetti D, MD, T Zhan,PhD, V Bar-Ad, MD, M Tuluc, MD; Thomas Jefferson University,Departments of Otolaryngology, Radiation Oncology, andPathology.April 10 - 11, 2013 · www.ahns.info 45

Wednesday, April 10, 2013 Thursday, April 11, 2013Scientific Session Thursday, April 11, 20134:09 PM Discussion (6 minutes)4:15 PM S031: ROLE OF HPV DNA DETECTION IN PLASMA AND SALIVA INTHE EARLY DETECTION AND PREDICTION OF RECURRENCE INHPV POSITIVE OROPHARYNGEAL CARCINOMA. Sun M Ahn, MD,Jason Y Chan, MBBS, Daria Gaykalova, PhD, Joseph A Califano,MD; Department of Otolaryngology, Head and Neck Surgery, JohnsHopkins Medical Institutions & Milton J Dance Head and Neck Center,Greater Baltimore Medical Center, Baltimore, Maryland.4:23 PM S032: PREVENTION OF DEPRESSION USING ESCITALOPRAMIN PATIENTS UNDERGOING TREATMENT FOR HEAD AND NECKCANCER. William Lydiatt, MD, Diane Bessette, PA, Kendra Schmid,PhD, Harlan Dayles, MS, William Burke, MD; Nebraska Medical Centerand Nebraska Methodist Hospital.4:31 PM S033: SIGNIFICANCE OF PIK3CA MUTATIONS IN OROPHARYNGEALSQUAMOUS CELL CARCINOMA. Andrew B Sewell, MD, NataliaIsaeva, PhD, Wendell G Yarbrough, MD, MMHC, FACS; Yale University,Vanderbilt University.4:39 PM Discussion (6 minutes)4:45 PM Meeting Adjourns4:45 - 5:30 PM Centurion Club Reception Amarante 15:30 - 7:00 PM President’s Poster Coquina BallroomDiscussion SessionPoster Tour Moderators: Tamer Ghanem, MDKelly M. Malloy, MDSusan D. McCammon, MDJason G. Newman, MDThe AHNS gratefully acknowledges educational grant support from ourSilver Level Supporter - Medtronic Surgical Technologies.7:15 - 8:30 PM AHNS President’s Reception Mediterranean 6-8Please join Dr. and Mrs. Mark Wax for anevening reception with the AHNS President.All registered AHNS attendees and guests are welcome.The AHNS acknowledges the following companiesin support of the President’s Reception:CelSci CorporationOmniGuide, Inc.PfizerDePuy Synthes, CMFStryker46 AHNS 2013 Annual Meeting

Faculty ListingNishant Agarwal, MD – Baltimore, MDDaniel Alam, MD – Cleveland, OHNigel J. Beasley, FRCS, MBBS –Nottingham, EnglandJay O. Boyle, MD – New York, NYJeffrey M. Bumpous, MD – Louisville, KYWilliam R. Carroll, MD – Birmingham, ALEzra E.W. Cohen, MD – Chicago, ILTerry A. Day, MD – Charleston, SCGregory D. Farwell, MD – Sacramento,CARobert L. Ferris, MD, PhD – Pittsburgh,PAEric Genden, MD – New York, NYTamer Ghanem, MD, PhD – Detroit, MIM. Boyd Gillespie, MD – Charleston, SCChristine G. Gourin, MD – Baltimore, MDPatrick J. Gullane, MD – Toronto, ON,CanadaMatthew M. Hanasono, MD – Houston,TXFloyd “Chris” Holsinger, MD – Houston,TXJonas T. Johnson, MD – Pittsburgh, PADennis H. Kraus, MD – New York, NYMichael Kupferman, MD – Houston, TXWilliam M. Lydiatt, MD – Omaha, NEEllie Maghami, MD – Duarte, CAJ. Scott Magnuson, MD – Birmingham,ALEduardo Mendez, MD – Seattle, WAOleg Militsakh, MD – Omaha, NEBrian A. Moore, MD – New Orleans, LACherie-Ann O. Nathan, MD – Shreveport,LABrian Nussenbaum, MD – St. Louis, MOKaren T. Pitman, MD – Gilbert, AZJeremy Richmon, MD – Baltimore, MDEben L. Rosenthal, MD – Birmingham,ALCecelia Schmalbach, MD, MS – LacklandAFB, TXHadi Seikaly, MD – Edmonton, AB,CanadaAshok R. Shaha, MD – New York, NYBrendan C. Stack, Jr., MD – Little Rock,ARKerstin M. Stenson, MD – Chicago, ILMarita S. Teng, MD – New York, NYDavid J. Terris, MD – Augusta, GAAndrea (Andy) Trotti, MD – Tampa, FLMark K. Wax, MD – Portland, ORRandal S. Weber, MD – Houston, TXMike Yao, MD – Scarsdale, NYWendell G. Yarbrough, MD – New Haven,CTApril 10 - 11, 2013 · www.ahns.info 47

Faculty, Presenter & Planning Committee DisclosuresThe following faculty & presenters provided information indicating they have a financialrelationship with a proprietary entity producing health care goods or services, with theexemption of non-profit or government organizations and non-health care related companies.(Financial relationships can include such things as grants or research support, employee,consultant, major stockholder, member of speaker’s bureau, etc.)Name Commercial Interest What Was Received For What RoleIndependentMedronicConsulting FeeM. Boyd Gillespie, MD*ContractorOlympus Consulting Fee ConsultantBristol Myers Squibb Honoraria SpeakerNeal Dwayne Gross, MD*Intuitive SurgicalHonorariaSurgicalProctorDennis H. Kraus, MD Endoethicon HonorariaSpeaker/TeachingEduardo Mendez, MD* Intuitive Surgical, Inc. HonorariaSpeaking/TeachingJason G. Newman, MD* Intuitive Surgical, Inc. Payment/Fee ProctoringJeremy Richmon, MD* Intuitive Surgical, Inc. Consulting Fee ConsultantBrendan C. Stack, Jr., MD Novartis/Hollingsworth LLP Consulting Fee ConsultantDavid J. Terris, MD Johnson and Johnson HonorariaSpeaking/TeachingThe following faculty, presenters and program committee members do not have any relevantfinancial relationships or significant commercial interests associated with their participation atthe AHNS 2013 Annual Meeting.Amit Agarwal, MD*Nishant Agarwal, MDDaniel Alam, MDStephen W. Bayles, MD*Nigel J. Beasley, FRCS, MBBSBrendon G. Bentz, MD*Jay O. Boyle, MDJeffrey M. Bumpous, MD*Brian B, Burkey, MD*William R. Carroll, MD*Ezra E.W. Cohen, MDMarion E. Couch, MD, PhD*Terry A. Day, MDDanny Enepekides, MD*Ramon Esclamado, MD*Gregory D. Farwell, MDRobert L. Ferris, MD, PhDThomas Gal, MD, MPH*Eric Genden, MDTamer Ghanem, MD, PhD*Christine G. Gourin, MDPatrick J. Gullane, MDPatrick K. Ha, MD*Matthew M. Hanasono, MD*Michael L. Hinni, MD*Floyd “Chris” Holsinger, MDJoshua Hornig, MDJonas T. Johnson, MDMichael Kupferman, MDWilliam M. Lydiatt, MDEllie Maghami, MD*J. Scott Magnuson, MDKelly Michele Malloy, MD*Susan D. McCammon, MD*Oleg Militsakh, MD*Brian A. Moore, MD*Cherie-Ann O. Nathan, MD*Brian Nussenbaum, MD*Karen T. Pitman, MDEben L. Rosenthal, MDVicente Resto, MD, PhD*James Rocco, MD, PhD*Cecelia Schmalbach, MD, MSHadi Seikaly, MD*Ashok R. Shaha, MDYelizaveta Lisa Shnayder, MD*Uttam K. Sinha, MD*Kerstin M. Stenson, MDMarita S. Teng, MD*Andrea (Andy) Trotti, MDTerance T. Tsue, MD*Mark A.S. Varvares, MD*J. Trad Wadsworth, MD*Mark K. Wax, MDRandal S. Weber, MDMike Yao, MDWendell G. Yarbrough, MD48 AHNS 2013 Annual Meeting*Denotes a 2013 AHNSProgram Committee Member

Oral PapersS001: TRANSORAL ROBOTIC SURGERYFOR OROPHARYNGEAL CANCER:LONG TERM QUALITY OF LIFE ANDFUNCTIONAL OUTCOMESPeter T Dziegielewski, MD, FRCSC, K Durmus,MD, T N Teknos, MD, FACS, M Old, MD, FACS,A Agrawal, MD, FACS, K Kakarala, MD, FACS,E Ozer, MD; The Ohio State UniversityObjective: To determine swallowing, speechand quality of life (QOL) outcomes followingtransoral robotic surgery for oropharyngealsquamous cell carcinoma (OPSCC).Design: Prospective cohort studySetting: Tertiary care academiccomprehensive cancer centerPatients: 80 consecutive patients withpreviously untreated OPSCCIntervention: Primary surgical resection viatrans-oral robotic surgery (TORS) and neckdissection as indicated.Main Outcome Measures: Patients wereasked to complete the Head and Neck CancerInventory (HNCI) pre-operatively and at 3weeks as well as 3, 6 and 12 months postoperatively.Swallowing ability was assessedby independence from a gastrostomyTube (G-Tube) at the same time points.Demographic, pathological and follow-updata were also collected. Factors predicitve ofa lower quality of life were identified with amultivariate analysis.Results: The median follow-up time was18.3 months. The HNCI response rates at 3weeks and 3, 6, and 12 months were 80%,80%, 63%, 54% respectively. There wereoverall declines in eating, aesthetic, socialand overall QOL domains in the early postoperativeperiods. However, at 1 year afterTORS scores for aesthetic, social and overallQOL remained high. Speech scores remainedhigh throughout time periods. T-classification,N-Classification, age and post-operativeradiation/chemotherapy correlated with lowerQOL (p

Oral Paperssignificantly shorter for patients initiallyclosed with either flap technique comparedto primary closure. Onlay or interposed flapclosure to reduce incidence and severity offistula should be considered when performingsalvage laryngectomy.S003: SO-CALLED TOTALTHYROIDECTOMY: MEASURING THEEXTENT OF THYROID SURGERY WITH RAIJuntian Lang, MD, , PhD, Uma Ramaswamy,Eric Rohren, MD, Naifa L Bussaidy, MD,Maria E Cabanillas, MD, Randal S Weber, MD,FACS, Christopher F Holsinger, MD, FACS;The University of Texas MD Anderson CancerCenterObjective: To investigate the rate of patientswith or without thyroid remnant and therelationship between postoperative stimulatedthyroglobulin(Tg) level and thyroid remnantsafter total thyroidectomy for patients withdifferentiated thyroid carcinoma.Patients and Methods: We evaluatedpatients undergoing total thyroidectomy atMD Anderson Cancer Center from 01/01/2001to 02/20/2012 for T1-3N0M0 differentiatedthyroid cancer (DTC) who received diagnosticpost-operative radioactive iodine imaging.Two hundred and twenty-nine patients hadquantitated uptake on RAI imaging and wereincluded in this study. Based on the calculationof I123 background signal, radioactive iodineuptake of 0.2% was taken as the cut-off ofpresence or absence of thyroid remnant.Average time to last follow-up was 45.2months.Results: Ninty-three patients (40.6%) withuptake of radioactive iodine less than 0.2% onpost-operative imaging suggesting that a totalthyroidectomy was performed. The remaining136 patients demonstrated some measurableiodine-avid thyroid tissue and/or tumor in thethyroid bed (112; 82.4%), the neck (6; 4.4%)or both (17, 12.5%). For those patients withpositive iodine signal, the average 24-houriodine uptake was 1.1% (0.2-7.0%). For theentire study population (229 pts), average 24-hour iodine uptake was 0.67%. Measurable Tg(≥1ng/ml) was found in 19/93 (20.4%) patientswithout thyroid remnant and in 82/136 (60.3%)(x2=38.5, p=0.000) with thyroid remnant. Therewere five recurrences (2%), three of whichwere RAIU positive, and two patients showedno postoperative thyroid remnant. One patientwith RAI proven thyroid remnant died ofdisease.Conclusion: One hundred and thirty-six of229(59.4%) DTC patients had residual thyroidtissue after total thyroidectomy. The rate ofdetectable Tg in thyroid remnant positivegroup is higher than that of thyroid remnantnegative group (60.3% vs. 20.4%, p=0.000).S004: DONOR SITE MORBIDITYIN ELDERLY PATIENTS AFTERFASCIOCUTANEOUS FREE TISSUETRANSFERJacob L Wester, BS, Amy Pittman, MD, RobertH Lindau, MD, Mark K Wax, MD; Oregon Healthand Science UniversityObjectives: Several studies have shownexcellent reconstructive outcomes usingfree tissue transfer in elderly patients. Thesestudies, however, are limited in size and fewdescribe long term donor site morbidity. Thepurpose of our study is to assess donor sitemorbidity after fasciocutaneous free tissuetransfer in patients 70 years and older.Methods: Patients were identified from2002-2011 at a tertiary-care center who wereover 70 years of age and had fasciocutaneousfree flap reconstruction of the head and neck.Donor sites included; radial forearm (RFFF),ulnar forearm (UFFF) and anterolateral thigh(ALT). 171 younger patients from the sametime period were randomly selected to act ascontrols. Demographic, surgical and clinicaldata were extracted from the electronicmedical record. Donor site morbidity wascompared between the two groups.Results: 622 fasciocutaneous free flapswere performed during the study period. 158(25.4%) flaps were performed on patients 70years and older, with a median age of 77 years(70-92). There were 100 RFFF, 9 UFFF, and 49ALT flaps performed. The median paddle sizewas 64 cm2 and median follow up time was10 months. Overall donor site morbidity inpatients 70 years and older was 22.2% vs.25.2% in patients less than 70 years, p=0.6.Infection was the most common morbidity inthe elderly (8.9%) and was not significantlydifferent from younger patients (9.4%),p=0.84. Complete loss of STSG (6.2% vs. 2.9%,p=0.34), forearm tendon exposure (7.1% vs.3.9%, p=0.38), extremity numbness (4.7% vs.3.2%, p=0.57) and seroma (5.2% vs. 2.5%,p=0.26) were not significantly different.Conclusion: Donor site morbidity maybe expected in up to 1 of 4 patients afterfasciocutaneous free tissue transfer. Age over70 years does not increase this risk.S005: USE OF THE SUPRACLAVICULARARTERY ISLAND FLAP IN HEAD ANDNECK ONCOLOGIC RECONSTRUCTION:APPLICATIONS AND LIMITATIONSNiels Kokot, MD, Grace Peng, MD, KashifMazhar, MD, Lindsay Reder, MD, UttamK Sinha, MD; Keck School of Medicine,University of Southern CaliforniaObjective: Free tissue transfer has becomethe standard of care for head and neckreconstruction in academic medical centers.The radial forearm free flap (RFFF) andanterolateral thigh (ALT) free flap are twoworkhorse flaps for soft tissue reconstruction.The supraclavicular artery island (SAI) flap isa local rotational flap that has been describedas an alternative to free tissue transfer inhead and neck reconstruction. We previouslypresented our initial experience using the SAIflap. The purpose of this study is to present ourcurrently larger experience using the SAI flap,including some of its limitations.Methods: Retrospective chart review of ourfirst 45 consecutive patients who underwentreconstruction with SAI flap following headand neck oncologic surgery was done, afterobtaining IRB approval. Information onprior treatment, size and location of defect,time required to raise the flap, time to deepithelializethe flap, flap viability, donor sitemorbidity, and complications was collected. Allstatistical analysis was done using SAS 9.1.Results: 38 out of 45 patients underwentablative surgery for head and neck carcinoma50 AHNS 2013 Annual Meeting

Oral Papersand had a SAI flap performed as their softtissue reconstruction, while 7 patients had aSAI flap for reconstruction of a non-cancerrelated defect. Defects of the oral cavity (n=13),oropharynx (n=7), laryngopharynx (n=8),esophagus (n=1), trachea (n=1), temporalbone (n=5), and cervical skin (n=10) werereconstructed. Mean flap width was 6.1cm(range 5-9cm), allowing for primary closure inall cases. Mean flap length was 21.4cm (range15-28cm), with the proximal portion of the flapde-epithelialized to match the defect resultingin a mean skin paddle length of 7.91 cm (range5-15cm). Mean harvest time was 34.9 minutes(range 17-60 min), and mean time for deepithelializationwas 15.2 minutes (range 5-40min). Minor donor site dehiscence occurredin 6 patients (13.6%), while dehiscencerequiring prolonged wound care occurred in2 patients (4.5%). No patients reported severelimitations of arm movement. Partial skin flapnecrosis occurred in 8 (17%) patients, while2 (4%) patients had complete loss of the skinpaddle. Salivary fistula developed in 7 (15.5%)patients, 4 of which healed spontaneously.A second reconstructive procedure usingan alternate flap was required in 4 patients(9.1%). There were 6 patients (13.6%) with neckrelated complications. There was a significantcorrelation between flap length greater than22 cm and flap necrosis (chi-sq p=0.01). Nosignificant correlation between flap location orflap necrosis and fistula was found.Conclusions: The SAI flap is a viablealternative to microvascular reconstructionof head and neck defect in select cases. Thisflap is fairly reliable, easy to harvest, andversatile. However, after initial success usingthis flap, we have determined that the SAI flaphas limitation in length, with flaps longer than22cm having a higher incidence of necrosis.Because it is a rotational flap, it is also limitedin reconstructing some complex head andneck defects. As a result, we have becomemore selective in its application.S006: DISPOSITION OF ELDERLYPATIENTS FOLLOWING HEAD AND NECKMICROVASCULAR RECONSTRUCTIONJeanne L Hatcher, MD, Elizabeth B Bell, BS,Joshua D Waltonen, MD; Wake Forest Schoolof MedicineINTRODUCTION: With the US populationaging, more elderly patients are beingdiagnosed with head and neck cancers.Comorbidities are more common in elderlypatients, and there are concerns about themorbidity of lengthy surgery, such as withmicrovascular head and neck reconstruction,and its impact on the elderly patient. Thepost-hospitalization needs and disposition ofthis patient population, for example dischargeto home versus a skilled nursing facility, hasnot been studied. The purpose of this studyis to investigate whether or not the elderly,as compared to younger patients, are morelikely to be discharged to a nursing or othercare facility as opposed to returning homefollowing microvascular reconstruction of thehead and neck.METHODS: The medical records of450 patients undergoing head and neckmicrovascular reconstruction were reviewed.The patients’ age at the time of procedure,primary diagnosis, site of tumor involvement,revision versus primary procedure, AmericanSociety of Anesthesiologists (ASA) score,length of postoperative stay, and dispositionfollowing hospitalization were analyzed.Associations between variables were analyzedusing the paired t, chi-square, Fisher exact,and Kruskal-Wallis tests to determine oddsratios (OR) on a multinomial regression model.RESULTS: The average age of participantswas 59.1; 278 of the 450 were under the ageof 65. The median length of stay was 10 days.Most patients were discharged home with orwithout home health services, n = 386 (85.8%).Of those discharged home, 267 (69.2%) wereunder 65 years old, the remaining 65 andover (p < 0.0001). The average age of thosedischarged home was 57.5; discharge to homewas the reference for comparison and oddsratio (OR) calculation. For those discharged toa skilled nursing facility (SNF), average agewas 67.1 (OR 5.5, p=0.0005). Average age ofthose discharged to a long-term acute care(LTAC) facility was 71.5 (OR 9.2, p=0.0024).With each year older a patient is, the odds ofgoing to a nursing facility are 5.5% higher thangoing home. When controlling for the ASAscore, the OR were even higher and remainedsignificant for discharge to SNF and LTAC.Length of stay also impacted the disposition.The average LOS for those under 65 was12.4 (3-75, SD=9.3), 65 and over 16.7 (3-80,SD=13.6). Primary versus salvage proceduresas well as the number of tumor sites involveddid not affect the disposition with statisticalsignificance.CONCLUSIONS: Previous research hasshown that the elderly patient is just as likelyto survive a major surgical procedure such ashead and neck reconstruction as one underage 65. However this study demonstrates thatolder patients are less likely to be dischargedhome at the end of the hospitalization. Age,independent of comorbidities as measured bythe ASA score, as well as the length of stay arerisk factors for discharge to a nursing or othercare facility as opposed to home followingmicrovascular reconstruction.S007: PATHOLOGICALLY DETERMINEDTUMOR VOLUME OUTPERFORMS TSTAGE IN THE PREDICTION OF OUTCOMEFOLLOWING SURGICAL TREATMENT OFOROPHARYNGEAL SQUAMOUS CELLCARCINOMA Frank L Palmer, Mr, NancyY Lee, Dr, Ian Ganly, Dr, Iain J Nixon, Dr;Memorial Sloan Kettering Cancer CenterIntroduction: Traditional prognostic modelsfor squamous cell carcinoma (SCC) of thehead and neck are based on the TNM stagingsystem. However, there is growing evidencethat tumor volume (TV) may be a moreaccurate predictor of outcome. The majority ofgroups who have investigated the impact of TVused radiological estimates prior to radiationtherapy rather than pathologically measureddimensions determined following surgery.The aim of our study was to determine ifpathological TV, in patients treated surgicallywith oropharyngeal SCC, is prognostic ofoutcome, and how it compares in prognosticvalue to pathological T stage.Patients and Methods: 159 consecutivepatients who had primary surgical resectionApril 10 - 11, 2013 · www.ahns.info 51

Oral Papersof oropharyngeal SCC, and had 3 dimensionsreported on histopathology within MemorialSloan Kettering Cancer Center between 1985-2005 were identified. The pathological TV wascalculated as the product of the 3 dimensionsexpressed in cubic centimeters. Diseasespecific mortality (DSM) local recurrence(LR), regional recurrence (RR) and distantrecurrence (DR) were calculated using theKaplan Meier method for all investigatedoutcomes except the disease specific deaththat was estimated by cumulative incidencefunctions after treating death from causes ascompeting risks. The relationship between pTstage and outcomes was evaluated using thelog rank test or the non-parametric Gray testfor disease specific death. The relationshipbetween pTV and outcome was based on theunivariable analysis by treating the volumeas a continuous predictor with splines toaccommodate non-linear relation withoutcategorization. For comparison of pT stagewith pTV in outcome prediction, concordanceindices were generated using the bootstrapmethod (n=1000) to quantify the predictiveaccuracy. Concordance indices were thencompared and a significant difference wasconsidered when p

Oral PapersS009: A COMPARISON OF OUTCOMESUSING IMRT AND 3DCRT IN TREATMENTOF OROPHARYNGEAL CANCER ShivangiLohia, BA, Mayuri M Rajapurkar, MD, AnandK Sharma, MD, Terry A Day, MD; MedicalUniversity of South CarolinaBackground: Head and neck squamous cellcarcinoma (SCC) represents approximately6% of all newly diagnosed cancers in theUnited States with the majority of patientsreceiving radiation during the course of theirtreatment either combined with chemotherapyor following surgery. While innovations intherapy have improved long-term survivalrates, treatment related toxicities and sideeffects from radiation therapy remain high.Approximately 50% of all head and neckcancer survivors suffer from dysphagiaand dysphagia-related morbidity. Thus,intensity modulated radiation therapy isbeing increasingly used in the treatment oforopharyngeal cancers for definitive treatmentwith excellent oncologic outcomes. However,there are few studies comparing outcomesbetween IMRT and conventional radiationtherapy (CRT).Methods: We performed a retrospectivereview of patients who underwent eitherIMRT or 3D-CRT for definitive treatment oforopharyngeal squamous cell carcinomaat MUSC. Primary endpoints included:gastrostomy (PEG) tube dependence 1 yearafter radiation start, time to PEG tube removal,weight loss during treatment, disease-freesurvival, and toxicity profiles at treatmentcompletion.Results: Of 315 patients identified in the Headand Neck database, 159 had oropharyngealprimaries and underwent definitive radiationtherapy. Fifty-six patients were treated with3D-CRT, and 103 with IMRT. Patients treatedwith IMRT had significantly lower rates of PEGtube dependence one year after treatmentinitiation regardless of dose (p=0.0223) orT-stage (p=0.012), and a shorter time to PEGtube removal (p

Oral Papersindependent predictor of local control andsurvival in OCSCC treated with TLM tonegative margins. We also demonstratethe feasibility of BGS risk assessment inthis group. High-BGS was associated withrecurrences and OS. Larger studies will benecessary to determine the adjuvant therapydeterminingutility of BGS. Strategies thatmaintain or restore tumor-specific immuneresponses in immunocompromised OCSCChosts need to be developed and applied.S011: TRANSORAL ROBOTIC SURGERY(TORS): SIMULATION-BASEDSTANDARDIZED TRAINING Ning Zhang,Baran D Sumer, MD; University of TexasSouthwestern Medical CenterObjective: To standardize introduction totransoral robotic surgery (TORS), we designeda training program based on the da VinciMimic Virtual Reality Simulator and tested thefeasibility of training robotic surgery naïvesubjects using the simulator.Study Design: Cross-sectional prospectivestudySetting: Academic tertiary referral centerSubject and MethodsSixteen medical students with no roboticsurgery experience, were trained with thesimulation program on the da Vinci SurgeonConsole. Participants had unlimited consoletime and attempts to perform 12 exercisesrelevant to TORS until competent. Competencewas achieving an overall score ≥91% foreach exercise, calculated by preprogrammedsimulator exercise metrics. Total training time(TTT) required to achieve competence wasrecorded, along with values for all metrics.Each participant was randomly assigned tofollow-up 1, 3, 5, or 7 weeks post-training (n=4per group) and repeated the exercises untilregaining competence. Participants had noexposure to the console or simulation betweeninitial training and follow-up. Follow-up totaltime (FTT) to re-achieve competence wasrecorded.ResultsAll participants successfully completedtraining, becoming competent. Average TTTwas 3.27 ± 1.22 hours. TTT distribution wasbimodal rather than a normal distribution(Figure 1A), dividing the subjects into ShortTraining Time (STT)(n=10, 62.5%), and LongTraining Time (LTT)(n=6, 37.5%) groups. TTTwas 2.44 ± 0.56 hours for the STT groupand 4.66 ± 0.46 hours for the LTT group(p =0.0003). Difference in average time for theexercises was insignificant between STTand LTT (p = 0.635), but the total numberof exercise attempts needed to completetraining was significantly different (p =0.003) with a mean 54.7 ± 14.8 and 100.2± 16.2 attempts respectively. STT and LTTdifferences in final score was insignificant(p = 0.635). All participants were able to reachievecompetence. Average follow-up totaltime (FTT) was 44 ± 5 min, 63 ± 3 min, 59± 23 min, and 82 ± 21 min for 1-, 3-, 5-, and7-weeks groups respectively; all significantlyshorter than TTT (p = 0.014, 0.014, 0.029, 0.014respectively). The larger standard deviationsat 5- and 7-weeks compared to 1- and 3-weekswere due to divergence between STT andLTT subjects (Figure 1B). While there was nosignificant difference between STT and LTT inaverage FTT for follow-up at 1 and 3 weeks, (p= 0.786) there were significant differences inFTT at 5 and 7 weeks (p = 0.036). There wereno differences between STT and LTT in followupfinal score (p=0.118).Conclusion: Physicians in training areable to acquire and retain robotic surgerycompetency using the simulator but exhibitdeclines in skill over time during a hiatus fromtraining. STT subjects, had a slower declinein robotic skills. Upon retraining all subjectswere able to regain equivalent competence.This information can establish a simulatortraining program for residents prior to clinicalintroduction to TORS. It also provides abenchmark for determining necessary TORSsurgical volume or simulator training, tomaintain competency.54 AHNS 2013 Annual Meeting

Oral PapersS012: ROBOT-ASSISTEDCOMPREHENSIVE NECK DISSECTIONVIA A TRANSAXILLARY ANDRETROAURICULAR (“TARA”) APPROACHIN PAPILLARY THYROID CANCER WITHCERVICAL LYMPH NODE METASTASES:A COMPARATIVE STUDY WITH THETRANSAXILLARY APPROACH Won ShikKim, MD, Yoon Woo Koh, MD, PhD, JaeWook Kim, MD, Hyun Jun Hong, MD, HyungKwon Byeon, MD, Young Min Park, MD,Hyo Jin Chung, MD, Sang Chul Park, MD,Michelle J. Suh, MD, Eun Jung Lee, MD,Eun Chang Choi, MD, PhD; 1Departmentof Otorhinolaryngology, Yonsei UniversityCollege of Medicine, Seoul, Korea2Department of Otolaryngology–Head andNeck Surgery, Soonchunhyang UniversityCollege of Medicine, Seoul, KoreaBackground: Cervical lymph nodemetastases are frequently encountered in themanagement of papillary thyroid carcinoma(PTC). Recently, robot-assisted neck dissection(ND) using a gasless transaxillary (TA)approach in thyroid cancer patients with lateralneck node metastases was studied and provento be feasible. Here, we devised a modifiedtransaxillary and retroauricular (TARA)approach with the addition of a retroauricularincision to the TA approach for the clearance oflevel II lymph nodes. The aim of this study wasto compare the surgical outcomes of TARA vs.TA in the management of cervical lymph nodemetastases in PTC.Methods: From October 2010 to May 2012, atotal of 29 patients with PTC underwent robotictotal thyroidectomy with central compartmentND, and robot-assisted modified radicalND except level I. Among the patients, 15unilateral and 3 bilateral NDs were performedvia the TARA approach, and 11 unilateral NDswere performed via the TA approach.Results: The TA group consisted of eightfemales and three males, with a mean age of43.2 years. The TARA group consisted of twelvefemales and six males, with a mean age of32.6 years. There was no significant differencein operation time for ND between both groups.However, the time from skin incision to thepoint immediately before docking of therobotic arms was significantly longer in theTARA group, and the console time was longerin the TA group. Level II and level IV specimensin the TARA group contained a relatively largernumber of lymph nodes than those in the TAgroup. There were no significant differencesin the development of postoperativecomplications between both groups. All NDswere successfully performed via a robotassistedtechnique.Conclusions: Robot-assisted NDs weresuccessfully performed via a novel TARAapproach in PTC patients with cervical lymphnode metastases. The surgical outcomes ofrobot-assisted ND via a TARA approach werecomparable or even superior to those of robotassistedND via the transaxillary approach,especially for upper-level ND. TARA is a useful,alternative approach for addressing cervicallymph node metastases in selected cases ofPTC.S013: SURGEON EXPERIENCE ANDCOMPLICATIONS WITH TRANSORALROBOTIC SURGERY (TORS) Stanley H Chia,MD, FACS, Neil D Gross, MD, FACS, JeremyRichmon, MD, FACS; Medstar WashingtonHospital Center, Medstar GeorgetownUniversity Hospital, Oregon Health SciencesUniversity, Johns Hopkins HospitalIntroduction: The application of transoralrobotic surgery (TORS) has increaseddramatically since FDA approval in 2009.Yet, there has been little published regardingperioperative care regimens for patientsundergoing TORS or the frequency ofpostoperative complications. The aim of thisstudy was to investigate surgeon preferencesfor perioperative management after TORSand to explore the frequency of postoperativecomplications.Methods: A multi-institutional retrospectivephysician survey was performed. Thesurvey was composed by the authors andadministered electronically via surveymonkey.com. Potential participants were identifiedby Intuitive Surgical, Inc. as TORS-trainedsurgeons in the United States. Participationwas voluntary and solicited by e-mailinvitations to participate three times over aone month period. There was no industryparticipation in data acquisition, analysis orinterpretation.Results: A total of 2015 procedures werereported by forty-five respondent TORStrainedsurgeons; 67% academic, 33%non-academic. Eighty-seven percent ofrespondents had industry-sponsored training.Nearly all respondents (91%) dedicated>50% of their practice to head and neckoncology. A minority of TORS procedures(n=214, 10.6%) were performed on previouslyirradiated patients. Surgeons performedneck dissections concurrently (n= 26, 58%)or as a staged procedure (n= 19, 42%). Fewerthan 4% (n= 74) of TORS procedures requiredtracheotomy or free tissue reconstruction.Most surgeons (62%) recommended initiationof oral intake on postoperative day 0-1.Of the patients that required readmission,bleeding (n=62, 3.1%) was the most commoncause followed by dehydration (n=26, 1.3%),aspiration pneumonia (n=22, 1.1%), andairway compromise (n=4, 0.2%). Postoperativehemorrhage was most frequently managedby transoral control in the operating room(77.4%), transoral management in theoutpatient setting (30.7%) and/or transcervicalcontrol in the operating room (16.1%). Othercomplications of surgery included tooth injury(n=29, 1.4% of all cases), PEG dependency >6months (n=21, 1.0%), temporary hypoglossalnerve injury (n=18, 0.9%), and lingual nerveinjury (n=11, 0.6%). A total of 6 deaths (0.3%)were reported within 30 days of TORS, and onedeath occurred after 30 days. Cause of deathwas reported in four cases, and all were due topostoperative hemorrhage.Conclusions: This is the first study examiningperioperative care regimens and complicationsencountered by a broad sampling of TORStrainedsurgeons in the United States. TORS isassociated with a low tracheotomy rate, a lowcomplication rate, early initiation of oral intakeand a low rate of long-term PEG dependency.April 10 - 11, 2013 · www.ahns.info 55

Oral PapersPostoperative hemorrhage was the mostcommon cause of hospital readmission andpostoperative mortality.S014: ANALYSIS OF POSTOPERATIVEBLEEDING IN TRANSORAL LASERMICROSURGERY OF THE OROPHARYNXTaylor R Pollei, MD, Michael L Hinni, MD, EricJ Moore, MD, Richard E Hayden, MD, LoganC Walter, BS, Kerry D Olsen, MD; Mayo ClinicPhoenix, Arizona; Mayo Clinic Rochester,MNObjective: To evaluate postoperativehemorrhage following transoral resectionof oropharyngeal squamous cell carcinomawith associated risk factors and preventativemeasures.Design: Multi-institution, retrospective chartreviewSetting: Tertiary academic referral center, levelof evidence: 2bPatients: 906 patients treated with transoralsurgery for oropharyngeal squamous cellcarcinoma between 1994 and 2012 wereanalyzed for postoperative bleed. Tumor stage,previous treatment (surgery or radiation),resection method (laser, robot, cautery), andconcomitant transcervical external carotidsystem ligation were analyzed in relationshipto bleed presence and severity. Presentationand management of postoperative bleed wasevaluated. Severity of bleed was graded asminor, major, severe, or catastrophic based onbleed control method and related sequellae.Results: Postoperative bleed occurred in5.4% (49/906) of patients with 32.7% (16/49)managed conservatively and 67.3% (33/49)requiring operative intervention. Transcervicalexternal carotid system vessel ligation wasperformed with the primary resection in15.6% of patients with no significant bleedrate difference between ligated (6.7%) andnon-ligated (5.5%) groups (p= 0.213). Vesselligation was performed more frequently inhigher T-stage patients (p= 0.002); specificallyT4 vs. T1 (p= 0.0014) and T3 vs. T1 (p= 0049).Intraoperative vessel ligation did not affectbleed severity. (p= 0.526) Numbers of severebleeds were small (n=10), only one occurred ina ligated patient.No increase in postoperative bleed rate wasseen in previously treated patients (7.8%)compared to previously untreated patients(5.4%) (p= 0.511). Bleed rates were similarbetween laser (5.6%) and robotic (5.9%)oropharyngectomy (p= 0.799) however,significantly larger T-stages were treated withlaser surgery vs. robot (T3 vs. T1 & T3 vs. T2;p< 0.0001).Larger T-stage tumors had a higher bleed rate(p= 0.015); specifically T4 vs. T1 (p= 0.0014)and T3 vs. T1 (p= 0049). No difference in bleedseverity was found between T-stages (p= 0.34).Male patients were more likely to have a bleedrequiring operative intervention (p= 0.018).Conclusions: Transcervical external carotidsystem vessel ligation performed at thetime of primary oropharyngectomy does notdecrease postoperative bleed rate, however,large T-stage tumors bleed more frequentlyand tend to be ligated more frequently. Forlarger T-stage tumors or previously treatedpatients, simultaneous vessel ligation shouldbe considered and may reduce the severity ofa severe bleed. Procedure method (laser vs.robot) does not alter bleed rate. Male gender iscorrelated with increased bleed severity.S015: SURGICAL FEASIBILITY ANDONCOLOGIC SAFETY OF ROBOT-ASSISTED NECK DISSECTION FOLLOWEDBY TRANSORAL ROBOTIC SURGERY(TORS) IN HEAD AND NECK CANCERHyung Kwon Byeon, MD, Jae Wook Kim,MD, Eun Sung Kim, MD, Hyo Jin Chung,MD, Eun Jung Lee, MD, Hyun Jun Hong,MD, Won Shik Kim, MD, Yoon Woo Koh,MD, PhD, Eun Chang Choi, MD, PhD;1Department of Otorhinolaryngology, YonseiUniversity College of Medicine, Seoul, Korea2Department of Otolaryngology–Head andNeck Surgery, Soonchunhyang UniversityCollege of Medicine, Seoul, KoreaIntroduction: Endoscopic head and necksurgery (Transoral Laser microsurgery &Transoral robotic surgery(TORS)) is no longernovel technique in head and neck cancer(HNC)treatment. But, there is few effort for minimallyinvasive neck dissection in HNC. We havetried to verify the possibility of Robot-assistedneck dissection (RAND) in HNC. We aimed toevaluate the surgical feasibility and oncologicsafety of RAND followed by TORS, whichis expected to maximize the posttreatmentcosmesis and functional outcome, in HNC.Methods: Thirty four patients who underwentTORS following RAND via a Modified faceliftor retroauricular approach in cN0 or cN+ HNCwere enrolled. The operation time, amountand duration of drainage, length of hospitalstay, complications, number of retrievedlymph nodes, satisfaction scores, and nodalrecurrence were evaluated.Results: The primary tumor sites werefound within the oropharynx for 20 patients(15 tonsil, 3 tongue-base, 2 soft palate),the hypopharynx for 8 patients, and thesupraglottis for six patient. Twenty-twocases of MRND including levels I or II toV, fifteen cases of SND from level II to IV(LND), and three cases of SND from level Ito III (SOND) were accomplished. BilateralRAND were performed in six patients. Thefree flap reconstructions were performed in7 cases. The mean total operating time forND was 242 min(MRND), 199 min(LND), and165 min(SOND), respectively and the meanpostoperative hospital stay was 11.45 ± 5.2days. The amount of postoperative drainagewas 251.82 ± 131.2 mL, and the drainageduration was 5.51 ± 3.4 days. An averageof 39.6(MRND), 22.1(LND), and 36.5(SOND)lymph nodes was retrieved respectively. Therewere 4 postoperative seroma, 1 postoperativebleeding, 2 chyle leakage, 1 Honer’s syndrome,and 6 temporary mouth corner deviation.Orocervical fistula didn’t occur. Twenty patientsunderwent postoperative chemoradiation and8 patients underwent postoperative radiation.During the follow-up period (mean of 10.3months), all patients were alive withoutlocoregional recurrence. All patients wereextremely satisfied with their cosmetic resultsafter the operation.Conclusions: RANDs followed by TORS werefeasible and showed a clear cosmetic benefit.Longer operation time remains the drawbackof this procedure. The safety, functional, and56 AHNS 2013 Annual Meeting

Oral Papersoncologic outcome of the procedure shouldbe verified with larger number of patients andlonger follow up period.S016: SIGNIFICANT FAMILIAL RISK INMULTIPLE GENERATIONS OF PAPILLARYTHYROID CARCINOMA PROBANDSGretchen M Oakley, MD, Karen Curtin, PhD,Luke O Buchmann, MD, Elke Jarboe, MD,Jason P Hunt, MD; University of Utah HealthSciences CenterIntroduction: Papillary thyroid carcinoma hasa well-recognized familial pattern. However,the specific risk to close and extended relativesof patients diagnosed with papillary thyroidcarcinoma has yet to be adequately defined.Methods:Using the Utah Population Database, anextensive genealogical database linked tomedical records and the Utah Cancer Registry,papillary thyroid carcinoma risk was calculatedfor 1st through 5th degree relatives andspouses of probands compared to randompopulation-based controls matched 5:1 on sex,year of birth, and place of birth. Familial riskwas estimated by calculating odds ratios usingconditional logistic regression, adjusting fornumber of biological relatives, their degreeof relatedness, and their person-years at risk.All relatives of pediatric cases and of matchedcontrols with follow-up who linked to apedigree of ≥2 generations were included. Thisapproach has been shown to lead to unbiasedfamilial risk estimates. As observationswithin families are non-independent, a robustvariance estimator for cluster-correlated datawas incorporated.Results: First-, second-, and third-degreerelatives of 4,460 papillary thyroid carcinomaprobands diagnosed from 1966-2011 hada significant increased risk of developingthis malignancy compared to populationcontrols. First-degree relatives of probandswere at 5.4-fold increased risk (P

Oral Papersto observation or surgery.Table 1: Histologic correlation in each AUSsubcategoryAUS caseswith surgery Benign MalignantAUS-NOS(n=218)41.3% (95% CI, 36.2% (95% CI, 29.4-36.0-46.6) 42.5)AUS-favor 76.9% (95% CI,benign (n=13) 69.2-84.6)7.7% (95% CI, 1.9-36.0)AUS-cannotexclude PTC(n=28)AUS-cannotexcludeHurthle cellneoplasm(n=44)AUS-cannotexcludefollicularneoplasm(n=78)28.6% (95% CI, 53.6% (95% CI, 33.9-9.4-47.8) 72.1)34.1% (95% CI,20.5-47.7)29.5% (95% CI, 16.8-45.2)24.4% (95%CI,11.9-36.9)56.4% (95% CI, 44.7-67.6)S018: CAUSES OF EMERGENCY ROOMVISITS FOLLOWING THYROID ANDPARATHYROID SURGERY William G Young,MD, Linda Hsu, BS, Eric Succar, BS, GaryTalpos, MD, FACS, Tamer A Ghanem, MD, PhD;Henry Ford HospitalObjectives: To describe the subset of patientsrequiring emergency room (ER) evaluationwithin 30 days of their thyroidectomy orparathyroidectomy and their associated riskfactors.Study design: Retrospective chart reviewMethods: Patients undergoing thyroidectomyor parathyroidectomy between 1/1/2009 and10/7/2010 were identified via the IRB approvedthyroid/parathyroid database. Postoperativepatients who visited the ER within the first30 days following surgery were selected.Univariate two-group t-tests, Wilcoxon Mann-Whitney tests, and chi-square tests were usedto evaluate the association of demographicand clinical characteristics between thepatients who required ER evaluation andthose who did not. Clinical characteristicsevaluated included type of surgery, medicalcomorbidities, and proton pump inhibitor (PPI)usage. Multiple logistic regression predictedthe odds of an ER visit based on presenceof diabetes or proton pump inhibitor usage.Odds ratios and 95% confidence intervals wereconsidered significant at p < 0.05.Results: Of the 571 patients who underwent652 thyroidectomy or parathyroidectomysurgeries between 1/1/2009 and 10/7/2010,62 patients required a visit to the emergencyroom within our tertiary medial care systema total of 77 times for issues includingparesthesias (n=28), wound complications(n=9), and weakness (n=7). Out of theseemergency room evaluations, 14 hospitaladmissions occurred for treatment of a varietyof post operative complications. There wereno significant age, gender, race, or body massindex differences between the two groups. Asignificant association was found between thepresence of diabetes (p=0.043) and the currentuse of proton pump inhibitors (p=0.028).When controlling for diabetes, patients takingPPIs were 1.71 times more likely to visit theemergency room than patients not on protonpump inhibitors (p-0.045).Conclusions: Postoperative complicationsfrom thyroidectomy and parathyroidectomyrequiringER evaluation are significant. Postoperativepatients taking proton pump inhibitors weremore likely to visit the ER than patients not onPPIs. Changes in calcium absorption with PPIusage has been documented and attributedto lower bioavailablity of oral calcium in thehigher gastric pH environment. Reducedcalcium absorption of patients undergoing PPItherapy may be the associated with higher ERevaluation rates following thyroidectomy orparathyroidectomy.S019: COMBINED MODALITY TREATMENTOUTCOMES FOR HEAD AND NECKCANCER: COMPARISON OF CARE AT ANACADEMIC CANCER CENTER VERSUSACADEMIC-TO-COMMUNITY TRANSFER,2002 - 2012 Jonathan R George, MD, MPH,Sue S Yom, MD, PhD, Steven J Wang, MD;University of California, San FranciscoObjective: To evaluate differences in canceroutcomes between patients with head & necksquamous cell carcinoma who underwentprimary surgical resection and postoperativeadjuvant treatment at an academic center(AC) and those who underwent surgery at theAC and then received adjuvant treatment at acommunity-based non-AC closer to home.Study Design: Retrospective cohort studyMethods: A retrospective cohort studywas performed on all patients with primarymucosal head and neck squamous cellcarcinoma treated with primary surgeryfollowed by postoperative adjuvant radiationfrom 2002 to 2012. Demographic, oncologic,histologic, and adjuvant treatment datawere collected. The authors then performedunivariate and multivariate survival analysesof the effect of AC versus non-AC adjuvanttreatment on cancer outcomes.Results: 214 patients were included inthis analysis. Significant differences indemographic variables existed between ACand non-AC groups. Patients returning homefor adjuvant treatment at a communitybasednon-AC had a significantly loweraverage radiation therapy (RT) dose, fewerRT fractions, and lower dose per fractioncompared to those receiving treatment atthe AC. They also had significantly more RTdelays, more breaks in RT, and more earlytermination of RT. The non-AC group hadsignificantly lower overall survival (p=0.013),lower disease-specific survival (p=0.002), andlower locoregional control (p=0.044) comparedto the AC treatment group. AC treatment wassignificantly associated with improved survivalon univariate analysis (HR 0.53, 95% CI 0.32- 0.88; p=0.015). This effect was not seen onmultivariate survival analysis (HR 0.75, 95% CI0.44-1.29; p=0.30).Conclusion: Important differences were notedin the metrics of adjuvant radiation providedat the AC compared to those provided atthe community-based non-ACs closer tothe patients’ homes. Significantly betteroncologic outcomes were also seen in the ACadjuvant treatment group as compared to thenon-AC adjuvant treatment group, includingsignificantly improved overall survival,disease-free survival, and locoregional58 AHNS 2013 Annual Meeting

Oral Paperscontrol, as noted on univariate analysis. Theseoutcomes were not upheld on multivariateanalysis, a finding that may be explained by apriori demographic and oncologic differencesnoted between these groups.S020: DESIGNING THE NEXTGENERATION OF BIOREACTORSFOR STEM-CELL TRACHEALTRANSPLANTATION Hunter Faircloth, BS,Don Mettenberg, AS, Aaron Cunningham,BS, Matt Jones, MSECE, Madelaine Dubin,Frederick Rueggeberg, DDS, Gregory Postma,MD, Paul Weinberger, MD; Georgia HealthSciences UniversityBACKGROUND: Patients with large segmenttracheal disease from benign processesor cancer (thyroid or squamous cell) havelimited treatment options. Reconstruction oflarge-segment tracheal defects is difficult,and allograft transplantation with therequisite immunosuppression is not anoption in patients with active malignancy.Regenerative medicine may offer a viablealternative. In 2008, a trachea was grown inan experimental bioreactor from a patient’sown stem cells and successfully transplanted.Problems encountered with this processinclude inability to sterilize the bioreactor,implementation barriers of scale, and potentialcross-contamination between repeated use thebioreactor vessel.The purpose of this study was to design asecond-generation bioreactor that couldpotentially be implemented in a wide varietyof end-user clinical locations.METHODS: We used computer aided design/ computer aided manufacturing (CAD-CAM)coupled with a custom-built 3-D printingdevice capable of directly fabricating designcomponents to construct a prototypesecond-generation bioreactor. Essentialdesign elements included the following: 1) Atwo chamber system allowing for separategrowth media conditions for the luminal(epithelial cells) and external (chondrocytes)graft surfaces. 2) Controlled rotation at 1RPM to induce optimal fluid shear forcesto induce chondrogenic differentiation andgrowth. 3) Continuous carbon-dioxide andoxygen gas exchange. 4) Single-use modulardesign, where the bioreactor vessel can bepre-sterilized and individually packaged.5) Easy media exchange if required duringgraft culturing. The bioreactor prototype wasconstructed using polylactic acid (PLA), tominimize any potential biocompatibility issues.RESULTS: The CAD-CAM system allowedrapid turnaround time (2-7 days) betweeniterative design changes. We successfullyfabricated a final prototype bioreactor meetingall design requirements. The prototype uses anovel “rock-tumbler” based approach wherethe sterile chamber is essentially a modular,single use cylinder-in-cylinder that can bepre-sterilized separate from the motor and gasexchange connectors.CONCLUSION: Our next-generationbioreactor model has the potential to allowhollow-tube organ production at large scale.The ability to test in nearly real-time, theeffects of various modifications was a uniqueadvantage of using the 3D printing system.While initially designed for growth of stem-cellseeded trachea, it can easily be modified forfuture use in a variety of other applications,such as esophageal or vascular grafts. Owingto the modular design and “single-usecartridge” approach, use of stem-cell mediatedregenerative techniques may eventually befeasible at a much broader range of clinicalsettings than previously thought possible.S021: RISK FACTORS FOR PLACEMENTOF A PERCUTANEOUS ENDOSCOPICGASTROSTOMY TUBE DURINGCHEMORADIOTHERAPY FOROROPHARYNGEAL SQUAMOUS CELLCARCINOMA Tobin Strom, MD, Andy Trotti,MD, Nikhil G Rao, MD, Julie A Kish, MD, JudithC McCaffrey, MD, Tapan Padhya, MD, Jimmy JCaudell, MD, PhD; H. Lee Moffitt Cancer CenterBackground. Percutaneous endoscopicgastrostomy tubes may be necessary forpatients with oropharyngeal squamouscell carcinoma (OPSCC) undergoingchemoradiotherapy (CRT) due to dehydrationor significant weight loss. We sought to reviewthe need for a reactive PEG tube placementand hypothesized there would be patient ortumor factors that would be associated withthe need for a reactive PEG tube placement.Methods. Of 430 patients receiving CRT forOPSCC from May 2004 through June 2012, weidentified 242 patients who did not receive aprophylactic PEG tube prior to, or within, 10days of initiation of CRT, unless an attemptto prevent upfront placement of a PEG tubewas explicitly indicated in the chart. Inclusioncriteria included treatment with IMRT andchemotherapy and a minimum follow-up of3 months. Exclusion criteria were prior headand neck surgery, prior head and neck cancer,induction chemotherapy, synchronous primaryor locoregional recurrence or persistenceof disease within 3 months of completingCRT. Patient demographics, tumor status,treatment, as well as information regardingwho reactively required a PEG tube duringor 3 months following completion of CRT,were abstracted. The Mann-Whitney U testand the Pearson’s Chi-square test were usedto compare groups. Multivariate analysiswas performed using a logistic regressionmodel on potential predictors from univariateanalysis.Results. We identified 128 patients who didnot receive a prophylactic PEG tube. ReactiveApril 10 - 11, 2013 · www.ahns.info 59

Oral Papersplacement of a PEG tube occurred during, or3 months following, CRT in 15 patients (12%).Nine patients (7%) had a PEG tube at 3 monthsfollow-up. On univariate analysis, a tumorT-stage ≥ 3 (p=0.05), a cumulative cisplatindose ≥ 200 mg/m 2 (p=0.03), and the DAHANCAradiation schedule (p=0.02), were significantlyassociated with the placement of a reactivePEG tube during treatment. A BMI < 25 kg/m 2 showed a trend toward significance onunivariate analysis (p=0.10). On multivariateanalysis, a tumor T-stage ≥ 3 (OR 3.5, 95%CI1.0-11.9, p=0.03), a cumulative cisplatin dose ≥200 mg/m 2 (OR 6.7, 95%CI 1.2-36.7, p=0.03), theDAHANCA radiation schedule (OR 4.2, 95%CI1.1-16.5, p=0.04), and a BMI < 25 kg/m 2 (OR5.8, 95%CI 1.4-23.9, p=0.02) were significantlyassociated with the placement of a reactivePEG tube.Conclusions. Only 12% of OPSCC patients atour institution required the reactive placementof a PEG tube at some point within 3 monthsof the completion of CRT. A tumor T-stage ≥ 3,a cumulative cisplatin dose ≥ 200 mg/m 2 , theDAHANCA radiation schedule, and a BMI < 25kg/m 2 are associated with symptomatic needfor PEG placement.S022: PROGNOSTIC FACTORSASSOCIATED WITH DECREASEDSURVIVAL IN ACINIC CELL CARCINOMADavid M Neskey, MD, Jonah D Klein, MS,Adam S Garden, MD, Diana Bell, MD, AdelK El-Naggar, MD, PhD, Merrill S Kies, MD,Randall S Weber, MD, Michael E Kupferman,MD; UT MD Anderson Cancer CenterSalivary gland neoplasms represent 2-7%of all head and neck neoplasms, but onlyapproximately 0.5% of malignancies. Aciniccell carcinoma comprises 3-9 percent of allsalivary gland neoplasm and up to 17 percentof salivary gland malignancies with themajority of occurring in the parotid gland.Although the overall survival for patientswith acinic cell in generally favorable, thisneoplasm does have the potential to recurboth locoregional and distant sites. Given therarity of this disease there have been only fewreports on prognostic factors associated withalterations in survival outcomes. The goals ofthis study were to to identify clinicopathologicfactors associated with adverse survivalas to assess the impact of local, regional,and distant recurrences on survival andfurthermore.Methods: Retrospective chart review ofpatients seen at MD Anderson Cancer Centerfrom January 1970 to November 2007 withthe diagnosis of acinic cell carcinoma. We 155patients identified with mean follow-up of 6.8years (range 0.2-38 years). The mean age atpresentation was 52 years old (range 11-100).Results: In this cohort, we observed amedian survival of 28.5 years (range 0.2-38years), with 8% (13) of patients dying fromtheir disease. Most of these deaths, 77%,were attributed to the development of distantmetastases with a mean time to death of3.8 years (range 0.73-11.2). Women (n=104)were affected twice as often as men (n=51)but appear to have a significantly improvedsurvival (p45 years old, neoplasms > 3 cm, and thedevelopment of a recurrence at a distantmetastatic site. These results suggest thatmaximizing local and regional control for thisdisease can offer substantial benefit when nodistant disease is detectable. Patients withadverse risk factors should be monitoredclosely and aggressive adjuvant therapyshould be considered for distant recurrences inthis subset of patients.S023: RACIAL AND ETHNIC DISPARITIESIN SALIVARY GLAND CANCER SURVIVALShani J Ortiz, BS, Vicente A Resto, MD, PhD,Travis P Schrank, MD, PhD; The University ofTexas Medical BranchBackground: Several studies havedocumented disparities in head and neckcancer outcomes for black patients in theUnited States. However, few studies have beenconducted to identify differences in long-termsurvival from salivary gland cancer amongstracial/ethnic minorities and Whites.Methods: 6344 cases of salivary gland cancerin the National Cancer Institute’s Surveillance,Epidemiology, and End Results database from1988-2003 were analyzed. Racial/ethnic groupswere studied for disease specific survival.Characteristics of each group including meanage at diagnosis, gender, tumor grade, meansize at diagnosis, extension, lymph nodeinvolvement, and treatment were determined.Groups were further analyzed by histologicsubtype.Results: Of 6344 patients, 538 (8.5%) and 253(4%) were Black and Hispanic, respectively.Twenty-year survival rates for Whites, Blacksand Hispanics were 76%, 83% and 81%,respectively. Blacks had significantly bettersurvival than Whites (p = 0.015). Hispanicsalso had significantly better survival thanWhites (p = 0.0363). This is likely due to thefact that Hispanics and Blacks had significantlylower percentages of high grade tumors.Additionally, the mean age at diagnosis forWhites was 64 compared to 54 and 52 forBlacks and Hispanics, respectively.There were 2026 cases of mucoepidermoidcancer with 11.9% and 5.2% Blacks andHispanics, respectively. Twenty-year survival60 AHNS 2013 Annual Meeting

Oral Papersrates in Whites, Blacks and Hispanics were88%, 89% and 95%, respectively. Hispanicshad significantly better survival than Whites(p = 0.049). Hispanics had significantly higherproportions of low grade tumors and lesstumor extension at the time of diagnosiswhen compared to both Whites and Blacks.Additionally, the mean age at diagnosis forWhites was 57 compared to 50 and 47 forBlacks and Hispanics, respectively.1307 cases of adenocarcinoma with 7.3% and3.7% Blacks and Hispanics, respectively, wereanalyzed. Twenty-year survival rates in Whites,Blacks and Hispanics were 60%, 79% and 56%,respectively. Blacks had significantly bettersurvival than Whites (p = 0.319). Hispanics hadpoorer survival than Whites and Blacks likelydue to the fact that they had larger tumor size,higher percentage of metastasis at diagnosisand lower percentage of patients receivingsurgery. Whites had a mean age at diagnosisof 64 compared to 61 and 53 for Blacks andHispanics.There were 1448 cases of squamous cellsalivary gland cancer with 5.7% and 2.4%Blacks and Hispanics, respectively. Thedifference in survival between the groupswith squamous cell cancer was small and notstatistically significant.399 cases of acinar salivary gland cancerwith 5.8% and 4.3% Blacks and Hispanics,respectively, were analyzed. Blacks andHispanics had better survival than Whites,although sample size was small and resultswere not statistically significant.Conclusions: Whites with salivary glandcancer have higher mean age at diagnosisthan Blacks and Hispanics suggesting arelationship between age and survival insalivary gland cancer. Tumor characteristicslikely account for the better survival observedin Hispanics when compared to Whitesand Blacks with mucoepidermoid cancer.Poor access to care may be responsible forlower-than-expected survival in Blacks withmucoepidermoid cancer.S024: MANAGEMENT OF THE NECK INCARCINOMA OF THE PAROTID GLANDSafina Ali, MD, Frank L Palmer, BA, MonicaWhitcher, BA, Jatin P Shah, MD, Snehal GPatel, MD, Ian Ganly, MDPhD; Memorial Sloan-Kettering Cancer CenterObjectives: The objectives of our study wereto review our experience in managementof regional lymph nodes, in patients withcarcinoma of the parotid gland, identifyclinico-pathological factors predictive of neckmetastases, identify neck levels pathologicallypositive for metastases following neckdissection and report neck recurrence rates.Materials and Methods: This was a singleinstitution retrospective cohort study. Weidentified 266 patients with previouslyuntreated carcinomas of the parotid glandbetween the years 1985- 2009. Three patientswere M1 at presentation and were excludedfrom analysis, leaving 263 patients forthe study. Patient, treatment and tumorcharacteristics were collected by retrospectivereview of patient charts. Patients werestratified by neck management into 3 groups:Observation (Obs), elective neck dissection(END) and therapeutic neck dissection (TND).The pathological positivity of each neck levelwas quantified for the END and TND groups.Clinico-pathological characteristics of theEND group and TND group vs Obs groupwere compared using the Chi square test ofassociation. Neck recurrence free survival wasdetermined for each group using Kaplan Meierstatistics.Results:There were 136 males and 127 females(median age 62 years). Of the 263 patients, 232were cN0 and 31 cN+. Of the cN0 patients, 158were selected to have neck observation and74 END. All cN+ patients had TND. Of the ENDgroup, occult neck metastases were detectedin 26 (35%) patients. The % positivity per necklevel was 19.2% level I (5/26), 84.6% level II(22/26), 61.5% level III (16/26), 26.9% level IV(7/26), 15.4% level V (4/26). Of the TND group,pathological positivity was found in 86.1%patients. The % positivity per neck level was59.3% level I (16/27), 85.2% level II (23/27), 85.2% level III (23/27), 59.3% level IV (16/27), 44.4%level V (12/27). Compared to the observationgroup, the END and TND groups were morelikely to be over 65 yrs of age and have clinicalstage T3/4 disease. Pathology showed theEND and TND groups had more aggressivehistology with a greater percentage highgrade, vascular invasion, perineural invasion,positive margins and pT stage. The majorityof patients who were pN+ in the END group(93%) and TND group (92%) had postoperativeradiation (PORT). Figure 1 outlines themanagement of the neck in our patient groups.The Obs group and END group (pN0) hadan excellent 5yr NRFS of 98.7% and 97.3%respectively. Patients who had pathologicallypositive neck on END or TND had a NRFS of88.6%.ConclusionPatients who are cN0 who present with clinicalstage T3/4 disease or high grade histologyhave a high rate of occult metastases involvingneck levels I-IV. Patients who are pN+ managedby END or TND followed by adjuvant PORTachieve a satisfactory NRFS of 88.6%.April 10 - 11, 2013 · www.ahns.info 61

Oral PapersS025: PROGNOSTIC FACTORS OFLOCALIZED SINONASAL MUCOSALMELANOMA Adil Benlyazid, MD, ThomasFilleron, PhD; Institut Claudius RegaudObjective: To report prognostic factorsof localized sinonasal mucosal melanoma(SNMM) treated in a multi-institutional setting.Design: Retrospective reviewSetting: French medical institutions.Patients: A total of 142 patients with nonmetastaticSNMM treated from 1980 through2008 with surgery alone or surgery andpostoperative radiotherapy.Results: On univariate analysis, only T stagewas significant(p=0.001) as a prognostic factorof 5-years relapse free survival : 42.8% forT1-2 vs 12.1% for T3-4. Locoregional controlwas significantly (p=0.018) improved bypostoperative radiotherapy : the locoregionalrecurrence rate was 55.1% with surgery alonevs 33.2% with postoperative radiotherapy.The 5-years metastatic recurrence rate wassignificantly higher for T3-4 tumors (43.1% vs21.6% for T1-2 tumors; p=0.016) and for sinustumors ( 41.7% vs 21.6% for nasal tumors;p=0.006).On multivariate analysis, T stage was foundas an independent risk factor of relapse freesurvival (HR = 2.36 ; p=0.003) and locoregionalcontrol (HR = 2.02 ; p=0.048). The hazard ratioof metastatic spreading of sinus tumors was2.5 (p=0.049) when compared to nasal tumors.Sinusal location and advanced T stage wereboth siginificantly associated to poorer 5-yearsoverall survival.Conclusion: This study shows that thereis a clear difference between sinusal andnasal mucosal melanomas : sinusal tumorsare associated to more frequent metastaticspreading and poorer prognosis.It also shows that AJCC T stage is still valid asa prognostic factor of relapse free survival,locoregional survival and overall survival.S026: SUPRACRICOID PARTIALLARYNGECTOMY FOR PRIMARY ANDRECURRENT LARYNGEAL CANCERSteven M Sperry, MD, Christopher H Rassekh,MD, Gregory S Weinstein, MD; University ofPennsylvaniaObjective: To review the oncologic outcomesfollowing supracricoid partial laryngectomy ina large U.S.-based cohort treated by a singlesurgeonDesign: Retrospective case seriesSetting: Tertiary-care university hospitalPatients: 83 consecutive patients withprimary or recurrent squamous cell carcinoma(SCCA) of the larynx undergoing supracricoidpartial laryngectomy (SCPL) from 1997-2010.Three radiation failure patients were convertedto total laryngectomy (TL) at the time ofsurgery due to positive margins, and thesecases were not included in the subsequentoutcomes analyses.Main Outcome Measures: 5-year localrecurrence free survival and laryngealpreservation, based on the Kaplan-Meiermethod, stratified by prior radiation treatmentResults: There were 44 primary laryngealtumors and 39 previously treated withradiation to the larynx; 22% were supraglotticor transglottic tumors. Of primary tumors,there were 18 T2 and 24 T3 tumors. The overall5-year local control rate for the series was95%, and for T2 and T3 primary tumors the ratewas 100% and 95%, respectively. In patientspreviously treated with radiation, the 5-yearlocal control was 91%, with a 91% laryngealpreservation rate. Amongst stage III or IVprimary laryngeal tumors for which concurrentchemoradiation was a treatment alternative,the 5-year local and locoregional control was95% and 79% respectively, and the 5-yearlaryngectomy-free survival was 90%. Ultimatelocal control was achieved for all patients inthe series. Hospital charts were available for76 patients, which demonstrated a significantcomplication rate of 21% and no perioperativedeaths. The rate of complications in previouslyradiated patients versus primary tumors wasnot significantly different. Complicationsincluded ruptured pexy (n=2), wound infection/fistula (n=4), aspiration/tracheitis (n=4), chyleleak (n=4), c. difficile colitis (n=2), and alcoholwithdrawal (n=1). No total laryngectomieswere performed for laryngeal dysfunction.Conclusions: We report the largest seriesof laryngeal SCC treated with SCPL in theU.S. This series demonstrates excellentlocal control for both primary and recurrentlaryngeal tumors, with functional larynxpreservation. In appropriately staged andselected patients with T2 or T3 primarylaryngeal tumors, or laryngeal tumorsfollowing prior radiation treatment, SCPLshould be considered as a treatmentalternative to radiation or total laryngectomy.S027: IMPACT OF SURGICAL RESECTIONON SURVIVAL IN PATIENTS WITHADVANCED REGIONAL METASTATICHEAD AND NECK CANCER INVOLVINGCAROTID ARTERY. Nauman Manzoor, MD,Jonathon Russell, MD, Shlomo Koyfman,MD, Joseph Scharpf, MD, Brian Burkey, MD,Mumtaz Khan, MD; Head and Neck Institute /Cleveland Clinic Foundation, Cleveland, Ohio,USA.Objective: To assess the outcome ofaggressive surgical management in patientswith advanced head and neck cancer involvingthe carotid artery.Patients and Methods: 22 patients weretreated between 2006 and 2012 for overt orsuspected involvement of common or internalcarotid artery with metastatic head and neckcancer. Patient demographics, disease andtreatment related factors were extracted fromthe charts retrospectively. 4 patients weretreated with carotid artery resection withreconstruction using the greater saphenousvein. Recurrence and disease specific survivaloutcomes were compared between differentgroups.Results: Median age at diagnosis was 66years (range 31- 84). Majority of the patientswere male (77%), were smokers (82 %) andhad recurrent regional metastatic disease atthe time of presentation (60%). 18 patientswere treated primarily with surgery whilethe remaining 4 were treated with chemoradiationas the primary treatment modality.Intra-operatively, 9 out of the 18 patientswho were treated with surgery had grossmalignant invasion of the carotid artery, with 9demonstrating involvement without invasion62 AHNS 2013 Annual Meeting

Oral Papersthat was able to be removed completely. 4 of9 patients with gross invasion of the carotidwere treated with resection and reconstructionwith the saphenous vein, while the remaining5 patients did not have resection of thecarotid. There were no major neurologicalcomplications except for 1 patient who had apost- operative stroke.Out of the 4 patients who were treated withcarotid resection, 2 died with a mediansurvival of 3.25 months while 1 is alivewith recurrence and 1 with no evidence ofrecurrence. In the group with unresectablecarotid disease, 4 patients died with mediansurvival of 7.15 months and 1 is alive withrecurrence.Out of the 9 patients who had completesurgical removal of tumor, 6 died with mediansurvival of 6 months while 1 is alive withdisease and 2 without disease. Out of the4 patients who received primary chemoradiationtherapy, 2 died with median survivalof 18.6 months while 2 are alive with noevidence of recurrence.This study included both primary andrecurrent head and neck cancer. Overall,patients who had a recurrent neck diseasehad a worse outcome (median survival =3.9months) compared to those whose neckdisease was part of their initial presentation(median survival = 10.2 months).Overall, 58 % of patients had local recurrencein the neck and 41 % had evidence of distantmetastasis during the course of follow upafter initiation of treatment for neck diseaseinvolving the carotid artery.Conclusion: Patients with advanced headand neck cancer involving the carotid arteryrepresent an unfortunate group with aninherent dismal prognosis. If the involvementof carotid is part of a recurrent regionalmetastasis, then the outcome is guarded.When disease burden merits, surgicalresection and reconstruction of the carotidartery may be completed without significantlycompromising overall survival.S028: FOLATE RECEPTOR BETATARGETING FOR IN VIVO OPTICALIMAGING OF HEAD AND NECKSQUAMOUS CELL CARCINOMA Joel Y Sun,Joel Thibodeaux, Gang Huang, Yiguang Wang,Jingming Gao, Philip S Low, Baran D Sumer;University of Texas Southwestern MedicalCenter; Purdue UniversityObjective: The folate receptor (FR) is a highaffinityfolic acid binding endocytic receptoruncommonly expressed in normal tissues. Thealpha isoform is overexpressed in a varietyof epithelial neoplastic cells. In contrast,functional expression of the beta isoform islimited to activated macrophages. Importantly,in many malignancies FR serves as aconvenient target for the delivery of tumorspecific drugs and imaging markers. Folic acidconjugated fluorescent dyes have been usedto guide tumor resection in mouse modelsand more recently in humans. However, theirpotential in HNSCC is unclear due to reporteddifferential FR expression and an incompletecharacterization of FR expression in tumors.We hypothesized that tumor infiltratingmacrophages expressing FR-beta could allowfluorescent visualization of HNSCC tumorsusing folate conjugated dyes even when FRexpression in cancer cells is low.Study Design: In vivo animal study andretrospective review of clinical pathologicspecimens.Setting: Academic tertiary referral center.Subjects and Methods:Immunohistochemistry was performed on atissue microarray (TMA) containing primarytumor tissue and matched tumor free surgicalmargins from 22 patients who underwentHNSCC resection. Primary tumor sitesincluded the oral tongue, base of tongue,tonsil, supraglottic larynx, glottic larynx andhypopharynx. We evaluated the expression ofFR-alpha, FR-beta, transforming growth factorbeta(TGF-B), the macrophage marker CD68and the alternatively activated macrophagemarker arginase-1 using appropriate positiveand negative controls for staining. Orthotopicxenograft tumor models were generated byinjecting HN5 and FaDu HNSCC cell lines intothe submental triangle of nude mice. The micereceived 0.8 mg/kg intravenous injections offluorescein isothiocyanate conjugated folate(Folate-FITC) and were imaged for fluorescentemission under 495nm light two hourslater. Mouse tissues were then sectioned forexamination using fluorescent microscopy.Results: No FR-alpha expression wasobserved in any TMA tumor or normal tissuespecimen. All tumor samples demonstratedstrongly positive FR-beta expression. Cellularmorphology and CD68 expression identifiedthe FR-beta expressing cells as tumorinfiltrating macrophages. No associationwas observed between FR-beta stainingand TGF-B or arginase-1 staining. In thexenograft models, tumors showed strongfluorescence in vivo after folate-FITC injection.Normal salivary glands and surroundingneck muscles did not demonstrate significantfluorescence. Histologic examination of themouse xenografts revealed that fluorescencewithin the tumors was confined to areas ofinflammatory cell infiltration and necrosis,consistent with our TMA data.Conclusion: HNSCC tumors contain asignificant population of FR-beta expressingmacrophages. In contrast to many othercarcinomas, the HNSCC tumor cells in ourTMA did not express FR-alpha. Despite this,folate conjugated FITC dye was able to targetand specifically label tumor xenografts in micedue to the FR-beta expression on infiltratingmacrophages, allowing macroscopicfluorescence imaging. Thus, the folate linkeddelivery of fluorescent dye into the tumormicroenvironment can facilitate image guidedsurgery even when HNSCC tumor cellsthemselves do not express FR.April 10 - 11, 2013 · www.ahns.info 63

Oral PapersS029: DECITABINE AND CISPLATINCOMBINATION THERAPY FOR HEAD ANDNECK SQUAMOUS CELL CARCINOMAChi T Viet, DDS, PhD, Dongmin Dang, MD, YiYe, PhD, Brian L Schmidt, DDS, MD, PhD; NewYork University, Bluestone Center for ClinicalResearchCisplatin is the primary chemotherapy for headand neck squamous cell carcinoma (HNSCC).No rescue agents are available when cisplatinresistance occurs. We hypothesize that DNAmethylation of key genes mediates cisplatinresistance; moreover, pre-treatment withdecitabine, a demethylating agent, restorescisplatin sensitivity by mediating geneexpression changes, which lead to inhibition ofproliferation and reduction in cancer pain.Objectives: 1) Evaluate the anti-proliferativeeffect of decitabine and cisplatin (i.e.combination treatment) on HNSCC in vitro andin a preclinical model. 2) Determine whethercombination treatment reduces cancer pain.3) Determine whether the differences in geneexpression between cisplatin-sensitive andcisplatin-resistant cell lines correlate withthose differences between cisplatin-sensitiveand cisplatin-resistant tumors in patients. 4)Determine whether decitabine treatment invitro reverses the gene expression differencespresent in the cisplatin-resistant cell lines.Methods: SCC-25, a cisplatin-sensitiveHNSCC cell line, and SCC-25/CP, a cisplatinresistantcell line, were pre-treated with 5µMdecitabine and then treated with cisplatin(3-300 µM) for 48 hours. Proliferation wasquantified using an MTS assay. A preclinicalmodel was created by inoculating SCC-25/CP cells into the hind-paw of BALB/c mice.Twenty-four mice were placed into one of fourtreatment groups: control sham, decitabineonly,cisplatin-only, or combination treatment.Decitabine (6 mg/kg) was administered onpost-inoculation days (PID) 7 and 9, andcisplatin (6 mg/kg) was administered onPID 12, 15, 18, and 21. Tumor growth wasquantified. Mechanical allodynia (i.e. pain)was quantified with a paw withdrawal assay.Formalin-fixed, paraffin-embedded biopsieswere obtained from HNSCC patients whounderwent chemotherapy with cisplatin.Tumors were classified as either cisplatinsensitive(RECIST 3 or 4) or cisplatin-resistant(RECIST 1 or 2). Gene expression wasquantified in these two sets of samples.Results: In the in vitro model, pre-treatmentwith decitabine restored cisplatin sensitivityin SCC-25/CP, the cisplatin-resistant line, andreduced the cisplatin dose required to inhibitproliferation by 50% (i.e. ED50) to levelscomparable to SCC-25, the cisplatin-sensitiveline. In the preclinical model, decitabine andcisplatin combination treatment resultedin significant reduction of tumor growthcompared to control, whereas decitabine orcisplatin treatment alone did not. Combinationtreatment significantly reduced mechanicalallodynia. We quantified gene expressionof IGFBP-3, hMLH1, S100, and SAT1, whichare genes shown to correlate with cisplatinresponse in other cancers. We showed thatcisplatin-sensitive and cisplatin-resistantpatient tumors have distinct expressionprofiles. Decitabine treatment of cisplatinresistantHNSCC cells in vitro reversed geneexpression toward a cisplatin-sensitive profile.Conclusion: Decitabine restores cisplatinsensitivity in a preclinical HNSCC model,and has potential use in the HNSCCchemotherapeutic regimen for cisplatinresistanttumors. The combination of cisplatinand decitabine significantly reduces HNSCCproliferation and HNSCC pain.S030: USE OF RETINOBLASTOMAPROTEIN (PRB) IMMUNOHISTOCHEMICALSTAINING AS A PROGNOSTIC INDICATORIN OROPHARYNGEAL SQUAMOUSCELL CARCINOMA. Adam L Baker, MD,Joseph Curry, MD, Gao W, BS, Cognetti D,MD, T Zhan, PhD, V Bar-Ad, MD, M Tuluc, MD;Thomas Jefferson University, Departmentsof Otolaryngology, Radiation Oncology, andPathologyObjectives and Background: Prognosis inpatients with oropharyngeal cancer appearsto be improved with HPV-related tumors, yetsome patients that appear to be HPV-relatedstill do poorly. The HPV E7 protein result ininactivation of pRB and thereby contributes totumorigenesis. Our objective was to determineif additional prognostic information could beobtained from pRb staining in patients withoropharyngeal carcinoma.Design: A retrospective cohort of all patientsdiagnosed with oropharyngeal squamouscell carcinoma (OPSCC) from 2006-2009 wereidentified. Immunohistochemical (IHC) stainingfor pRb was performed on tumor samplescorresponding to patients within the cohort.Patients were stratified by p16 status as asurrogate for HPV positivity. Kaplan-Meiersurvival estimates, Cox proportional hazardregression models, and recursive partitioningtrees were used for statistical analysis of thedata.Setting: Single tertiary care institutionPatients: Seventy two patients were identifiedwith oropharyngeal cancer.Main Outcomes Measures: Overall survival(OS) and disease free survival (DFS) weremeasured for each patient within the cohort, aswere additional variables such as pRB status,age tobacco use.Results: The Kaplan-Meier OS estimate for2 and 5 year survival rate was 83.3% and67.6%, respectively. DFS for 2 and 5 yearswas 76.9% and 73.8% respectively. The64 AHNS 2013 Annual Meeting

Oral Papersproportional hazards model found that pRbpositive individuals had a decreased risk ofboth death (p=0.033) and recurrence (p=0.004)when compared to individuals who are pRbnegative among both p16 positive or negativeindividuals. On recursive partitioning analysiswithin the p16 positive patients, there washigher risk of death of among the Rb negativetumors versus those who are pRb positive(p=0.004).Conclusions: This study suggests that thereis an increase in median OS and DFS in pRbpositive OPSCC. pRB may offer additionalprognostic in patients with OPSCC beyondcurrently used markers such as p16.S031: ROLE OF HPV DNA DETECTIONIN PLASMA AND SALIVA IN THEEARLY DETECTION AND PREDICTIONOF RECURRENCE IN HPV POSITIVEOROPHARYNGEAL CARCINOMA SunM Ahn, MD, Jason Y Chan, MBBS, DariaGaykalova, PhD, Joseph A Califano, MD;Department of Otolaryngology, Head and NeckSurgery, Johns Hopkins Medical Institutions &Milton J Dance Head and Neck Center, GreaterBaltimore Medical Center, Baltimore, MarylandBackground: Human papilloma virus (HPV)16 is a major causative factor in squamous cellcarcinoma (SCC) of the oropharynx. Previousstudies have demonstrated that HPV-16 DNAcan be detected in the pre-treatment plasmaand salivary rinses from these patients. Herewe investigated the feasibility of HPV-16 DNAdetection in both pre and post-treatmentplasma and salivary rinses and its potentialrole as a marker of recurrent disease.Methods: A cohort of 54 patients withoropharyngeal and unknown primary SCC withknown HPV-16 tumor status, pre- and posttreatmentplasma and salivary samples wasassembled. Real time quantitative polymerasechain reaction was utilized and the CaSki(American Type Culture Collection, Manassas,VA) cell line, with 600 copies/ genome HPVwas used to develop standard curves for theHPV viral copy number. Standard curves forHPV-16 E6 and E7 were developed using DNAextracted from CaSki cells serially diluted to5ng, 0.5ng, 0.05ng, 0.005ng and 0.0005ng.A standard curve was also developed forthe housekeeping gene β-actin (2 copies/genome). HPV-16 E6 and E7 DNA copynumbers were determined in the plasma andsalivary samples and considered positive if>0.001 copy/genome. Simple sensitivity andspecificity analyses were performed.Results: Forty (74%) patients had HPV-16detected in their primary tumors prior totreatment, and of these HPV positive patients,5 (12.5%) recurred (Figure 1). Of the 40 patientswith HPV positive tumor, 30 (75%) patientshad HPV-16 DNA detected in pre-treatmentsamples and one (2.5%) patient had HPV-16DNA detected in post-treatment surveillancesamples. None of the patients with HPVnegative tumor had detectable HPV-16 DNAin the pre-treatment samples. The one (100%)patient with HPV positive post-treatmentsample ultimately developed recurrence. Ofthe 14 patients with HPV negative tumors and29 patients with HPV positive tumors who didnot recur, none were HPV-16 positive in posttreatmentplasma and saliva. The sensitivity,specificity, negative predictive value (NPV)and positive predictive value (PPV) of pretreatmentcombined salivary-based andplasma-based HPV-16 DNA status are 75%,100%, 58% and 100% respectively (Table 1).The sensitivities of saliva or plasma alonewere 64.86% and 63.64%, respectively. Thepresence of HPV-16 DNA in post-treatmentplasma and salivary rinse was 100% specificand 25% sensitive in detecting loco-regional ormetastatic recurrence (Table 2) .Conclusion:Using a combination of pre-treatment plasmaand salivary rinses can increase the sensitivityof pre-treatment HPV-16 status as a tool forscreening patients with HPV positiveoropharyngeal HNSCC. In addition, patientswith the presence of HPV-16 DNA insurveillance plasma or salivary rinse may be ata significant risk of developing recurrence.Quantitative analysis of HPV-16 DNA insalivary rinses after primary treatment mayallow for early detection of recurrence inpatients with HPV positive oropharyngealHNSCC.S032: PREVENTION OF DEPRESSIONUSING ESCITALOPRAM IN PATIENTSUNDERGOING TREATMENT FOR HEADAND NECK CANCER William Lydiatt, MD,Diane Bessette, PA, Kendra Schmid, PhD,Harlan Dayles, MS, William Burke, MD;Nebraska Medical Center and NebraskaMethodist HospitalContext: Major depressive disorder developsin up to half of patients undergoing treatmentfor head and neck cancer resulting insignificant morbidity. Preventing depressionduring the course of cancer treatment may,thus, be of great benefit.Objective: To determine whether prophylacticuse of the antidepressant escitalopram woulddecrease the incidence of depression inApril 10 - 11, 2013 · www.ahns.info 65

Oral Paperssubjects receiving primary therapy for headand neck cancer.Design, Setting, Participants andOutcome Measures: A randomized, doubleblind,placebo-controlled trial of escitalopramversus placebo was conducted in a groupof non-depressed subjects diagnosed withhead and neck cancer who were aboutto enter cancer treatment. Subjects werestratified by gender, site, stage (early versusadvanced), and by primary modality oftreatment (radiation versus surgery). Theprimary outcome measure was the numberof participants who developed moderateor greater depression (scores on the QuickInventory of Depressive Symptomology-SelfRated > 11).Results: From January 6, 2008 to December28, 2011, 148 patients were randomized.Significantly fewer subjects receivingescitalopram developed depression (24.6%placebo vs. 10% escitalopram, stratified logranktest p=0.04). A Cox proportional hazardregression model compared the two treatmentgroups after controlling for age, baselinesmoking status, and stratification variables.The hazard ratio of 0.37 (95% CI: 0.14, 0.96)demonstrated an advantage of escitalopram(p=0.04). Patients undergoing radiotherapyas the initial modality were significantlymore likely to develop depression than thosereceiving surgery (radiotherapy, comparedto surgery group, HR 3.6 [95%CI: 1.38, 9.40,p=0.009]). Subjects in the escitalopram groupwho completed the study and were notdepressed rated their overall quality of life assignificantly better for 3 consecutive monthsfollowing cessation of drug.Conclusions: In non-depressed subjectsundergoing treatment for head and neckcancer, prophylactic escitalopram reducedthe risk of developing depression by morethan 50%. In non-depressed subjects whocompleted the trial, quality of life wasalso significantly better for 3 consecutivemonths following cessation of the drug inthe escitalopram group. These findings haveimportant implications for management ofhead and neck patients.Trial Registration: ClinicalTrials.gov ProtocolRegistration System, ID=NCT00536172, https://register.clinicaltrials.gov/prs/app/action/SelectProtocol?sid=S00017GX&selectaction=View&uid=U0000GD7&ts=6&cx=-a8i1r4S033: SIGNIFICANCE OF PIK3CAMUTATIONS IN OROPHARYNGEALSQUAMOUS CELL CARCINOMA AndrewB Sewell, MD, Natalia Isaeva, PhD, Wendell GYarbrough, MD, MMHC, FACS; Yale University,Vanderbilt UniversityDespite the shared histology of HPV-positive(HPV+) and HPV-negative (HPV-) oropharyngealsquamous cell carcinoma (OPSCC), HPV(+)tumors have fewer cytogenetic abnormalitiesand fewer mutations than HPV(-) tumors,confirming different mechanisms drivingtumor development and progression.Previously, we found that up to 40% of HPV(+)tumors harbor PIK3CA mutations, which areinvolved in tumorigenesis and represent anemerging potential target for drug therapy.Many Phase II studies have demonstratedthe safety and efficacy of various PI3K/AKT/mTOR inhibitors in patients with breast, lung,and prostate cancer with PIK3CA mutations.However, we have discovered that OPSCCtumors with activating mutations of PIK3CAdid not have significantly activated levels ofthe downstream targets, including AKT andmTOR, most likely due to increased levels ofthe tumor suppressor PTEN.Using a combination of genomic profilingand proteomic studies, we screened 40prospectively collected OPSCC tumors (23HPV+, 17 HPV-) for the most common cancerrelatedPIK3CA mutations. We detectedthree PIK3CA mutations in eight tumors,with known activating mutations (exon 9,E542K, E545K) seen in 7 tumors; one tumorhad a mutation which has been has beenshown to be functionally indistinguishablefrom wild-type PIK3CA. All of the mutanttumors were detected in HPV(+) patients(7/23, 30.4%). Interestingly, in these similarlytreated patients, 5-year disease-free survivalwas 100% in HPV(+) PIK3CA mutant patients,versus 61% in HPV(+) PIK3CA wild-type. Thesedata suggest that PIK3CA mutations maybe beneficial and may represent a positiveprognostic marker for OPSCC patientsreceiving traditional chemo- and radiotherapy.Reverse phase protein array (RPPA)probed with 137 antibodies and analysesdemonstrated that PIK3CA mutants and wildtypetumors separate into two groups withdistinct protein expression profiles, includingdown-regulated proteins (ERK2, MRE11,mTOR, caspases 3 and 7) and up-regulatedproteins (PTEN, p100α, and E-cadherin,among others) in mutant specimens. Incontrast, there was no significant differencein phosphorylation of p70S6K, mTOR, andAKT. Immunoblotting for randomly selectedtumors, including HPV(+) PIK3CA mutant andwild-type tumors, validated RPPA findings.Activation of downstream targets of PIK3CAsignaling can be blocked at several levels,including activation of phosphatases, and/orinhibition of kinase activity. Since we foundthat the protein levels of the tumor suppressorPTEN were increased in PIK3CA mutanttumors, we suggest that up-regulation of PTENinhibits PI3K activity by dephosphorylatingphosphatidylinositol.Although there are many PI3K/AKT/mTORinhibitors in clinical trials for different typesof cancer, it is very important to determinein pre-clinical studies if these inhibitors areeffective in PIK3CA-mutant OPSCC tumors.Two available HPV(+) HNSCC cell lines, UM-SCC-47 and UT-SCC-090, harbor wild-typePIK3CA; therefore, E542K and E545K mutationswere introduced into wild-type PIK3CA vectorusing site-directed mutagenesis, and stablyoverexpressed in HPV(+) cells to performboth short-term cell viability and long-termclonogenic survival assays with the PI3K/AKT/mTOR inhibitors BEZ-235, MK-2206, andGDC-0941. Stable PIK3CA-mutant clones wereimplanted into NUDE mice to evaluate the invivo sensitivity of PI3K/AKT/mTOR inhibitors.Future directions and detailed results will bediscussed.66 AHNS 2013 Annual Meeting

Poster ListingP001 (COSM Poster #051) EXPRESSIONPROFILE AND IN VITRO BLOCKADE OFPD-1/PD-L1 IN PATIENTS WITH HEAD ANDNECK SQUAMOUS CELL CARCINOMAIan-James Malm, Tullia C Bruno, PhD, MikhailGorbounov, BA, Janis Taube, MD, CharlesDrake, MD, PhD, Young Kim, MD, PhD; JohnsHopkins Medical InstitutionsP002 (COSM Poster #052) PD-1BLOCKADE COMBINED WITH TEGVAX(TLR AGONISTS-ENHANCED GVAX) CANINDUCE REGRESSION OF ESTABLISHEDPALPABLE TUMORS Ian-James Malm, BA,Juan Fu, MD, PhD, Qi Zheng, MD, PhD, DrewPardoll, MD, PhD, Young J Kim, MD, PhD;Johns Hopkins Medical InstitutionsP003 (COSM Poster #053) THE ROLE OFTHE PD-1:PD-L1 PATHWAY IN INNATEAND ADAPTIVE IMMUNE RESISTANCEIN HPV NEGATIVE HEAD AND NECKCANCERS. Geoffrey D Young, MD, PhD,Belinda Akpeng, Justin A Bishop, MD, WilliamH Westra, MD, Suzanne L Topalian, MD, DrewM Pardoll, MD, PhD, Sara I Pai, MD, PhD,Shiwen Peng; Departments of Otoloryngology-Head and Neck Surgery, Surgery, Oncology,and Pathology, The Johns Hopkins UniversitySchool of Medicine, Baltimore, MD, USA.P004 (COSM Poster #054) MULTITIERCOMPUTATIONAL GENETIC ANALYSISIDENTIFIES IMMUNE PATHWAYSASSOCIATED WITH INCREASEDSUSCEPTIBILITY TO HPV-ASSOCIATEDHEAD AND NECK CANCER Chaya Levovitz,Sarah Alshawish, Weijia Zhang, PhD, PaoloBoffetta, MD, MPH, Andrew Sikora, MD, PhD;Mount Sinai School of MedicineP005 (COSM Poster #055) SENSORYNEURONS REGULATE HEAD ANDNECK SQUAMOUS CELL CARCINOMAPROLIFERATION AND GENEEXPRESSION. Scott H Troob, MD, Andrea NFlynn, PhD, Yi Ye, PhD, Chi T Viet, DDS, PhD,Brian L Schmidt, DDS, MD, PhD; Department ofOtolaryngology - Head and Neck Surgery, NewYork University Langone Medical Center andBluestone Center for Clinic Research, New YorkUniversity, New York, NYP006 (COSM Poster #056) OCT-4 STEMCELL GENE IS OVEREXPRESSED INORAL SQUAMOUS CELL CARCINOMAMaria Fernanda D Rodrigues, PhD, FlaviaCalo A Xavier, PhD, Eloiza H Tajara, PhD, Headand Neck Genome Project Gencapo, Fabio DNunes, PhD; Department of Oral Pathology,Dental School University of São Paulo, SãoPaulo-SP, BrazilP007 (COSM Poster #057) MALIGNANTTRANSFORMATION OF MURINE3T3 CELLS BY CO-CULTURING WITHNASOPHARYNGEAL CARCINOMACELLS Wen-son Hsieh, Dr, Fredrik Petersson,Associate, professor, De -Yun Wang, Associate,professor, Kwok Seng Loh, Associate,professor, Fenggang Yu, PhD; NationalUniversity of SingaporeP008 (COSM Poster #058) RECURRENTGENOMIC ALTERATIONS OF FHITGENE WITH IMPACT ON LYMPHATICMETASTASIS IN EARLY ORALSQUAMOUS CELL CARCINOMA Inn-ChulNam, MD, Young-Hoon Joo, MD, Kwang-JaeCho, MD, Sung-Won Park, Yeon-Soo Lee, MD,Yeun-Jun Chung, MD, Min-Sik Kim, MD; TheCatholic University of KoreaP009 (COSM Poster #059) GENEEXPRESSION ALTERATIONS ASSOCIATEDWITH TP53 LOSS AND AGGRESSIVEBEHAVIOR IN AN ORTHOTOPIC MOUSEMODEL OF HEAD AND NECK SQUAMOUSCELL CARCINOMA (HNSCC) Thomas J Ow,MD, MS, Vlad C Sandulache, MD, PhD, DaisukeSano, MD, PhD, Pickering R Curtis, PhD, HeathD Skinner, MD, PhD, Mitchell Frederick, PhD,Wang Jing, PhD, Jiexin Wang, MS, ZhaoMei, MD, Tongxin Xie, MD, PhD, Harris MThomas, PhD, Prystowsky B Michael, MD,PhD, Richard V Smith, MD, Lleras A Roberto,MS, Belbin J Thomas, PhD, Myers N Jeffrey,MD, PhD; Albert Einstein College of Medicine;Montefiore Medical Center; University ofTexas, MD Anderson Cancer CenterP010 (COSM Poster #060) COLLAGEN,TYPE XIV, ALPHA 1 PROMOTERHYPERMETHYLATION IS ASSOCIATEDWITH ADVANCED SALIVARY GLANDADENOID CYSTIC CARCINOMA MariettaTan, MD, Chunbo Shao, MD, PhD, Justin ABishop, MD, Elana J Fertig, PhD, MichaelConsidine, MS, William H Westra, MD, PatrickK Ha, MD; Departments of Otolaryngology-Head and Neck Surgery, Pathology, andOncology Biostatistics, Johns Hopkins MedicalInstitutions, Baltimore, MD, USA; Milton J.Dance Jr. Head and Neck Center, GreaterBaltimore Medical Center, Baltimore, MD, USAP011 (COSM Poster #061) TUMOR-ASSOCIATED ENDOTHELIAL CELLSPROMOTE TUMOR METASTASIS BYCHAPERONING CIRCULATING TUMORCELLS AND PROTECTING THEM FROMANOIKIS Arti Yadav, MS, Bhavna Kumar, MS,Jun-Ge Yu, MD, Matthew Old, MD, TheodorosN Teknos, MD, Pawan Kumar, PhD; Departmentof Otolaryngology-Head and Neck Surgery andComprehensive Cancer Center, The Ohio StateUniversity, Columbus, OH 43210P012 (COSM Poster #062) THE TUMORPROMOTING CHEMOKINES GRO-A ANDIL-8 ARE UP-REGULATED IN HEAD ANDNECK SQUAMOUS CELL CARCINOMA.Tammara L Watts, MD, PhD, Ruwen Cui, BA;Unviversity of Texas Medical BranchP013 (COSM Poster #063) CLINICAL ANDMOLECULAR DIFFERENCES BETWEENSMOKERS AND NONSMOKERS WITHORAL TONGUE CANCER Ryan Li, MD,Carole Fakhry, MD, MPH, Wayne M Koch, MD,Nishant Agrawal, MD; Johns Hopkins MedicalInstitutions-Department of Otolaryngology/Head and Neck SurgeryApril 10 - 11, 2013 · www.ahns.info 67

Poster ListingP014 (COSM Poster #064) TMEM16A, AFUNCTIONALLY ACTIVE ION CHANNELIN H&N CANCER AND POTENTIALTARGET FOR ENHANCING CYTOTOXICTHERAPIES Jason Kass, MD, PhD, Dong Xiao,PhD, Douglas Holt, BS, Carol Bertrand, PhD,Umamaheswar Duvvuri, MD, PhD; Universityof Pittsburgh Medical Center, Veteran AffairsMedical CenterP015 (COSM Poster #065)INHIBITION OF PROTEIN ARGININEMETHYLTRANSFERASE-5 (PRMT-5)DECREASES CELL GROWTH, DIVISION,AND MIGRATION IN HEAD AND NECKSQUAMOUS CELL CARCINOMA BrianBoyce, MD, Matthew Old, MD, TheodorosTeknos, MD, Robert Baiocchi, MD, ManchaoZhang, Quintin Pan, PhD; The Ohio StateUniversityP016 (COSM Poster #066) GENEEXPRESSION PROFILE OF HNSCCCANCER STEM CELLS Vivian F Wu, MD,MPH, Sudha Krishnamurthy, PhD, MaureenSartor, PhD, Mark E Prince, MD, Jacques E Nor,DDS, MS, PhD; University of MichiganP017 (COSM Poster #067) BIOLOGICALMARKERS AS PREDICTORS OFCLINICAL OUTCOME IN ADENOIDCYSTIC CARCINOMA OF THE HEAD ANDNECK Minoru Toyoda, MD, Koichi Sakakura,MD, Kyoichi Kaira, MD, Yuki Yokobori, MD,Kazuaki Chikamatsu, MD; Department ofOtolaryngology-Head and Neck Surgery,Gunma University Graduate School of MedicineP018 (COSM Poster #068) EVALUATIONOF WT1 PROMOTER METHYLATIONIN SALIVARY ADENOID CYSTICCARCINOMA (ACC) Ryan H Sobel, MD,Marietta Tan, MD, Chunbo Shao, PhD, JustinBishop, MD, Elana J Fertig, PhD, Patrick KHa, MD; Johns Hopkins Medical Institutions,Baltimore, MD, USA; Milton J Dance Jr Headand Neck Center, Greater Baltimore MedicalCenter, Baltimore, MD, USAP019 (COSM Poster #069) HIGHLYAGGRESSIVE HPV-RELATEDOROPHARYNGEAL CANCER: CLINICAL,RADIOLOGIC, AND PATHOLOGICCHARACTERISTICS Azeem Kaka, MD,Bhavna Kumar, MS, Pawan Kumar, MS, PhD,Paul E Wakely Jr., MD, Claudia M Kirsch,MD, Matthew O Old, MD, Amit Agrawal, MD,Enver Ozer, MD, Ricardo L Carrau, MD, DavidE Schuller, MD, Farzan Siddiqui, MD, PhD,Theodoros N Teknos, MD; The Ohio StateUniversity, Henry Ford Health SystemP020 (COSM Poster #070) EXPRESSIONOF THE WILMS’ TUMOR 1 GENE INVASCULAR ANOMALIES OF THE HEADAND NECK Chun-Yang Fan, MD, PhD, JohnR Sims, BS, Gresham T Richter, MD, YuemengDai, MD, PhD, James Y Suen, MD; Universityof Arkansas for Medical SciencesP021 (COSM Poster #071) THE IMPACTOF TISSUE HANDLING FACTORS ONPHOSPHORYLATED BIOMARKERSIN HEAD AND NECK CANCERBIOSPECIMENS Jacob I Tower, Mark WLingen, DDS, PhD, Tanguy Y Seiwert, MD,Alexander Langerman, MD; University ofChicagoP022 (COSM Poster #072) SERUMBIOMARKERS IN HEAD AND NECKSQUAMOUS CELL CANCER Nadine Kaskas,Tara Moore-Medlin, Gloria McClure, JohnVanchiere, MD, Cherie-Ann Nathan, MD, FACS;Department of Otolaryngology/Head and NeckSurgery, Department of Microbiology andthe Feist-Weiller Cancer Center, LSU HealthSciences Center, Shreveport, LouisianaP023 (COSM Poster #073) FRACTALANALYSIS OF NUCLEAR HISTOLOGYINTEGRATES TUMOR ANDMICROENVIRONMENT INTO A SINGLEPROGNOSTIC FACTOR IN OSCC PinakiBose, PhD, Kevin Hynes, MSc, ElizabethKornaga, MSc, Nigel T Brockton, PhD, MauroTambasco, PhD, Joseph C Dort, MD, AlexanderC Klimowicz, PhD; Ohlson Research Initiative,Southern Alberta Cancer Research Institute,University of CalgaryP024 (COSM Poster #074)CHARACTERIZATION OF 22Q13.31REGION AND ITS ASSOCIATION WITHTUMOR SUPPRESSOR GENES IN HEADAND NECK CARCINOMAS Fernanda BBertonha, PhD, Mateus C Barros Filho, MsC,Hellen Kuasne, MsC, Luiz P Kowalski, PhD,Claudia A Rainho, PhD, Silvia R Rogatto, PhD;Universidade Estadual Paulista (UNESP);Hospital AC Camargo; Londrina StateUniversityP025 (COSM Poster #075) ERBB FAMILYIS PREDICTOR OF POOR OUTCOMESIN ORAL CANCER PATIENTS WITHCAPSULAR RUPTURE IN THE LYMPHNODES Sabrina Daniela Silva, PhD, Moulay AAlaoui-Jamali, PhD, Michael Hier, Dr, EdgardGraner, PhD, Luiz Paulo Kowalski, PhD; McGillUniversity, AC Camargo Hospital, School ofDentistry of PiracicabaP026 (COSM Poster #076) ALTERATIONOF COPIES NUMBER AND METHYLATIONOF TUMOR SUPPRESSOR GENESINVOLVED IN CARCINOGENESISOF CARCINOMA EX-PLEOMORPHICADENOMA Fernanda V Mariano, DDS,PhD, Rogério O Gondak, DDS, PhD, RicardoD Coletta, DDS, PhD, Albina Altemani,MD, PhD, Oslei P Almeida, DDS, PhD,Luiz P Kowalski, MD, PhD; Department ofOral Diagnosis, Piracicaba Dental School,University of Campinas (UNICAMP)/Department of Pathology, Medical SciencesFaculty, University of Campinas (UNICAMP)/Departament of Head and Neck, AC CamargoHospital, São PauloP027 (COSM Poster #077) RELATIONSHIPBETWEEN PAPILLARY THYROIDCANCER, BRAFV600E AND FUNCTIONALBIOMARKERS OF DISEASE Edward Shin,MD, Joe Rousso, MD, Ashlie Darr, MD, JamesP Azzi, MD, Raj Tiwari, PhD, Jan Geliebter, PhD,Theodore Nowicki, PhD, Nicolas Kummer, MD,Melanie MacEwan, PhD; NYEE NYMC68 AHNS 2013 Annual Meeting

Poster ListingP028 (COSM Poster #078)RADIOSENSITIZATION OF HPV POSITIVEHEAD AND NECK SQUAMOUS CELLCARCINOMAS (HNSCC) BY CHK1INHIBITION Chia-Jung Busch, Dr, ThorstenRieckmann, Dr, Simon Laban, Dr, CordulaPetersen, Prof, Dr, Rainald Knecht, Prof, Dr,Ekkehard Dikomey, Prof, Dr, Malte Kriegs,Dr; Department of Otorhinolaryngology andHead and Neck Surgery, Head and NeckCancer Center of the University Cancer CenterHamburg, University Medical Center HamburgEppendorf, Hamburg, GermanyP029 (COSM Poster #079) OPTIMIZATIONOF RADIOSENSITIZING STRATEGIESUSING REAL-TIME MAGNETICRESONANCE IMAGING (MRI) INANAPLASTIC THYROIC CANCER Vlad CSandulache, MD, PhD, Heath D Skinner, MD,PhD, Yunyun Chen, PhD, Jaehyuk Lee, PhD,Christopher M Walker, BS, James A Bankson,PhD, Stephen Y Lai, MD, PhD; Baylor College ofMedicine, U.T.M.D. Anderson Cancer CenterP030 (COSM Poster #080) THERAPEUTICPOTENTIALS OF HISTONE DEACETYLASEINHIBITORS FOR CANCER STEM CELL-LIKE PHENOTYPE IN SQUAMOUS CELLCARCINOMA OF THE HEAD AND NECKKoichi Sakakura, MD, PhD, Takaaki Murata, MD,PhD, Minoru Toyoda, MD, Yuki Yokobori, MD,Kazuaki Chikamatsu, MD, PhD; Departmentof Otolaryngology-Head and Neck Surgery,Gunma University Graduate School ofMedicineP031 (COSM Poster #081) NOVELTREATMENT OF HYPOPHARYNGEALCANCER USING DACHPT-LOADEDPOLYMERIC MICELLE Miwako Kimura, MD,PhD, H Cabral, PhD, Y Miura, PhD, M R Kano,MD, PhD, S Tanaka, PhD, H Nishihara, MD,PhD, Y Matsumoto, MD, PhD, K Toh, PhD, NNishiyama, PhD, K Kataoka, PhD; Departmentof Otolaryngology, International University ofHealth and Welfare, Sanno HospitalP032 (COSM Poster #082) SALIVA FROMORAL CANCER PATIENTS PROMOTESHNSCC GROWTH, WHILE CURCUMINTREATMENT RESULTS IN DECREASEDEXPRESSION OF SALIVARY CYTOKINESSaroj Basak, PhD, Suejung G Kim, BS, AlborzZinabadi, BS, Meera Srivastava, PhD, Eri SSrivatsan, PhD, Marilene B Wang, MD; UCLADavid Geffen School of Medicine, VA GreaterLos Angeles Healthcare SystemP033 (COSM Poster #083) C-FOS/ACTIVATOR PROTEIN-1 INHIBITORPREVENTS LYMPH NODE METASTASISWITH HEAD AND NECK CANCER INORTHOTOPIC IMPLANTATION MODELDaisuke Kamide, MD, Taku Yamashita, MD,PhD, Koji Araki, MD, PhD, Masayuki Tomifuji,MD, PhD, Shunichi Shiozawa, MD, PhD,Akihiro Shiotani, MD, PhD; Department ofOtolaryngology-Head and Neck Surgery,National Defense Medical College of Japan.Department of Medicine, Kyushu UniversityBeppu Hospital of JapanP034 (COSM Poster #084)ENHANCEMENT OF ANTITUMORACTIVITY OF OHSV (34.5ENVE) FORHEAD AND NECK SQUAMOUS CELLCARCINOMA CELLS BY BORTEZOMIBMatthew Old, MD, Jun-Ge Yu, MD, Ji Y Yoo,Brian Hurhuiz, Chelsea Boyard, Quintin Pan,PhD, Pawan Kumar, PhD, Bhavna Kumar,Theodoros Teknos, MD, Balveen Kaur, PhD;James Comprehensive Cancer Center, WexnerMedical at The Ohio State UniversityP035 (COSM Poster #085) THE PRO-TUMORIGENIC ROLE OF TLR2 INHEAD AND NECK SQUAMOUS CELLCARCINOMA Lovisa Farnebo, MD, PhD,Ferenc Scheeren, PhD, Yunqin Lee, BS, MichaelClarke, MD, John B Sunwoo, MD; 1Institutefor Stem Cell Biology and the Ludwig CancerCenter, 2Department of Otolaryngology, Headand Neck Surgery, 3Department of InternalMedicine, Division of Oncology, 4StanfordImmunology Program, Stanford UniversitySchool of Medicine.P036 (COSM Poster #086)SUBEROYLANILIDE HYDROXAMIC ACID(SAHA) - MEDIATED REACTIVATION OFTUMOR SUPPRESSOR MICRORNAS INHEAD AND NECK CANCER Jharna Datta,PhD, Mozaffarul Islam, PhD, Quintin Pan,PhD, Theodoros N Teknos, MD; Departmentof Otolaryngology-Head and Neck Surgery,Arthur G. James Cancer Hospital andRichard J. Solove Research Institute andComprehensive Cancer Center, The Ohio StateUniversity, Wexner Medical Center, Columbus,OH 43210, USAP037 (COSM Poster #087) POLYMERENCAPSULATION OF CPT: A PROMISINGNOVEL THERAPEUTIC FOR HEAD ANDNECK SQUAMOUS CELL CARCINOMALuis E Santaliz-Ruiz IV, MD, Zhun Zhou,BS, Theodoros Teknos, MD, Dennis Bong,PhD, Quintin Pan, PhD; Department ofOtolaryngology- Head and Neck Surgery,Comprehensive Cancer Center, The Ohio StateUniversity Medical Center, & Departmentof Chemistry , The Ohio State University,Columbus, Ohio, USA.P038 (COSM Poster #088) GENETIC ANDCHEMICAL TARGETING OF EPITHELIAL-RESTRICTED WITH SERINE BOX REDUCESEPIDERMAL GROWTH FACTOR RECEPTORAND POTENTIATES THE EFFICACY OFAFATINIB M Zhang, PhD, Ce Taylor, PhD,J Datta, PhD, S Bhave, PhD, Tz Su, PhD, JcLang, PhD, Tn Teknos, MD, Ak Mapp, PhD, QPan, PhD; Department of Otolaryngology-Head and Neck Surgery, The Ohio StateUniversity Medical Center, Columbus, OH43210; Department of Chemistry, University ofMichigan, Ann Arbor, MI 48109P039 (COSM Poster #089) EFFECT OFE6, E7 AND E2 SILENCING ON GENEPATTERN IN HPV POSITIVE HUMANHEAD AND NECK SQUAMOUS CANCERCELL LINES Monika J Agrawal, PhD, ManishK Patel, MS, Seunghee Kim-Schulze, PhD,Marshall Posner, MD; The Tisch Cancer InstituteDivision of Hematology/Medical OncologyMount Sinai School of Medicine, New YorkApril 10 - 11, 2013 · www.ahns.info 69

Poster ListingP040 (COSM Poster #090) COMBINEDINHIBITION OF COX2 AND INOSSUPPRESSES TUMOR-INFILTRATINGMYELOID CELLS AND INHIBITS GROWTHOF METASTATIC HEAD AND NECKSQUAMOUS CELL CARCINOMA IN AMURINE MODEL Peter Svider, BA, ErdenGoljo, BA, Nathaniel Villanueva, BS, PadminiJayaraman, PhD, Matthew Alfarano, BA,Esther L Rivera, PhD, Falguni Parikh, MS, YerielEstrada, BA, Julio Aguirre-Ghiso, PhD, AndrewG Sikora, MD, PhD; Mount Sinai School ofMedicine, Department of Otolaryngology,Tisch Cancer Institute, Head and Neck CancerResearch Program, Immunology InstituteP041 (COSM Poster #091) Themanagement of early glotticcancer in a Veterans AffairsMedical Center patient cohort:impact of risk factors on diseaserecurrence and treatmentalgorithms. Vlad C. Sandulache, MD,PhD, Alexander H Gelbard, MD, Mark W Kubik,Joseph A Malsky, Earlie H Thorn, Jose PZevallos, MDP042 (COSM Poster #092) PREVELANCEOF HIGH-RISK HPV IN UNKNOWNPRIMARY SQUAMOUS CELL CARCINOMAOF THE HEAD AND NECK Shane Gailushas,MD, David Yang, MD, Paul Harari, MD, GregoryHartig, MD; University of Wisconsin HospitalP043 (COSM Poster #093) EFFECT OFSOCIOECONOMIC STATUS ON PERI-OPERATIVE MORBIDITY IN HEAD ANDNECK CANCER PATIENTS Caroline C Xu,MD, Andre Isaac, Peter T Dziegielewski, MD,FRCSC, Daniel A O’Connell, MD, FRCSC,Jeffrey R Harris, MD, FRCSC, Hadi Seikaly, MD,FRCSC; University of AlbertaP044 (COSM Poster #094)CONCORDANCE RATES OF HEAD ANDNECK TUMOR CLINICAL STAGING VS.PATHOLOGICAL STAGING IN A TERTIARYCARE CENTER: HOW ACCURATE AREWE?. Paul D Kim, MD, Kien Tran, MSII, NiklausEriksen, MD; Loma Linda UniversityP045 (COSM Poster #095) SURGICALMANAGEMENT OF SYMPTOMATICVERTEBRAL ARTERY COMPRESSION BYTHE SUPERIOR CORNU OF THE THYROIDCARTILAGE Maria C Buniel, MD, ShannonKraft, MD, Gary M Nesbit, MD, Helmi L Lutsep,MD, Joshua S Schindler, MD, Bronwyn EHamilton, MD; Oregon Health and ScienceUniversity, Portland, OR USAP046 (COSM Poster #096) PROSPECTIVESTUDY TO COMPARE CLINICAL,RADIOGRAPHIC AND PATHOLOGICDEPTH MEASUREMENT IN ORAL TONGUESQUAMOUS CELL CARCINOMA HussainA Alsaffar, MBBS, FRCS, Jonathan C Irish,MD, MSc, FRCSC, FACS, Colleen Simpson,Research, Coordinator, David Goldstien, MD,FRCSC, Ralph Gilbert, MD, FRCSC, PatrickJ Gullane, MD, FRCSC, FACS, FRA, Dale HBrown, BSc, BCh, FRCSC, MB, Emma Barker,MD; University health network- PrincessMargaret Cancer CentreP047 (COSM Poster #097) PRESENTATIONAND OUTCOME OF MELANOMA ARISINGFROM THE MUCOUS MEMBRANES OFHEAD AND NECK IN COMPARISONTO OTHER MUCOSAL MELANOMASAND CUTANEOUS MELANOMA: ASURVEILLANCE EPIDEMIOLOGY ANDEND RESULTS (SEER) DATABASE REVIEWAnteneh Tesfaye, MD, Ioana Morariu, MD,Radhika Kakarala, MD, David Eilender, MD,Sunil Nagpal, MD; McLaren Healthcare-Flint/Michigan State UniversityP048 (COSM Poster #098) ASSESSMENTOF ORAL CAVITY AND LARYNGEALCANCER QUALITY MEASURES IN AREGIONAL HEAD AND NECK TUMORCLINIC Matthew G Yantis, MD, Peter Hunt,MD; University of Tennessee Health ScienceCenter-ChattanoogaP049 (COSM Poster #099) RADIATIONINDUCED SARCOMAS OF THE HEAD ANDNECK Timothy S Wong, FRACDS, OMS, ColinLiew, MD, Nicholas Kalavrezos, Mr, AmritaJay, Bagrat Lalabekyan, MD, Timothy Beale,MD, Simon Morley, MD, Phillip Pirgoussis,FRACDS, OMS; University College LondonHospitalP050 (COSM Poster #100) ANALYSIS OFREADMISSIONS AFTER THYROIDECTOMYAND PARATHYROIDECTOMY ?DOES PPI THERAPY INCREASE RISKOF READMISSION SECONDARY TOPOSTOPERATIVE HYPOCALCEMIA NargesMazloom, DO, Tamer A Ghanem, MD, PhD,Francis T Hall, MD, Kathleen L Yaremchuk, MD;Department of Otolaryngology, Head and NeckSurgery, Henry Ford Hospital, Detroit, MIP051 (COSM Poster #101) SQUAMOUSCELL CARCINOMA OF THE HEAD ANDNECK OF UNKNOWN PRIMARY: AFIFTEEN-YEAR SINGLE INSTITUTIONEXPERIENCE Leslie Kim, MD, MPH, JoshuaWaltonen, MD, David E Schuller, MD, EnverOzer, MD, Theodoros N Teknos, MD, MatthewO Old, MD, Ricardo Carrau, MD, Agrawal Amit,MD; The Ohio State University Wexner MedicalCenterP052 (COSM Poster #102) IMPACT OFIRRADIATION OF INDEX HEAD ANDNECK SQUAMOUS CELL CARCINOMA(HNSCC) ON DEVELOPMENT OF ANDOUTCOME AFTER SECOND PRIMARYHNSCC. Alisa Zhukhovitskaya, CaitlinMcMullen, MD, Richard V Smith, MD,Catherine Sarta, Bradley A Schiff, MD, MissakHaigentz, MD, Michael Prystowsky, MD, PhD,Nicolas F Schlecht, PhD, Thomas J Ow, MD;Montefiore Medical Center, Albert EinsteinCollege of MedicineP053 (COSM Poster #103) ACCURACYOF COMPUTED TOMOGRAPHY IN THEPREDICTION OF EXTRACAPSULARSPREAD OF LYMPH NODE METASTASESIN SQUAMOUS CELL CARCINOMA OFTHE HEAD AND NECK Raymond L Chai,MD, Tanya J Rath, MD, Jonas T Johnson, MD,Robert L Ferris, MD, PhD, Gregory J Kubicek,MD, Umamaheswar Duvvuri, MD, PhD, BartonF Branstetter, MD; University of PittsburghMedical Center70 AHNS 2013 Annual Meeting

Poster ListingP054 (COSM Poster #104) HEAD & NECKSYNOVIAL SARCOMA – 50 YEARS OFEXPERIENCE AT A TERTIARY MEDICALCENTER Matthew G Crowson, Ian J Lalich,MD, Andrew L Folpe, MD, Joaquin J Garcia,MD, Daniel L Price, MD; The Mayo Clinic,Department of OtorhinolaryngologyP055 (COSM Poster #105) PREDICTORSOF SURVIVAL IN CARCINOMA EXPLEOMORPHIC ADENOMA: AN ANALYSISOF 278 PATIENTS Michelle M Chen, BA,Sanziana A Roman, MD, Julie A Sosa, MD,MA, Benjamin L Judson, MD; Department ofSurgery, Yale University School of Medicine,New Haven, CTP056 (COSM Poster #106) SURGICALTREATMENT TRENDS IN THEMANAGEMENT OF THICK MELANOMASOF THE HEAD AND NECK: A USPOPULATION-BASED STUDY. MarcusM Monroe, MD, Jeffrey N Myers, MD, PhD,Michael E Kupferman, MD; Department ofHead and Neck Surgery, University of TexasMD Anderson Cancer CenterP057 (COSM Poster #107) CREATIONOF A BUNDLED PAYMENT FOR HEADAND NECK SURGERY Robert R Lorenz, MD;Cleveland ClinicP058 (COSM Poster #108)CLINICOPATHOLOGIC PREDICTORS OFRECURRENCE AND OVERALL SURVIVALIN ADENOID CYSTIC CARCINOMAOF THE HEAD AND NECK: A SINGLEINSTITUTIONAL EXPERIENCE AT ATERTIARY CARE CENTER Anna Marcinow,MD, Lai Wei, PhD, Enver Ozer, MD, TheodorosTeknos, MD, O H Iwenofu, MD; The Ohio StateUniversityP059 (COSM Poster #109) PROSPECTIVESTUDY OF VENOUS THROMBOEMBOLISMIN HEAD AND NECK CANCER PATIENTSAFTER SURGERY: INTERIM ANALYSISDaniel Clayburgh, MD, PhD, Will Stott, BS,Teresa Kochanowski, ANPC, Renee Park, MD,Kara Detwiller, MD, Paul Flint, MD, JoshuaSchindler, MD, Peter Andersen, MD, MarkWax, MD, Neil Gross, MD; Oregon Health andScience UniversityP060 (COSM Poster #110) PROGNOSTICSIGNIFICANCE OF MEDULLARY BONEINVASION IN ALVEOLAR ORAL CAVITYCARCINOMA Pablo H Montero, MD, PurviD Patel, MD, Andrew G Shuman, MD, FrankL Palmer, BA, Ian Ganly, MD, PhD, Jatin PShah, MD, Snehal G Patel, MD; Head and NeckService, Department of Surgery, MemorialSloan-Kettering Cancer CenterP061 (COSM Poster #111) ACOMPARISON OF NOMOGRAMSVERSUS TNM STAGING IN OUTCOMEPREDICTION FOR PATIENTS WITH ORALCANCER Pablo H Montero, MD, ChanghongYu, MS, Frank L Palmer, BA, Purvi D Patel,MD, Andrew G Shuman, MD, Ian Ganly, MD,PhD, Jatin P Shah, MD, Michael W Kattan,PhD, Snehal G Patel, MD; 1 Head and NeckService, Department of Surgery, MemorialSloan-Kettering Cancer Center. 2 Departmentof Quantitative Health Sciences, The ClevelandClinic, Cleveland, OhioP062 (COSM Poster #112) ISPOSTOPERATIVE RADIATION THERAPYINDICATED IN ALL ORAL CANCERPATIENTS WITH CLOSE MARGINS? PabloH Montero, MD, Purvi D Patel, MD, Frank LPalmer, MD, Andrew G Shuman, MD, Snehal GPatel, MD, Nancy Y Lee, MD, Jatin P Shah, MD,Ian Ganly, MD, PhD; 1 Head and Neck Service,Department of Surgery; 2 Department ofRadiation Oncology; Memorial Sloan-KetteringCancer CenterP063 (COSM Poster #113) SHOULDTUMOR DEPTH MEASURED FROMAN INCISIONAL BIOPSY BE USED TOGUIDE THE DECISION TO PERFORM ANELECTIVE NECK DISSECTION? Allen CCheng, DDS, MD, M A Pogrel, DDS, MD,Brian L Schmidt, DDS, MD, PhD; University ofCalifornia San Francisco, New York UniversityP064 (COSM Poster #114) CORRELATINGTHE PRESENCE OF HPV-16 IN THEORAL MICROENVIRONMENT TO THEHISTOPATHOLOGIC GRADE OF ORALCAVITY LESIONS Benjamin J Greene,MD, Vijay Jayaprakash, PhD, KanitsakBoonanantanasarn, DDS, PhD, MaureenSullivan, DDS, Mihai Merzianu, MD, SaurinPopat, MD, Thom Loree, MD, Shawn DNewlands, MD, PhD, MBA, Steven Gill, PhD;University of Rochester School of Medicineand Dentistry and State University of New Yorkat Buffalo School of Medicine and BiomedicalSciencesP065 (COSM Poster #115) ELECTIVECERVICAL LYMPHADENECTOMYDURING SALVAGE SURGERY FORLOCALLY RECURRENT HEAD AND NECKSQUAMOUS CELL CARCINOMA AFTERTHERAPEUTIC NECK RADIATION BrandonL Prendes, MD, Annick Aubin-Pouliot, BS, NitinEgbert, William R Ryan, MD; University ofCalifornia, San FranciscoP066 (COSM Poster #116) HEAD ANDNECK PARAGANGLIOMAS: A REVIEWOF 92 PATIENTS Theresa Tran, MD, MichaelPersky, MD, Sophie Scherl, BA, Jason B Clain,BS, Jonathan Wallach, MD, Kenneth Hu, MD,Mark L Urken, MD, Adam S Jacobson, MD,Louis B Harrison, MD, Mark S Persky, MD;Head and Neck Institute at Beth Israel MedicalCenter, New York NYP067 (COSM Poster #117) ORAL CAVITYCANCER IN PATIENTS UNDER 40 YEARSOF AGE Kyle Mannion, MD, Adam Luginbuhl,MD, Sarah Rohde, MD, Robert Sinard, MD,Kristin Stevens; Vanderbilt University MedicalCenterP068 (COSM Poster #118) MEDICARECOST IMPLICATIONS IN TREATMENT OFT1-T3 LARYNGEAL CARCINOMA Ali Razfar,MD, Tristan Grogan, MS, Steve Lee, MD, DavidElashoff, PhD, Elliot Abemayor, MD, PhD, MaieSt. John, MD, PhD; UCLA Department of Headand Neck SurgeryApril 10 - 11, 2013 · www.ahns.info 71

Poster ListingP069 (COSM Poster #119) DIVERGENTEFFECTS OF CHEMORADIOTHERAPYON IMMUNOSUPPRESSIVE HOST CELLPOPULATIONS, AND IMPLICATIONS FORIMMUNOTHERAPY Arjun Yerasi, FalguniParikh, Amelia Clark, Manishkumar Patel,Rachel Abbott, Krzys Misiukiewicz, MarcelloBonomi, Vishal Gupta, Marshall Posner,Seunghee Kim-Schulze, Andrew G Sikora;Mount Sinai School of MedicineP070 (COSM Poster #120) SURGICALMANAGEMENT OF OROPHARYNGEALSQUAMOUS CELL CARCINOMA:SURVIVAL AND FUNCTIONALOUTCOMES Bhavna Kumar, MS, MichaelCipolla, MD, Nicole Arradaz, PhD, PeterDziegielewski, md, Kasim Durmus, MD, EnverOzer, md, Matthew Old, md, Amit Agrawal,md, Ricardo Carrau, md, David E Schuller,md, Marino Leon, md, Quintin Pan, phd,Pawan Kumar, phd, Valerie Wood, md, JessicaBurgers, md, Paul Wakely, md, Theodoros NTeknos, MD; The Ohio State University MedicalCenter, James Cancer Hospital and SoloveResearch InstituteP071 (COSM Poster #121) OUTPATIENTCHEMOTHERAPY WITH S-1 FORUNRESECTABLE AND/OR DISTANTMETASTATIC HEAD AND NECK CANCERMayuka Maeda, MD, Taku Yamashita, MD,PhD, Takeshi Matsunobu, MD, PhD, KojiAraki, MD, PhD, Masayuki Tomifuji, MD, PhD,Akihiro Shiotani, MD, PhD; Department ofOtolaryngology-Head and Neck Surgery,National Defense Medical Collage of JapanP072 (COSM Poster #122) PREDICTIVEFACTORS FOR PROPHYLACTICPERCUTANEOUS ENDOSCOPICGASTROSTOMY (PEG) TUBE PLACEMENTAND USE IN INTENSITY MODULATEDRADIATION THERAPY (IMRT)TREATED HEAD AND NECK PATIENTS:CONCORDANCE, DISCREPANCIES ANDTHE ROLE OF GABAPENTIN Wuyang Yang,MD, MS, Sara Madanikia, Rachit Kumar, MD,Heather Starmer, MS, Todd McNutt, PhD,Kimberly Evans, Nichole Mills, RN, BSN,Marian Richardson, MSN, Christine Gourin,MD, MPH, Susannah Ellsworth, MD, NishantAgrawal, MD, Jeremy Richmon, MD, PhD,Young Kim Kim, MD, Christine Chung, MD,Wayne Koch, MD, Joe Califano, MD, DavidEisele, MD, Harry Quon, MD, MS; JohnsHopkins School of MedicineP073 (COSM Poster #123) PROPRANOLOLAS A PHARMACOTHERAPEUTIC AGENTIN THE TREATMENT OF ARTERIOVENOUSMALFORMATIONS: A PILOT STUDYBradley A Hobbs, MD, James Y Suen, MD,Gresham T Richter, MD; University of Arkansasfor Medical Sciences, Arkansas Children’sHospital, Department of Otolaryngology-HeadP074 (COSM Poster #124) COMPARATIVESTUDY BETWEEN TRANSORAL ROBOTICSURGERY AND CONVENTIONALSURGERY FOR TREATMENT OFSQUAMOUS CELL CARCINOMA OF THEUPPER AERODIGESTIVE TRACT KarimHammoudi, MD, Eric Pinlong, MD, Soo Kim,MD, Patrice Beutter, PhD, Sylvain Moriniere,PhD; CHRU Bretonneau, TOURS, FRANCEP075 (COSM Poster #125) HEATGENERATION DURING ABLATION OFPORCINE SKIN WITH ER:YAG LASERVERSUS A NOVEL PICOSECONDINFRARED LASER (PIRL) Nathan Jowett,MD, FRCSC, Wolfgang Wöllmer, PhD, Alex MMlynarek, MD, MSc, FRCSC, Paul Wiseman,PhD, Bernard Segal, PhD, Kresimir Franjic,PhD, Peter Krötz, MSc, Arne Böttcher, MD,Rainald Knecht, MD, PhD, RJ Dwayne Miller,PhD; Dept. of Otolaryngology - Head andNeck Surgery, McGill University and Dept. ofOto-, Rhino-, Laryngology, University MedicalCentre Hamburg - EppendorfP076 (COSM Poster #126) EFFECT OFPOLYGLYCOLIC ACID SHEETS ANDFIBRIN GLUE ON WOUND HEALINGAFTER PARTIAL RESECTION OF ORALCANCER Morimasa Kitamura, MD, RyoAsato, MD, Shigeru Hirano, MD, phD, IchiroTateya, MD, phD, Shinpei Kada, MD, phD, SeijiIshikawa, MD, Kuninobu Mizuta, MD, NaoHiwatasi, MD, Juichi Ito, MD, phD; Departmentof Otolaryngology, Head and Neck Surgery,Kyoto UniversityP077 (COSM Poster #127) THE ROLEOF ON-SITE CYTOTECHNOLOGISTASSESSMENT FOR FNA OF SALIVARYGLAND MASSES AND NECK MASSESLamont Jones, MD, Tamer Ghanem, MD,Matthew Smith, MD, Ziyang Zhang, MD,Catherine Lumley; Henry Ford HospitalP078 (COSM Poster #128) TRANSORALKTP ANGIOLYTIC LASER TREATMENT OFEARLY LARYNGEAL CANCER: A REPORTOF 62 PATIENTS Mark N Segal; KaiserPermanente, SCPMGP079 (COSM Poster #129) ASSESSINGTHE VALUE OF TRANSORAL ROBOTICSURGERY VERSUS DEFINITIVERADIOTHERAPY (WITH OR WITHOUTCHEMOTHERAPY) FOR EARLY T-STAGEOROPHARYNGEAL CANCER: A COST-UTILITY ANALYSIS John R de Almeida, MD,MSc, Alan Moskowitz, MD, Brett Miles, MD,DDS, Marita S Teng, MD, Vishal Gupta, MD,Marshall Posner, MD, Eric M Genden, MD;Mount Sinai School of MedicineP080 (COSM Poster #130) A MODULARPOLYMER PLATFORM SIGNIFICANTLYREDUCES THE REQUIRED DOSE OFXRT Maie St. John, MD, PhD, Yuan Lin, PhD,Jie Luo, MS, Matthew Lee, MD, NopawanVorasubin, MD, Ben Wu, DDS, PhD, DavidElashoff, PhD, Elliot Abemayor, MD, PhD;University of California, Los AngelesP081 (COSM Poster #131) INTERSTITIALPHOTODYNAMIC THERAPY INCOMBINATION WITH CETUXIMAB FORRECURRENT UNRESECTABLE HEAD ANDNECK SQUAMOUS CELL CARCINOMANestor Rigual, MD, Gal Shafirstein, PhD;Roswell Park Cancer InstituteP082 (COSM Poster #132)TRANSFORMING HEAD AND NECKCLINICAL DATA COLLECTION WITHCOMPUTER TABLET TECHNOLOGY MichaelD Otremba, MD, Graeme M Rosenberg, BA,Wendell G Yarbrough, MD, Benjamin L Judson,MD; Yale University School of Medicine72 AHNS 2013 Annual Meeting

Poster ListingP083 (COSM Poster #133) NON-INVASIVEOPTICAL IMAGING MODALITIES ASA DIAGNOSTIC AID IN MANAGINGPATIENTS WITH ORAL LEUKOPLAKIAVijayashree Bhattar, Ann M Gillenwater,MD, Rebecca Richards-Kortum, PhD, SharonMondrik, Richard Schwarz, PhD, Sohini Dhar,Mark Pierce, PhD, Jana Howe, Michelle DWilliams, MD; University of Texas M.D.Anderson Cancer Center, Houston, Texas; RiceUniversity, Dept. of Bioengineering, Houston,TexasP084 (COSM Poster #134) APPLICATIONOF SALIVARY STENTS IN ENDOSCOPICMANAGEMENT OF SALIVARYGLAND DISORDERS: A PRELIMINARYEXPERIENCE Matthew A Bowen, MD, RohanR Walvekar, MD; Louisiana State UniversityHealth Sciences Center - New OrleansP085 (COSM Poster #135) USE OFULTRASOUND BEFORE SIALENDOSCOPYDURING EVALUATION OF OBSTRUCTIVEPAROTID GLAND DISEASE Arjun Joshi, MD,Sean Hashemi, BS; The George WashingtonUniversity - Division of Otolaryngology - Headand Neck SurgeryP086 (COSM Poster #136) USE OFULTRASOUND BEFORE SIALENDOSCOPYDURING EVALUATION OF OBSTRUCTIVESUBMANDIBULAR GLAND DISEASEArjun Joshi, MD, Sean Hashemi, BS; TheGeorge Washington University - Division ofOtolaryngology - Head and Neck SurgeryP087 (COSM Poster #137)CORNICULATE FLAP RECONSTRUCTIONAFTER SUPRACRICOID PARTIALLARYNGECTOMY Myriam Loyo, MD,Chistopher Holsinger, MD, PhD, OllivierLaccourreye, MD; Johns Hopkins, MDAnderson, and Université Paris DescartesSorbonneP088 (COSM Poster #138) LEVEL IIBLYMPH NODE METASTASIS IN ORALCAVITY SQUAMOUS CELL CARCINOMABrian C Gross, MD, Steven Olsen, MD, Jean ELewis, MD, Daniel L Price, MD, Kerry D Olsen,MD; Mayo Clinic - Rochester, MNP089 (COSM Poster #139) TREATMENTOUTCOMES OF ORGAN PRESERVATIONSTRATEGIES FOR LOCALLY ADVANCEDLARYNGEAL CANCER BASED ONPROSPECTIVE MULTI-DISCIPLINARYTREATMENT PLANNING David W Timme,MD, Sashikanth Jonnalagodda, MD, RaunakPatel, BS, Krishna Rao, MD, PhD, K ThomasRobbins, MD; Southern Illinois UniversitySchool of MedicineP090 (COSM Poster #140) ONCOLOGICAND FUNCTIONAL OUTCOMES OFTRANSORAL ROBOTIC SURGERY FOROROPHARYNGEAL CANCER Young MinPark, Won Shik Kim, Hyung Kwon Byeon, EunChang Choi, Se-Heon Kim; Yonsei UniversityCollege of MedicineP091 (COSM Poster #141) SURGICALTECHNIQUES AND TREATMENTOUTCOMES OF TRANSORALROBOTIC SUPRAGLOTTIC PARTIALLARYNGECTOMY Young Min Park, Won ShikKim, Hyung Kwon Byeon, Eun Chang Choi,Se-Heon Kim; Yonsei University College ofMedicineP092 (COSM Poster #142) MANAGEMENTOF UNKNOWN PRIMARIES WITHTRANSORAL LASER MICROSURGERYAND NECK DISSECTION IN THEPRESENCE OF P16-POSITIVITY Evan MGraboyes, MD, Parul Sinha, MBBS, MS, JasonT Rich, MD, Bruce H Haughey, MBChB, FACS,FRACS; Washington University in Saint LouisP093 (COSM Poster #143) THE IMPACT OFPARAGLOTTIC SPACE IN SUPRACRICOIDPARTIAL LARYNGECTOMY Min Sik Kim,MD, PhD, Kwang Jae Cho, MD, PhD, Jun OokPark, MD, In Chul Nam, MD, Chung Soo Kim,MD; The Catholic University of KoreaP094 (COSM Poster #144) ENDOSCOPEASSISTED SUBMUCOSAL DISSECTIONFOR EARLY PHARYNGEAL CANCERDETECTED BY NARROW BAND IMAGINGTECHNOLOGY Ichiro Tateya, MD, PhD,Manabu Muto, MD, PhD, Shuko Morita, MD,Shin-ichi Miyamoto, MD, Shigeru Hirano, MD,PhD, Morimasa Kitamura, MD, Seiji Ishikawa,MD, Juichi Ito, MD, PhD; Kyoto UniversityP095 (COSM Poster #145) FUNCTIONALOUTCOME, SURVIVAL, ANDAPPLICABILITY OF TRANSORAL LASERSURGERY IN A COMPLETE COHORTOF PATIENTS WITH SUPRAGLOTTICSQUAMOUS CELL CARCINOMA. GraemeM Rosenberg, Stewart I Adam, MD, MichaelD Otremba, MD, Clarence T Sasaki, MD,Benjamin L Judson, MD, MPA; Yale UniversitySchool of MedicineP096 (COSM Poster #146) ACOMPARISON OF SURVIVAL ANDFUNCTIONAL OUTCOMES INADVANCED STAGE BUT EARLY T-STAGEOROPHARYNGEAL SQUAMOUS CELLCARCINOMA TREATED WITH TRANSORALRESECTION OR CHEMORADIOTHERAPYMatthew J Ward, MRCS, Emma V King, PhD,FRCS, Gareth J Thomas, PhD, Christopher JRandall, FRCS, Christopher A Baughan, FRCR,Ram Shanmugasundsaram, FRCR, NimeshN Patel, MSc, FRCS; Cancer Sciences Unit,University of Southampton, UK. Departmentof ENT, Southampton General Hospital, UK.Department of Oncology, SouthamptonGeneral Hospital, UK.P097 (COSM Poster #147) INITIALNEGATIVE MARGINS MAY BEASSOCIATED WITH OVERALL SURVIVALIN PATIENTS UNDERGOING TRANSORALROBOTIC SURGERY FOR HEAD ANDNECK CANCER Alexandra E Kejner, MD, J.Scott Magnuson, MD, Eben L Rosenthal, MD,William R Carroll, MD; University of Alabama- BirminghamApril 10 - 11, 2013 · www.ahns.info 73

Poster ListingP098 (COSM Poster #148)EVALUATION OF SWALLOW AFTERSUPRACRICOID LARYNGECTOMY WITHCRICOHYOIDOEPIGLOTTOPEXY (SCL-CHEP) BY VIDEOFLUOROSCOPY YutomoSeino, MD, PhD, Jacqui Allen, MD, FRACS,Meijin Nakayama, MD, PhD, Anna Miles,Makito Okamoto, MD, PhD; Department ofOtorhinolaryngology Kitasato UniversitySchool of Medicine/ North Shore Hospital/ TheUniversity of AucklandP099 (COSM Poster #149) MANAGEMENTOF UNTREATED GLOTTIC SQUAMOUSCELL CARCINOMA BY TRANSORALLASER MICROSURGERY: ONCOLOGICOUTCOMES, MANAGEMENT OFRECURRENCE, AND PROGNOSTICFACTORS Andrew T Day, MD, Parul Sinha,MBBS, MS, Kallogjeri Dorina, MD, BrianNussenbaum, MD, FACS, Bruce Haughey,MBChB, FACS, FRACS; Washington UniversitySchool of MedicineP100 (COSM Poster #150) PREDICTIVENOMOGRAMS FOR SURVIVALAFTER SURGICAL MANAGEMENT OFMALIGNANT TUMORS OF THE MAJORSALIVARY GLANDS. Safina Ali, MD, FrankL Palmer, BA, Changhong Yu, MS, MonicaWhitcher, BA, Jatin P Shah, MD, Michael WKattan*, PhD, Snehal G Patel, MD, Ian Ganly,MD, PhD; Memorial Sloan-Kettering CancerCenter, New York, *Department of QuantitativeHealth Sciences, The Cleveland Clinic, OhioP101 (COSM Poster #151) THE ROLE OFTRANSORAL ROBOTIC SURGERY IN THEWORK-UP OF THE UNKNOWN PRIMARYHEAD AND NECK SQUAMOUS CELLCARCINOMA Sapna A Patel, MD, J. ScottMagnuson, MD, F. Christopher Holsinger, MD,Ron J Karni, MD, Jay K Ferrell, MD, JeremyD Richmon, Neil D Gross, MD, EduardoMendez, MD, MS; University of WashingtonMedical Center, M.D. Anderson Cancer Center,University of Alabama- Birmingham Hospital,University of Texas Medical School at Houston,Johns Hopkins Hospital and Oregon HealthSciences UniversityP102 (COSM Poster #152)RETROSPECTIVE ANALYSIS OF ADULTHEAD AND NECK SARCOMA: A SINGLE-CENTER EXPERIENCE FROM 2000-2012Xiaoyu Chai, Amy E Chang, Kris S Moe,MD, Neal Futran, MD, Robin L Jones, MD;University of Washington School of MedicineP103 (COSM Poster #153) LARYNGEALCARCINOMA: COMPARING A SINGLEACADEMIC TERTIARY HOSPITAL TONATIONAL DATA Blake J LeBlanc, MD, GlennMills, MD, Runhua Shi, MD, PhD, FedericoAmpil, MD, Cherie-Ann Nathan, MD; LSUHealth - ShreveportP104 (COSM Poster #154) MANAGEMENTOF LYMPHEDEMA IN PATIENTS WITHHEAD AND NECK CANCER Brad G Smith,MS, CLT, Katherine A Hutcheson, PhD, RomanJ Skoracki, MD, Leila G Little, MS, CLT, DavidI Rosenthal, MD, Stephen Y Lai, MD, PhD, JanS Lewin, PhD; The University of Texas MDAnderson Cancer CenterP105 (COSM Poster #155) ANALYSISOF DISTANT FAILURE PATTERNSAND SECOND PRIMARY CANCERS INPATIENTS TREATED WITH DEFINITIVEINTENSITY MODULATED RADIATIONTHERAPY (IMRT) FOR OROPHARYNGEALSQUAMOUS CELL CARCINOMA (OPSCC)Edwin F Crandley, MD, David D Wilson, MD,Austin J Sim, Neil Majithia, Asal S Rahimi, MD,Edward B Stelow, MD, Mark J Jameson, MD,PhD, David S Shonka, MD, Paul W Read, MD,PhD; University of Virginia, University of Texas-SouthwesternP106 (COSM Poster #156) FUNCTIONAFTER TORS FOR OROPHARYNGEALCANCER: A SYSTEMATIC REVIEWKatherine A Hutcheson, PhD, F. ChristopherHolsinger, MD, Michael E Kupferman, MD,Jan S Lewin, PhD; The University of Texas MDAnderson Cancer CenterP107 (COSM Poster #157) THE USE OFINPATIENT PALLIATIVE CARE SERVICESIN PATIENTS WITH METASTATICINCURABLE HEAD AND NECK CANCERChristine G Gourin, MD, MPH, Thomas JSmith, MD, Sydney M Dy, MD, MPH; JohnsHopkins University and Johns HopkinsBloomberg School of Public HealthP108 (COSM Poster #158) IMPROVINGTIME FROM FIRST CONTACT TO INITIALAPPOINTMENT FOR HEAD AND NECKCANCER PATIENTS Carol M Lewis, MD,MPH, Jeremy Meade, MS, Judy Moore, RN,MSN, Sheila Harris, RN, MBA, Pheba Philip,BS, LaToya Spears, BS, Hettie Hebert, RN, AmyC Hessel, MD, Ehab Y Hanna, MD, Randal SWeber, MD; University of Texas MD AndersonCancer CenterP109 (COSM Poster #159) DISPARITIESIN SURVIVAL FOR AMERICAN INDIANSWITH HEAD AND NECK SQUAMOUS CELLCARCINOMA Sunshine Dwojak, MD, MPH,Thomas D Sequist, MD, MPH, Kevin Emerick,MD, John Lee, MD, Daniel Petereit, MD, DanielG Deschler, MD; Massachusetts Eye and EarInfirmary, Harvard Medical School, Divisionof General Medicine, Brigham and Women’sHospital, Sanford Cancer Research Center,John T. Vucurevich Cancer Care Institute atRapid City Regional HospitalP110 (COSM Poster #160) COMPARATIVEEFFECTIVENESS OF SURGICALAND NON-SURGICAL THERAPY FORADVANCED LARYNGEAL CANCER: ASEER-MEDICARE STUDY 1997-2007 KaraK Prickett, MD, Chun Chieh Lin, PhD, Amy YChen, MD, MPH; Emory University Departmentof Otolaryngology, American Cancer SocietyP111 (COSM Poster #161) THE EFFECTOF MARRIAGE ON OUTCOMES FORHEAD AND NECK CANCER Christopher SHollenbeak, PhD, Eric W Schaefer, MS, DavidGoldenberg, MD, Heath Mackley, MD, WayneKoch, MD; Penn State College of Medicine;Johns Hopkins University74 AHNS 2013 Annual Meeting

Poster ListingP112 (COSM Poster #162) INCIDENCEAND RISK FACTORS OF SURGICALCOMPLICATIONS IN ORAL CAVITYCANCER Pablo H Montero, MD, Claudia RAlbornoz, Andrew G Shuman, MD, FrankL Palmer, MD, Ian Ganly, MD, PhD, Jatin PShah, MD, Snehal G Patel, MD; Head and NeckService, Department of Surgery, MemorialSloan-Kettering Cancer CenterP113 (COSM Poster #163) THEPROGNOSTIC SIGNIFICANCE OFEXTRACAPSULAR SPREAD IN HPV-ASSOCIATED OROPHARYNGEALSQUAMOUS CELL CARCINOMA Brieze RKeeley, BA, Eitan Prisman, MD, Nathaniel LVillanueva, BS, Erden Goljo, BS, Eric Genden,MD, Andrew G Sikora, MD, PhD; The MountSinai School of Medicine, Department ofOtolaryngology, Immunology InstituteP114 (COSM Poster #164) WHATVARIABLES PREDICT TRACHEOSTOMYOR GASTROSTOMY PLACEMENT INOROPHARYNGEAL CANCER PATIENTSUNDERGOING TORS? Eitan Prisman, MD,Brieze R Keeley, BA, Erden Goljo, BS, BrettMiles, MD, DDS, Andrew G Sikora, MD, PhD,Eric M Genden, MD; The Mount Sinai School ofMedicine, Department of OtolaryngologyP115 (COSM Poster #165) IS PERSISTENTPET/CT SURVEILLANCE USEFUL INHPV-ASSOCIATED HEAD AND NECKSQUAMOUS CELL CARCINOMA?Yekaterina Koshkareva, MD, Barton FBranstetter IV, MD, William E Gooding, MS,Robert L Ferris, MD, PhD; University ofPittsburgh Medical CenterP116 (COSM Poster #166)EXTRACAPSULAR NODAL SPREADDOES NOT PREDICT OUTCOME INCLINICALLY NODE NEGATIVE ORALCAVITY SQUAMOUS CELL CARCINOMAVolkert B Wreesmann, MD, PhD, Ronald AGhossein, MD, Diane Carlson, MD, Ian Ganly,MD, Frank Palmer, MSc, Pablo Montero, MD,Jatin Shah, MD, Snehal Patel, MD; MemorialSloan-Kettering Cancer CenterP117 (COSM Poster #167) HEAD ANDNECK CANCER MULTIDISCIPLINARYCONFERENCE: IMPROVING PATIENTOUTCOMES Carol M Lewis, MD, MPH,Zhannat Nurgalieva, PhD, Erich M Sturgis, MD,MPH, Stephen Y Lai, MD, PhD, Beth M Beadle,MD, PhD, William N William, MD, Randal SWeber, MD; University of Texas MD AndersonCancer CenterP118 (COSM Poster #168)THE USE OF GIA STAPLER FORSTERNOCLEIDOMASTOID MUSCLEFLAP IN PAROTIDECTOMY DEFECTRECONSTRUCTION Neil Gildener-Leapman,MD, Kashif Mazhar, MD, James Attra, MD, DaleRice, MD; University of Southern California,University of Pittsburgh Medical CenterP119 (COSM Poster #169)INTRALUMINAL NEGATIVE PRESSUREWOUND THERAPY FOR OPTIMIZINGPHARYNGEAL RECONSTRUCTION Scott AAsher, MD, Hilliary N White, MD, Elisa A Illing,MD, William R Carroll, MD, J S Magnuson,MD, Eben L Rosenthal, MD; The University ofAlabama at BirminghamP120 (COSM Poster #170) FUNCTIONALOUTCOMES OF SCAPULAR ANGLEOSTEOMUSCULAR FLAP INPOSTMAXILLECTOMY RECONSTRUCTIONCesare Piazza, MD, Francesca Del Bon, MD,Valentina Taglietti, MD, Alberto Paderno,MD, Piero Nicolai, Professor; Departmentof Otorhinolaryngology ? Head and NeckSurgery, University of Brescia, ItalyP121 (COSM Poster #171) USE OFINTEGRA DERMAL REGENERATIONTEMPLATE AS AN ALTERNATIVE TOOLIN COMPLEX HEAD RECONSTRUCTION.Fedele Lembo, MD, Domenico Parisi, MD,Aurelio Portincasa, MD, FEBOPRAS; Plasticand Reconstructive Surgery Department -University of FoggiaP122 (COSM Poster #172)THE STAIRCASE TECHNIQUE: ARATIONAL APPROACH TO LOWER LIPRECONSTRUCTION Fedele Lembo, MD,Domenico Parisi, MD, Aurelio Portincasa, MD,FEBOPRAS; Plastic and Reconstructive SurgeryDepartment - University of FoggiaP123 (COSM Poster #173) ZITELLI FLAPAN VALUABLE OPTION FOR NOSERECONSTRUCTION Fedele Lembo, MD,Domenico Parisi, MD, Aurelio Portincasa, MD,FEBOPRAS; Plastic and Reconstructive SurgeryDepartment - University of FoggiaP124 (COSM Poster #174)SEGMENTAL MANDIBULECTOMYAND MICROVASCULAR FREE FLAPRECONSTRUCTION FOLLOWINGBISPHOSPHONATE-RELATEDOSTEONECROSIS OF THE JAWS: CASESERIES Matthew M Hanasono, MD, OlegN Milisakh, MD, Jeremy D Richmon, MD,Eben L Rosenthal, MD, Mark K Wax, MD; MDAnderson Cancer, University of Nebraska,Johns Hopkins University, University ofAlabama, and Oregon Health SciencesUniversityP125 (COSM Poster #175) OUTCOMESIN RECONSTRUCTION AFTERPHARYNGECTOMY: RADIAL FOREARMVS ANTEROLATERAL THIGH FREE FLAPSMichael R Kinzinger, BA, Chad Zender,MD, Rod Rezaee, MD; University HospitalsCase Medical Center, Case Western ReserveUniversity School of MedicineP126 (COSM Poster #176) CRANIOFACIALBONE RECONSTRUCTION WITH A NOVELBIOACTIVE COMPOSITE IMPLANT KalleJ Aitasalo, Professor, Jaakko M Piitulainen,MD, Jami Rekola, PhD; 1. Department ofOtorhinolaryngology – Head and NeckSurgery, Turku University Hospital 2.Biomaterials Research, Institute of Dentistryand Biomaterials Science, University of Turku,Turku Finland.P127 (COSM Poster #177) OUTCOMES OFFASCIO-CUTANEOUS FREE FLAPS FORHYPOPHARYNGEAL WITH OR WITHOUTCERVICAL ESOPHAGEAL DEFECTSRECONSTRUCTION Cesare Piazza, MD,Francesca Del Bon, MD, Valentina Taglietti,MD, Piero Nicolai, Professor; Departmentof Otorhinolaryngology – Head and NeckSurgery, University of Brescia, ItalyApril 10 - 11, 2013 · www.ahns.info 75

Poster ListingP128 (COSM Poster #178)COMPLICATIONS ANDFUNCTIONAL OUTCOMES AFTERPHARYNGOESOPHAGEAL DEFECTRECONSTRUCTION: A COMPARISON OFPEDICLED REGIONAL FLAPS VS. FREETISSUE TRANSFER Lucia S Olarte, MD, RajanDang, BA, Jamie Pak, BA, Joshua Rosenberg,MD; Mount Sinai School of MedicineP129 (COSM Poster #179) COMPARISONOF SKIN GRAFT DONOR SITES FORFIBULA FREE FLAP SKIN PADDLERECONSTRUCTION Tyler P Litton, JacobL Wester, Neil D Gross, MD, FACS, Amy LPittman, MD, Mark K Wax, MD, FACS, FRCS;New York University School of Medicine, NewYork, New York. Department of Otolaryngology,Oregon Health and Science University,Portland, Oregon.P130 (COSM Poster #180)MICROVASCULAR HEAD AND NECKRECONSTRUCTION IN THE PACIFICISLAND HEALTH CARE PROJECT:EXPERIENCE THAT TRANSLATES TOOPTIMAL CARE FOR COMBAT WOUNDEDKelly G Groom, MD, Christopher Klem, MD;Tripler Army Medical CenterP131 (COSM Poster #181) COMPARATIVESTUDY OF FREE FLAP RECONSTRUCTIONAFTER ROBOT-ASSISTED NECKDISSECTION VERSUS CONVENTIONALNECK DISSECTION IN ORAL CAVITYAND OROPHARYNGEAL CANCER YoungMin Park, MD, Won Jai Lee, MD, Dong WonLee, MD, In Sik Yoon, MD, Dae Hyun Lew,MD, PhD, Won Shik Kim, MD, Yoon WooKoh, MD, PhD, Eun Chang Choi, MD, PhD;1Department of Otorhinolaryngology, YonseiUniversity College of Medicine, Seoul, Korea2Department of Plastic and ReconstructiveSurgery, Yonsei University College ofMedicine, Seoul, KoreaP132 (COSM Poster #182) DISTRIBUTIONOF EPSTEIN-BARR VIRAL LOADIN SERUM OF PATIENTS WITHNASOPHARYNGEAL CARCINOMA ANDHIGH-RISK FAMILIES IN SINGAPORE.Joshua K Tay, MBBS, MRCS, MMed, Soh HaChan, MBBS, FRCPA, PhD, Chwee Ming Lim,MBBS, MRCS, MMed, Thomas Loh, MBBS,FRCS; National University Health System,SingaporeP133 (COSM Poster #183) EVALUATIONOF UTILIZATION OF HEALTH WORKERSAND REMOTE DIAGNOSIS IN A MOBILEBASED ORAL CANCER SCREENING ININDIA Praveen Birur, MDS, Rani Desai, MA,Ashifur Rahman, BDS, Chetan Mukundan, BE,Moni Abraham Kuriakose, FDSRCS; BioconFoundationP134 (COSM Poster #184) OUTCOMES OFA HEAD AND NECK CANCER SCREENINGCLINIC Andrew G Shuman, MD, Prateek Patel,Dorothy Thomas, BA, Frank Palmer, BA, BrianT Shaffer, MD, Janet T McKiernan, RN, MS,OCN, Jatin P Shah, MD, FACS, Snehal G Patel,MD, FRCS, Jay O Boyle, MD; Memorial Sloan-Kettering Cancer CenterP135 (COSM Poster #185)SOCIOECONOMIC FACTORS IMPACTSTAGE AT PRESENTATION IN HNSCCPATIENTS Julianna Pesce, MD, AbieH Mendelsohn, MD, Yas Sanaiha, ElliotAbemayor, MD, PhD, Maie St. John, MD, PhD;Division of Head and Neck Surgery , Universityof California, Los AngelesP136 (COSM Poster #186) RISK OFSECOND PRIMARY MALIGNANCY INSURVIVORS OF RETINOBLASTOMA KunalS Jain, MD, Andrew G Sikora, MD, PhD,Jeffrey C Liu, MD, Luc G Morris, MD; MemorialSloan-Kettering Cancer Center, SUNY UpstateMedical University, Mount Sinai Schoolof Medicine, Temple University School ofMedicineP137 (COSM Poster #187) HEAD ANDNECK SQUAMOUS CELL CARCINOMAAND DISPARITIES: A MODEL FOR EARLYDETECTION Lutecia H Pereira, PhD, IsildinhaReis, PhD, Robert Duncan, PhD, Erika PReategui, MS, Claudia Gordon, BS, LaurianWalters, BS, Aymee Perez, PhD, Elizabeth JFranzmann, MD; University of Miami MillerSchool of MedicineP138 (COSM Poster #188) ANINVESTIGATION OF THE EFFECTIVENESSOF MOLECULAR ASSAYS Eliza Kostas-Polston, PHD, APRN, WHNPBC, Mark Varvares,MD; University of South FloridaP139 (COSM Poster #189) RECURRENTPAPILLARY THYROID CANCER OFTHE SPHENOID WING, ORBIT ANDINFRATEMPORAL FOSSA Elliott Kozin, MD,Gillian Diercks, MD, Josef Shargorodsky, MD,Alice Lin, MD, Frederick Barker, MD, DerrickLin, MD; Massachusetts Eye and Ear Infirmary,Massachusetts General Hospital, HarvardMedical SchoolP140 (COSM Poster #190) ANALYSIS OFTHE DISTINGUISHING HISTOLOGICALAND IMMUNOHISTOCHEMICALCHARACTERISTICS OF CHONDROIDCHORDOMA, CHONDROSARCOMA ANDCLASSIC CHORDOMA OF THE CLIVUSAndrew M Terrell, MD, Christopher H Rassekh,MD, Jeffery P Hogg, MD, Charles L Rosen, MD,PhD, Barbara S Ducatman, MD; West VirginiaUniversity and University of PennsylvaniaP141 (COSM Poster #191) PROSPECTIVESTUDY OF HEAD AND NECK QUALITY OFLIFE IN A COMPREHENSIVE SKULL BASESURGICAL PRACTICE Emily E Cohn, BSPH,Stephen A Wheless, MD, Kibwei A McKinney,MD, Robert J Taylor, BS, Adam M Zanation,MD; Department of Otolaryngology/Head andNeck Surgery, University of North CarolinaHospitals, Chapel Hill, NC 27514, USA;Department of Otolaryngology, University ofVermont Hospitals, Burlington, VT, USAP142 (COSM Poster #192) PATTERNSOF CARE FOR WELL-DIFFERENTIATEDTHYROID CANCER Harry M Baddour, MD,Stacey A Fedewa, PhD, MPH, Amy Y Chen, MD,MPH, FACS; Department of Otolaryngology-Head and Neck Surgery, Emory UniversitySchool of Medicine, Atlanta, GA, USA;American Cancer Society, Atlanta, GA, USA76 AHNS 2013 Annual Meeting

Poster ListingP143 (COSM Poster #193) PREDICTIVEVALUE OF STIMULATED POSTOPERATIVETHYROGLOBULIN LEVELS IN PATIENTSWITH DIFFERENTIATED THYROIDCARCINOMA Chih H Chen-Ku, MD, FACE,Efrain Cambronero, MD; Hospital San Juan deDios, Instituto Costarricense de OncologíaP144 (COSM Poster #194) LOCAL-REGIONAL FAILURE IN LOCALLYADVANCED DIFFERENTIATED THYROIDCANCER AFTER SURGERY ANDRADIOACTIVE IODINE THERAPY AdamWillson, BS, Mark Weissler, MD, DavidFried, BS, Yeh Jin Jin, MD, Arif Sheikh, MD,Benjamin Calvo, MD, Carol Shores, MD,William Shockley, MD, Trevor Hackman,MD, Adam Zanation, MD, Bhishamjit Chera,MD; Department of Radiation Oncology,Department of Otolaryngology/Head & NeckSurgery, Department of Surgical Oncology,Lineberger Comprehensive Cancer Center,University of North Carolina Hospitals, ChapelHill, NCP145 (COSM Poster #195)COMPARISON OF PATIENT AND TUMORCHARACTERISTICS OF INCIDENTALLY-DISCOVERED THYROID CANCERS ANDCLINICALLY-EVIDENT THYROID CANCERSFrederick Yoo, BA, Irina Chaikhoutdinov, MD,Jason Liao, PhD, David Goldenberg, MD,FACS; Department of Surgery, Division ofOtolaryngology - Head and Neck Surgery,Pennsylvania State University - Milton S.Hershey Medical CenterP146 (COSM Poster #196) RISK FACTORSASSOCIATED WITH PERIOPERATIVEAIRWAY COMPLICATIONS AMONGPATIENTS UNDERGOING SURGERY FORMULTINODULAR GOITER Patricia A Loftus,MD, Bianca Siegel, MD, Tj Ow, MD, AndrewTassler, MD, Richard Smith, MD, BradleySchiff, MD; Albert Einstein College of Medicine/Montefiore Medical CenterP147 (COSM Poster #197) PRESERVATIONOF INFERIOR THYROIDAL VEIN PREVENTSPOST-THYROIDECTOMY HYPOCALCEMIADoh Young Lee, MD, Wonjae Cha, MD,Woo-jin Jeong, MD, PhD, Myung-WhunSung, MD, PhD, Kwang Hyun Kim, MD,PhD, Soon-hyun Ahn, MD, PhD; Departmentof Otorhinolaryngology, Seoul NationalUniversity HospitalP148 (COSM Poster #198) RISKOF MELANOMA IS INCREASED ININDIVIDUALS WITH PAPILLARY THYROIDCARCINOMA Gretchen M Oakley, MD, KarenCurtin, PhD, Lester J Layfield, MD, Elke AJarboe, MD, Luke O Buchmann, MD, Jason PHunt, MD; University of Utah Health SciencesCenterP149 (COSM Poster #199) SELECTIVEINDICATION OF PROPHYLACTICCENTRAL NECK DISSECTION INPAPILLARY THYROID CANCER Andre Y DeCarvalho, MD, Thiago C Chulam, MD, WladyrB Fernandes Junior, MD, Luiz P Kowalski, MD;AC CAMARGO HOSPITALP150 (COSM Poster #200)COMPARISON OF MINIMAL ACCESSPARATHYROIDECTOMY WITH INTRA-OPERATIVE PTH DETERMINATIONVERSUS STANDARD FOUR GLANDEXPLORATION Matthew J Magarey, JeremyL Freeman; Mt. Sinai Hospital, TorontoP151 (COSM Poster #201) ISINTRAOPERATIVE PTH JUSTIFIEDIN ALL PATIENTS UNDERGOINGPARATHYROIDECTOMY? Faisal Zawawi,MD, Alex M Mlynarek, MD, Arielle Cantor,Rickul Varshney, MD, Michael Hier, MD, MartinBlack, MD, Richard J Payne, MD; McGillUniversityP152 (COSM Poster #202) IMPLICATIONSOF MULTIPLE LOCALIZATION STUDIESIN PRIMARY HYPERPARATHYROIDISMRussell B Smith, MD, Maria Evasovich, MD,Gerry F Funk, MD, Douglas A Girod, MD, JohnH Lee, MD, Daniel D Lydiatt, MD, DDS, RobertP Zitsch, MD; Midwest Head and Neck CancerConsortiumP153 (COSM Poster #203) PAPILLARYTHYROID CARCINOMA INTHYROGLOSSAL DUCT CYSTS: ANANALYSIS OF TREATMENT REGIMENSAND OUTCOMES Aimee A Kennedy, BS,Alexander Gelbard, MD, Vlad C Sandulache,MD, Robert B Parke, MD, MBA; Baylor Collegeof MedicineP154 (COSM Poster #204) BRAFMUTATION IN PAPILLARY THYROIDCARCINOMA: THE UNIVERSITYOF CALIFORNIA, SAN FRANCISCOEXPERIENCE Christopher J Gouveia, MD,Nhu Thuy T Can, MD, Alan Bostrom, PhD,James P Grenert, MD, PhD, Annemiekevan Zante, MD, PhD, Lisa A Orloff, MD;Northwestern University, University ofCalifornia, San FranciscoP155 (COSM Poster #205)IMMUNOHISTOCHEMISTRY IS HIGHLYSENSITIVE AND SPECIFIC FOR THEDETECTION OF BRAF V600E MUTATIONIN THYROID CANCER Aron Pollack, MD,Jonathan Zagzag, MD, Linda A Dultz, MD,Shuman Dhar, BA, Jennifer B Ogilvie, MD,Keith S Heller, MD, Fang-Ming Deng, MD,PhD, Kepal N Patel, MD; Department ofOtolaryngology-Head and Neck Surgery, NewYork University Langone Medical CenterP156 (COSM Poster #206) OPTIMALTIMING FOR A REPEAT THYROID BIOPSYRamsy Abdelghani, MD, Salem I Noureldine,MD, Ali Abbas, MD, MPH, Rizwan Aslam, DO,FACS, Paul Friedlander, MD, FACS, EmadKandil, MD, FACS; Tulane University School ofMedicineP157 (COSM Poster #207) ENLARGEDCERVICAL LYMPH NODES INCREASETHE PREDICTIVE VALUE IN DIAGNOSINGPAPILLARY THYROID CARCINOMA INSUSPICIOUS THYROID NODULES. RamsyAbdelghani, MD, Ali Abbas, MD, MPH, RizwanAslam, DO, FACS, Paul Friedlander, MD, FACS,Emad Kandil, MD, FACS; Tulane UniversitySchool of MedicineApril 10 - 11, 2013 · www.ahns.info 77

Poster ListingP158 (COSM Poster #259) Anexperimental approach todefine functional kinomicsand druggable targets in oralsquamous cell carcinoma usingpathway-specific inhibitors:Identification of Polo-likeKinase (PLK) activity and targetmodulation in CAL-27 cells WeiZhang, Pinaki Bose, PhD, Nigel T Brockton,Joseph C Dort, MD, Aru Narendran, MD, PhDP 159 (COSM Poster #260) Metforminuse increases survival in patientswith laryngeal squamous cellcarcinoma John S Hamblin, Vlad CSandulache, MD, PhD, Heath D Skinner, MD,PhD, Mark W Kubik, Jose P Zevallos, MDP160 (COSM Poster #261) FalseNegative Fine Needle AspirationCytology in Parotid MalignancyMarianne Abouyared, Christopher EFundakowski, MD, Johnathan Castano, MD,Andrew Rivera, MD, Rosemary Ojo, MD,Zoukaa Sargi, MDP161 (COSM Poster #262) Electiveneck dissection for N0neck during salvage totallaryngectomy: Findings,complications, and oncologicaloutcome Naveed Basheeth, Gerard O’Leary,Patrick SheahanP162 (COSM Poster #263) Feasibilityand Relevance of Level ISubstation Node Counts in NeckDissections for Oropharygealcarcinoma Christopher H Rassekh, MD,Bert W. O’Malley, Jr, MD, Arnaud F. Bewley,MD, Kathleen T. Montone, MD, Virginia A.Livolsi, MD, Gregory S. Weinstein, MDP163 (COSM Poster #264) SecondaryTEP Placement In-Office UsingSeldinger Technique: Case SeriesChristopher J Britt, MD, Gregory K Hartig, MD,Dylan C Lippert, MD, Christopher J Britt, MDP164 (COSM Poster #265) RecurrencePatterns and Management ofOral Cavity Premalignant LesionsDemetri Arnaoutakis, BA, Joseph Califano, MDP165 (COSM Poster #266) Developmentof an objective trainingcurriculum for transoral roboticsurgery (TORS) and its applicationto resident surgical training RyanH Sobel, MD, Patrick K Ha, MD, Joseph ACalifano, MD, Ray G Blanco, MD, Gyusung Lee,PhD, Jeremy Richmon, MDP166 (COSM Poster #267) ComicBooks, Graphic Novels, and theNovel Approach to Teaching Headand Neck Surgery through theGenre of the Comic Book Aa Chalian,Cs BabaianP167 (COSM Poster #268) FunctionalAssessment After Total orSubtotal Glossectomy AmongPatients With Locally AdvancedOral Tongue Squamous CarcinomaKatherine A Hutcheson, PhD, Hong Ju Park,PhD, Thomas J Ow, MD, Curtis R Pickering,PhD, Dianna Roberts, PhD, Mark S Chambers,DMD, MS, Jan S Lewin, PhD, Jeffrey N Myers,MD, PhDP168 (COSM Poster #2269)Preoperative Chemoradiationin Microvascular Free Flapreconstruction: What is the Risk?Isaac E Schwartz, Rod P Rezaee, MD, FACS,Chad A Zender, MD, FACSP169 (COSM Poster #270) How Reliableare Thyroid Nodule FNA Resultsin the Pediatric Population? ASystematic Review Celeste Gary, MD,Rohan Walvekar, MD78 AHNS 2013 Annual Meeting

AHNS 2013 New MembersThe AHNS extends a warm welcome to the following newmembers.ActiveMouwafak Al-RawiAkash AnandGenevieve AndrewsRizwan AslamMihir BhayaniJennifer BockerJames BonnerAndrew CowanCarole FakhryMark FurinTamer GhanemAvik Kumar JanaMumtaz KhanPaul KonowitzTeresa KroekerSteve LeeJason LeibowitzDavid LesnikKyle MannionBecky MasseyVikas MehtaZvonimir MilasBrett MilesNadia MohyuddinLuc MorrisMelonie NanceThomas OwBenjamin SaltmanJoshua SckolnickDavid ShonkaCatherine SinclairClementino SolaresWilliam SpanosNilesh VasanHilliary WhiteFrancis WordenMark ZafereoJosé ZevallosAssociateGideon BacharSteven EvelhochBasem JamalCathy LazarusVirginia LiVolsiScott McLeanMauricio MorenoJacques NörGal ShafirsteinCandidateSafina AliHussain AlsaffarRichard BakstNatalya ChernichenkoAlessandro CusanoLouise DaviesRobert DeFattaWilliam DukeNeerav GoyalAllen HoRussel KahmkeFrank LeusinkDavid LudlowWojciech MydlarzGrace NimmonsRyan OroscoDouglas RuhlMarika RussellWilliam RyanSteven SperryJeremiah TracyScott TroobKevin WangVivian WuGeoffrey YoungCorrespondingSalma Al SheibaniChristoph BergmannAndrés ChalaJean-Pierre JeannonMasahiro KikuchiIchiro OtaVinidh PaleriSandro PorcedduKyung TaeAigo YamasakiSeiichi YoshimotoBin ZhangApril 10 - 11, 2013 · www.ahns.info 79

Certificate of IncorporationCertificate of Incorporation ofThe American Head and Neck Society, Inc.Under Section 803 of the Not-for-Profit Corporation Law1. The name of the Corporation is THE AMERICAN HEAD AND NECKSOCIETY, INC.2. This Corporation has not been formed for pecuniary profit orfinancial gain, and shall not be conducted or operated for profit, andno part of the assets, income or net earnings of the Corporation isdistributable or shall inure to the benefit of the directors, officers, orother private persons, except to the extent permitted under the Notfor-ProfitCorporation Law. Upon the dissolution of this Corporation,no director, officer, or other private person shall be entitled to anydistribution or division of its remaining property or its proceeds, andthe balance of all money and property of the Corporation shall passto, or shall inure to the benefit of, those organizations described inSection 201 of the Not-for-Profit Corporation Law and Section 501(c)(3) of the Internal Revenue Code of 1986, which are not privatefoundations described in Section 509(a) of such Code. Any suchassets not so disposed of shall be disposed of by the Supreme Courtof the State of New York for the County in which the principal officeof the Corporation is then located, as provided by law, exclusively forsuch purposes or to such organization or organizations as said Courtshall determine, which are organized and operated for the purposesset forth in Paragraph “3” below.3. The purposes for which the Corporation is formed and the powerswhich may be exercised by the Corporation, in addition to the generalpowers set forth in Section 202 of the Not-for-Profit Corporation Lawof the State of New York, are:(a) to advance knowledge relevant to medical and surgical control ofneoplasms of the head and neck;(b) to solicit, obtain, apply for, and spend funds in furtherance of anyactivities or purposes of the Corporation;(c) in general, to do any and all acts or things and to exercise anyand all powers which may now or hereafter be lawful for theCorporation to do or exercise under and pursuant to the laws ofthe State of New York for the purpose of accomplishing any otherpurpose of the Corporation as set forth herein;(d) to engage in any and all lawful activities incidental to any of theforegoing purposes of the Corporation.4. The Corporation is organized exclusively to achieve publicobjectives, including for such purposes, the making of distributionsto organizations that qualify as exempt organizations described inSection 115 or Section 501(c)(3) of the Internal Revenue Code of1986, provided that such organizations are not private foundationsdescribed in Section 509(a) of such Code. The Corporation shall notcarry on any other activities not permitted to be carried out by acorporation exempt from federal income tax under Section 501(c)(3) of such Code or by a corporation contributions to which aredeductible under Section 170(c)(2) of such Code (or the correspondingprovisions of any future United States Internal Revenue Law.)80 AHNS 2013 Annual Meeting

Certificate of Incorporation5. Nothing contained herein shall authorize this corporation toundertake or to carry out any of the activities specified in paragraphs(b) through (u) of Section 404 of the Not-for-Profit Corporation Law,or to establish, maintain or operate a hospital or to provide hospitalservice or health-related service, a certified home health agency, a;hospice, a; health maintenance organization, or a comprehensivehealth services plan, as provided for by Article 28, 36, 40 and 44,respectively, of the Public Health Law or to solicit, collect or otherwiseraise or obtain any funds, contributions or grants from any source,for the establishment, maintenance or operation of any hospital or toengage in the practice of medicine or any other profession requiredto be licensed by Title VIII of the Education Law.6. No substantial part of the activities of this Corporation shall consistof carrying on propaganda or otherwise attempting to influencelegislation, and the Corporation shall not participate in, or intervenein (including the publication or distribution of statements), anypolitical campaign on behalf of any candidate for public office.7. The Corporation is a corporation as defined in subparagraph (a)(5) ofSection 102 of the Not-for-Profit Corporation Law, and it is a Type BCorporation.8. The territory in which the Corporation’s activities are principally tobe located is the territorial limits of the United States of America, theDomain of Canada and the Pan-American countries.9. The number and manner of election or appointment of the directorsconstituting the Board of Directors shall be as provided in the Bylaws,except that the number of said Board members shall not be less thanthree (3). Members of the Board of Directors need not be residentsof the State of New York. The names and addresses of the Directorsof the Corporation who shall act until the first meeting of the Boardof Directors, all of whom are over the age of eighteen (18) and arecitizens of the United States, are:NamesAddresses[Names and Addresses omitted.]10. Management of the business and affairs of the Corporation is vestedin the Board of Directors which shall use its best efforts to carry out ingood faith the purposes of the Corporation.11. To further the Corporation’s objectives and purposes, the Corporationshall have and may exercise all of the powers conferred by theNew York Not-for-Profit Corporation Law in pursuit of the purposesexpressed in Paragraph THREE hereof. Without limiting the generalityof the foregoing, the Corporation shall have power to sue and besued, to own, take title to, receive and hold, lease, sell and resell, infee simple or otherwise, property real, personal or mixed whereversituated and however acquired, without limitation as to amount orvalue. The Corporation shall have authority to encumber propertyby deed of trust, pledge or otherwise; to borrow money and securepayment of same by lien or liens of the realty or personal propertyof the Corporation; to lease, build, erect, remodel, repair, constructand/or reconstruct any and all buildings, houses or other structuresnecessary, proper or incident to its needs and proposes; and to doApril 10 - 11, 2013 · www.ahns.info 81

Certificate of Incorporationany and all things incident to the carrying out of the objectives andpurposes as stated and as limited herein. The Corporation shall havefull powers or management, investment and reinvestment and thecollection of all rents, revenues, issues and profits arising therefrom.12. The Corporation is to have members.13. The Corporation is to be divided into such classes of members asthe By-Laws provide. The designation of each class of members, themanner of election or appointment, and the qualification and rights ofthe members of each class (including conferring, limiting, or denyingthe right to vote) shall be set forth in the By-Laws.14. The Secretary of State of the State of New York is hereby designatedas the agent of the Corporation upon whom process may be served,and the post office address to which the Secretary of State shall maila copy of any such process served upon him is as follows:BSC Management, Inc., 11300 W. Olympic Blvd., Suite 600,Los Angeles, CA 90064.ConstitutionArticle ISection 1. The name of the Corporation shall be The American Headand Neck Society, Inc.Article IISection 1. The purpose of this Society is to promote and advance theknowledge of diagnosis, treatment and rehabilitation of patients withneoplasms and other diseases of the head and neck and the preventionof neoplasms and other diseases of the head and neck.Section 2. It is the objective of this Society to promote and advanceresearch in neoplasms and other diseases of the head and neck.Section 3. It is the objective of this Society to promote the highestprofessional and ethical standards.Article IIISection 1. Members of this Society shall be designated as Fellows, andshall consist of six classes(a) Active(b) Honorary(c) Corresponding(d) Senior(e) Associate(f) CandidateSection 2. Active Fellows of this Society shall be those who maintain alicense to practice medicine and who are actively engaged in diagnosis,treatment and rehabilitation of patients with neoplasms and otherdiseases of the head and neck and the prevention of neoplasms and otherdiseases of the head and neck.Section 3. Qualifications for Active Fellowship. An applicant for ActiveFellowship shall be a Diplomate of a particular specialty board, or havecredentials that are equivalent to those issued by member boards of theAmerican Board of Medical Specialties. Surgeons must be a member82 AHNS 2013 Annual Meeting

Constitutionof the American College of Surgeons, a Fellow of the Royal College ofSurgeons (Canada), or have similar credentials. A significant portionof practice shall be concerned with managing patients with neoplasmsand other diseases of the head and neck. Further qualifications andrequirements for Active Fellowship are contained in the By-Laws, ArticleVI, Sections 1 and 2.Section 4. Qualifications for Honorary Fellowship. Honorary Fellowshipshall be a distinction bestowed by the Society on an individual who hasmade outstanding contributions to the field of head and neck oncology.Section 5. Qualifications for Corresponding Fellowship. CorrespondingFellowship shall be granted to those who, in the judgment of theCouncil, are actively engaged in the prevention, diagnosis, treatmentand rehabilitation of patients with neoplasms and other diseases of thehead and neck and who reside in a country other than the United Statesor Canada.Section 6. Qualifications for Senior Fellowship. Any Active Fellow, uponcessation of active practice, may request by writing to the Secretary achange in status to Senior Fellowship.Section 7. Qualifications for Associate Fellowship. A candidate for electionto Associate Fellowship shall be a physician, dentist or allied scientistwho has demonstrated a special interest in the field of head and neckoncology, but a significant portion of whose practice is concerned withmanaging patients with non-neoplastic diseases of the head and neck.Section 8. Qualifications for Candidate Member. The trainee currentlyenrolled in, or a graduate of, an approved residency program inOtolaryngology, Plastic Surgery, or General Surgery or in a FellowshipProgram approved by the Joint Training Council may become a CandidateMember. This nonvoting membership is subject to fees established by theCouncil. The membership shall expire if the candidate member has notmade application for Active Fellowship in The American Head and NeckSociety, Inc. within five years after the completion of training.Section 9. Privileges of Members. All members shall have the samerights and privileges except that only Active Fellows in good standingshall have the privileges of voting in the conduct of the affairs andbusiness of the Society or of holding office or of chairing StandingCommittees.Article IVMeetingsSection 1. The annual meeting of this Society shall be held at such timeand place as may be fixed by the Council at its annual meeting.Section 2. The annual meeting shall consist of at least one scientificsession and one business session.Section 3. The scientific session shall be open to all Fellows of theSociety and members of the medical profession. Attendance at anybusiness session is limited to Fellows of the Society.Section 4. Only Active Fellows in good standing shall have the privilegeof a vote in conduct of the affairs and business of the Society.April 10 - 11, 2013 · www.ahns.info 83

ConstitutionArticle VOfficersSection 1. The officers of this Society shall be President, President-Elect,Vice-President, Secretary, and Treasurer.Article VIBoard of DirectorsSection 1. The governing body of this Society shall be the Council,consisting of the President, President-Elect, Vice-President, Secretary,Treasurer, and Past Presidents (for a period of three years following thetermination of term of office). In addition, there shall be nine Fellows-at-Large, three of whom shall be elected each year to serve terms of threeyears each. At no time shall the Council exceed eighteen in number. Themanner of election of officers and members of the Council is stated inthe By-Laws, Article VII, Sections 1 and 2.Article VIIAmendments to the Constitution or BylawsSection 1. A proposed amendment to the Constitution or By-Lawsmust be communicated to the Secretary in written form not less thantwo months before a meeting of the Council, and must be signed byat least two Active Fellows. The Secretary shall forward the proposedamendment to the Constitution and Bylaws Committee for review andcomment. The Constitution and Bylaws Committee will make a periodicreview of the Constitution and Bylaws and recommend modificationwhich may be submitted as amendments. Any proposed amendmentmust first be acted upon by the council. The Secretary shall submit inwritten form a copy of any proposed amendment to each Active Fellownot less than one month prior to the annual meeting of the Society. Twothirdsvote of the Active membership present at the meeting shall berequired for acceptance.BylawsArticle IRights and Duties of MembersSection 1. Any Active Fellow shall have all the rights of Fellowship,shall be subject to all the duties, roles and responsibilities incumbentupon the members of any scientific parliamentary body.Article IISection 1. Delinquints. Unless excused by the Council, a Fellowdelinquent in dues for two consecutive years shall be dropped fromFellowship. Delinquency in dues is defined as failure to pay by the end ofthe calendar year.Article IIIDuesSection 1. The amount of the Society’s dues shall be determined by theCouncil. The Council shall have the authority to establish an initiation feeor special assessment.84 AHNS 2013 Annual Meeting

BylawsArticle IVOrder of BusinessSection 1. The regular order of business at annual meetings shall becarried out in a manner prescribed by the Council.Article VSpecial ProvisionsSection 1. All conditions, circumstances, emergencies or contingenciesnot covered by this Constitution and its Bylaws shall be dealt withand administered by the directive of the Society’s Council, subject toapproval by the membership at the next annual meeting.Article VIQualifications for FellowshipSection 1. Candidates desiring election to Fellowship in any classother than Associate Fellow must hold a valid, unrestricted licenseto practice medicine in the state or country in which they reside andshall be proposed by two Active Fellows with at least one from theapplicant’s local geographical area. A special form will be provided bythe Secretary for this purpose. Both of the sponsors must submit lettersof recommendation pertaining to the qualifications of the candidate.Section 2. Special Qualifications for Active Membership.A. In addition to fulfilling the requirements under the Constitution,Article III, Section 3, surgeon candidates must submit evidence thatthey have the skill and capacity to diagnose and treat neoplasms andother diseases of the head and neck.B. An applicant for Active Fellowship shall provide documentation thathe or she has received adequate training in the management ofpatients with head and neck tumors and that a significant portion ofcurrent professional activity is devoted to the care of such patients.Such documentation will include a description of experience duringresidency and/or fellowship training, a summary of subsequent posttraining experience, and a listing of at least 35 patients with head andneck tumors managed during preceding year. Additional evidence ofacademic activity such as one paper published on cancer of the headand neck is required.C. Active Fellows must be members of the American College ofSurgeons or its equivalent.D. Active Fellows are expected to adhere to ethical standards, asdetailed in the ethics code of the American Head and Neck Society.Section 3. Special Qualifications for Corresponding Fellowship.A. Corresponding Fellows shall be physicians who, by their professionalassociations and publications, would appear in the judgment of theCouncil to be qualified to treat neoplasia and diseases of the headand neck. All proposals for candidates for Corresponding Fellowshipshall be accompanied by a curriculum vitae of the candidate and aletter of recommendation from at least two Active Fellows.Section 4. Election to FellowshipA. All proposals for candidates for any class of Fellowship shall be sentto the Council through the Secretary. Subsequent to approval by theApril 10 - 11, 2013 · www.ahns.info 85

BylawsCouncil, nominees’ names must be circulated to the membership atleast 120 days before the annual meeting. Fellows shall be given anopportunity to make written objections at least 60 days in advance ofthe annual meeting. Objections will be investigated by the CredentialsCommittee and presented to the Council for a vote. The Council willuse the AMA Code of Ethics as a guide in this matter.B. Election to any class of membership shall require three-fourthsfavorable vote of the Council.C. A candidate for Active Fellowship must be present at the annualmeeting to be inducted.ARTICLE VIIOfficers of the SocietySection 1. Election of Officers. The officers of the Society shall be aPresident, President-Elect, Vice-President, Secretary, and Treasurer, whoshall be elected at regular annual business meetings of the Society.Section 2. Accession to Office. The newly elected officers shall assumetheir duties before the adjournment of the meeting at which they havebeen elected.Section 3. Tenure of Office.A. The President and President-Elect, and Vice-President shall serve fora term of one year. The vice-president would be expected to advanceduring the next two years to president-elect and then president,unless the Council specifically directs the Nominating committeedifferently. The Secretary and the Treasurer shall serve for a term ofthree years and may be elected to one additional term.B. An outgoing President (Past President) automatically becomes amember of the Council to serve for a period of three years. A pastpresident’smembership on the Council which shall be terminated bydeath or other incapacity to serve shall remain vacant until filled byregular succession.Section 4. Vacancies in Office. Vacancies in office occurring betweenelections shall be filled by appointment by the President. Theseappointments shall be subject to written approval of a majority of theCouncil. Should the office of the President become vacant betweenelections, it shall automatically be filled by the President-Elect. Shouldthe offices of both President and President-Elect become vacant, theseoffices will be served by the Secretary.Article VIIIDuties of the OfficersSection 1. Duties of the President.A. The President shall preside at meetings of the Society and shallhave the power to preserve order and to regulate the proceedingsaccording to recognized rules.B. The President shall serve as Chairman of the Council.C. The President shall appoint standing and special committees, exceptthe Nominating Committee. See Article X, Section 3.D. The President shall fill vacancies in offices that occur in the interimbetween regular meetings subject to approval by a Council majority.E. The President shall be an ex-officio member of all standingcommittees.86 AHNS 2013 Annual Meeting

BylawsSection 2. Duties of the Vice President.A. The Vice-President shall serve and assist the President and President-Elect.B. The Vice-President shall oversee the work of the committees and shalldirect, plan and implement the long range and strategic planningretreat of the Council listed in Article IX section 2E.Section 3. Duties of the President-Elect.A. The President- Elect shall perform all duties that may be delegated tohim or her by the President.B. In the absence of the President, the President-Elect shall perform allduties of the President and shall preside at all meetings.Section 4. Duties of the Secretary.A. The Secretary shall keep or cause to be kept in permanent form anaccurate record of all transactions of the Society.B. The Secretary shall send due notice of all meetings to members;notice of at least 15 days shall be provided prior to Council meetings.C. The Secretary shall notify all committee members of theirappointments and the duties assigned to them.D. The Secretary shall notify all applicants for membership of the actiontaken by the Society.E. The Secretary shall keep a correct alphabetical list of members,together with their current addresses and shall supply applicationforms to members who apply for same.F. The Secretary shall act as custodian of all papers of the Society andits committees.Section 5. Duties of the Treasurer.A. The Treasurer shall collect, receive and be accountable for fundsaccrued by the Society from dues or other sources.B. The Treasurer shall deposit all moneys in a special bank accountunder the official name of the Society, in a city of his choice.C. The Treasurer shall disburse from the treasury such funds as may benecessary to meet appropriations and expenses of the Society.D. The Treasurer’s financial records shall be audited at each regularannual meeting by the Finance committee, who will report at thebusiness session.E. The Treasurer shall prepare and submit an annual budget for thefollowing year to the Finance committee for subsequent approval ofthe Council at the fall meeting.ARTICLE IXThe CouncilSection 1. Composition of the Council. The Council shall consist of theofficers, the three immediate Past Presidents, and nine Fellows at Large,three of whom shall be elected annually to serve staggered three-yearterms. A Fellow at Large elected to the Council may not succeed himselfor herself.Section 2. Duties of the Council.A. The Council shall conduct the affairs of the Society during the interimbetween sessions.April 10 - 11, 2013 · www.ahns.info 87

BylawsB. The Council shall pass on all applicants for Fellowship and presentits recommendations to the Society at one of its business sessions sothat necessary action may be taken.C. The Council shall report to the members at regular business sessionsall decisions and recommendations made so as to obtain approval ofthe whole membership of its actions.D. Should the membership disapprove of any action of the Councilthe questions shall be referred back for further consideration andreported at the next business meeting.E. The Council shall have a long range and strategic planning retreat atleast every three years.F. The Council shall review all Society service contracts with a minimumfrequency of five years. This includes, but is not limited to, the officialjournal of the society and the society management vendor.G. The Council shall evaluate requests for endorsement of policiespresented by other societies. The President will charge theappropriate committee with reviewing the policy endorsementrequest and making a recommendation to the Council. The Councilwill vote on the recommendation and the Secretary will be chargedwith contacting the requesting society with regard to the outcomeof that deliberation. Whenever possible, the President will askthe requesting society to include an active fellow in the initialdevelopment of policies which may be related to the AHNS.Section 3. Quorum and Manner of Acting.A. A majority of officers and Council members shall constitute aquorum. A majority of the quorum at any meeting of the Council shallconstitute action by the Council unless otherwise provided by law orby these By-Laws.B. Any action required or permitted to be taken at a meeting of theCouncil may be taken without a meeting if a consent in writingsetting forth the action to be taken shall be signed by all Councilmembers entitled to vote.C. Meetings may be conducted by telephone provided that allofficers and Council members participating in such a meeting maycommunicate with each other. A majority of officers and Councilmembers shall constitute a quorum for telephone meetings and theact of a majority of the quorum shall constitute action by the Council.D. Officers and Council members shall not receive compensation fortheir services, but, by action of the Council, expenses may be allowedfor attendance at meetings of the Council or for official representationof the Society and the Council may underwrite any activities that itdeems essential to the functioning of the Society.ARTICLE XCommittees and RepresentativesSection 1. Other than as specifically stated below, The Presidentshall appoint committee members to serve for three years. Initialappointments shall be staggered such that approximately one-third ofcommittee members shall change each year (other than the ScientificProgram Committee and Nominating Committee).88 AHNS 2013 Annual Meeting

BylawsSection 2. Scientific Program Committee. This committee shall beappointed by the President to serve for one year and shall consist ofat least three Active Fellows. It shall be the duty of this committee toestablish a scientific program at the Annual Meeting.Section 3. Nominating Committee. The Nominating Committee shallconsist of the three immediate past presidents and two Active Fellowselected at the business meeting. The Nominating Committee shall bechaired by the immediate past President. This committee shall prepare aslate of officers, three members-at-large of the Council, two NominatingCommittee members, one Subspecialty Advisory Council (SSAC)representative of the AAO-HNS (when necessary) and one FinanceCommittee member for vote at the next annual meeting (See Article VII,section 2).Section 4. Credentials Committee. This committee shall be chairedby the President and shall additionally consist of the two immediatePast Presidents plus two Active Fellows appointed by the President. Inaddition, the Secretary shall be a member, ex officio. The CredentialsCommittee shall advise the Council on the credentials of candidates formembership.Section 5. Education Committee. This committee shall consist of at leastthree Active Fellows. It shall be the duty of this committee to developappropriate educational activities for the Society.Section 6. Research Committee. This committee shall consist of at leastsix Active Fellows. It shall be the duty of this committee to: increase thequality and quantity of research conducted in head and neck oncology;encourage the design and implementation of new research protocols;review applications for research funds; and suggest possible newmethods of research funding.Section 7. Council for Advanced Training in Oncologic Head andNeck Surgery. This committee shall consist of ten Active Fellows, eachto serve a five-year term, with appointments staggered so that twoActive Fellows are appointed to membership on this committee eachyear. The committee shall be chaired by a member chosen from itsranks, by a majority vote, and the chair’s term shall be two years withthe possibility of a second term. The President’s appointments to thiscommittee shall be submitted for approval by the Council. It shall bethe duty of this committee to evaluate training programs as to whetherthey qualify for Phase III training and to make recommendations to thisSociety concerning what constitutes adequate training in head and neckoncologic surgery.Section 8. Constitution and By-Laws Committee. This committee shallconsist of at least five Active Fellows, with the Secretary serving exofficio.It shall be the duty of this committee to completely evaluate theConstitution and By-Laws a minimum of every three years to maintaintheir relevance.Section 9. Finance Committee. This committee shall consist of threeActive Fellows elected at the business meeting to serve three yearterms so that one member is elected each year. The Treasurer shall bean ex officio member. It shall be the duty of this committee to audit thefinancial records of the Society and review investments and to report atthe annual business meeting. This committee shall review the financialreports of the Treasurer prior to the presentation to the Council.April 10 - 11, 2013 · www.ahns.info 89

BylawsSection 10. CME Compliance Committee. This committee shouldconsist of at least three Active Fellows. It shall be the duty ofthis committee to monitor and ensure compliance with the CMErequirements of the Accreditation Council for Continuing MedicalEducation; to review and improve the quality of the educationalprograms of the Society; and to review annually, prior to the annualmeeting, any potential financial conflict of interest of members of theProgram Committee, Program Chairs, faculty, and presenters.Section 11. Quality of Care Committee. This committee should consistof at least three Active Fellows. It shall be the duty of this committeeto formulate quality of care standards for patients with head and neckneoplasms; to promote compliance with these standards as a frameworkfor the measurement of quality head and neck care; to disseminatethese standards to the membership of the Society; and to provide AHNSrepresentation to the applicable committees of other head and neckmedical societies that are charged with the development of specialtyspecific quality standards upon which pay-for-performance benchmarksmay be based.Section 12. Publications Committee. This committee should consist ofat least three Active Fellows appointed by the President. This committeeshall be chaired by the Associate Editor for the Head and Neck Sectionof the Archives of Otolaryngology-Head and Neck Surgery. In addition,the Archives of Otolaryngology-Head and Neck Surgery Editor, if amember of the Society, shall be a member of this committee, ex-officio.The Secretary and President will be members of this committee. It shallbe the duty of this committee to assure manuscript submission to theofficial journal of the Society, the Archives of Otolaryngology-Head andNeck Surgery, prior to presentation at the annual meeting; to assurerapid peer review of submitted manuscripts; and to facilitate the timelypublication of the proceedings of the annual meeting in a dedicatedissue of the official journal of the Society.Section 13. Prevention and Early Detection Committee. This committeeshall consist of at least six Active Fellows. It shall be the duty of thiscommittee to: develop, facilitate the implementation, and participate inprograms directed toward the prevention and early detection of oral andhead and neck cancers and to cooperate with national and internationalorganizations in these efforts.Section 14. Endocrine Surgery Committee. This committee shouldconsist of at least three Active Fellows. It shall be the duty of thiscommittee to increase research and education related to head and neckendocrine disorders, to encourage endocrine-related contributions to theannual meeting, and to foster interaction between the Society and othersocieties and organizations with interests in endocrine disorders.Section 15. Website Committee. This committee shall consist of atleast three Active Fellows. It shall be the duty of this committee torecommend and implement newer methods to optimize communicationor dissemination of information within the organization. The committeeshall develop and showcase new and emerging technologies and shallalso be responsible for updating and revising the AHNS web site andmaking sure it is kept with the most current and accurate information.90 AHNS 2013 Annual Meeting

BylawsSection 16. Awards Committee. This committee shall consist of atleast six active fellows, including the Chair. Committee members areappointed by the President. It shall be the duty of this committee toevaluate manuscripts submitted for awards to be given at the annualmeeting of the AHNS. An author may submit only one manuscriptper award category. Fellows are not eligible for resident awards.Manuscripts will be redacted of all author and institutional identifyinginformation by the chair prior to being sent to committee membersfor scoring. Manuscripts should be scored by at least five committeemembers. Manuscripts will not be scored by a committee member ifhe/she is an author on the paper. The Chair may request a scoring byanother qualified AHNS fellow; if not enough committee membersare available to score a manuscript. Deadlines for submission ofmanuscripts will be determined annually and announced during the callfor abstracts. Authors of abstracts accepted for oral presentation will beinvited to submit a manuscript for an award. The Chair will work withthe Program Committee to ensure that award-winning papers are givenpodium time for oral presentations.Section 17. History Committee. This committee shall consist of at leastthree Active Fellows. It shall be the duty of this committee to preservethe history of the society by conducting interviews of past leaders,researching and organizing past records and promoting historicalinformation on the web site and through other mediums.Section 18. Humanitarian Committee. This committee shall consistof at least three active Fellows. It shall be the duty of this committee toencourage and support volunteer efforts of AHNS members to assistin the care of underserved populations and to develop information,communication, and organizational resources regarding humanitarianoutreach activities.Section 19. Ethics and Professionalism Committee. This committeeshall consist of six Active Fellows appointed by the President. Membersshall serve for three years. The Committee shall be chaired by onemember chosen by the President for a three year term. This committeeshall meet on an ad hoc basis at the request of the President todeliberate and offer advice on specific ethical issues that involve theSociety or its members. The committee will also maintain and modify asneeded, the ethics code of the American Head and Neck Society.Section 20. Ad hoc Committee(s). As necessary, the President mayappoint one or more Ad Hoc committees to serve for one year.Section 21. Standing Committees. Other standing Committees shall beconstituted as described in the Policies and Procedures.Section 22. Subspecialty Advisory Council (SSAC) Representative. Thisrepresentative shall be nominated by the Nominating Committee,and elected at regular annual business meetings of the Society. Therepresentative shall have a three year term, with the potential forreappointment for a second term. The person should be someone whohas served on Council or the Executive Committee, and is intimatelyinvolved with the Society’s activities.Section 23. Head and Neck Reconstruction Committee. This committeeshould be composed of at least six active fellows. Two membersApril 10 - 11, 2013 · www.ahns.info 91

Bylawsare to be appointed annually for a 3 year term by the president ofthe society. The chairman of the committee will be appointed by thepresident of the society for a three year term. It shall be the duty of thiscommittee to promote research and education related to head and neckreconstruction, to encourage reconstructive-related contributions to theannual meeting, and to foster interaction between the Society and othersocieties and organizations with interest in reconstruction or plasticsurgery of the head and neck.ARTICLE XIQuorumSection 1. A quorum for any meeting of the Council shall be a majorityof those persons then serving as members of the Council.Section 2. A quorum for the regular business session of the societyshall be 18 Active Fellows.ARTICLE XIISociety AssetsSection 1. The interest in the funds property and other assets ofthe Society of any member whose membership shall terminate forany reason except the dissolution of the Society shall, ipso facto,immediately cease and such members and the representatives of suchmember shall have no claim against the Society or against the othermembers of their representatives or any of them.Section 2. In the case of dissolution of the Society, the funds, property,and other assets shall be used for the purpose of furthering theexpressed purposes for which this Society was formed and no membershall be entitled to receive any of the assets upon liquidation.Section 3. If the Society’s annual receipts exceed the annual expensesin any given year, the Council may, by a majority vote, elect to distributethe surplus for such scientific or educational uses as the Council shalldeem to be most consistent with the Society’s purposes; or it may,should it reasonably anticipate a need for operating surplus to meetfuture expenses, accumulate such surplus in an interest bearing accountor otherwise.Section 4. On an annual basis, when the Society accrues moneysurpassing the agreed upon amount of reserves needed in the accounts($200,000 in checking and $1,000,000 in savings), the Society willtransfer x % of the surplus to the corpus of the Foundation. The Councilof the Society will determine the percentage of transfer annually byvoting at the Council Meeting during the AHNS Annual Meeting.ARTICLE XIIIIndemnificationSection 1. The Society shall indemnify any and all of the directors orofficers former directors or officers, employees, agents, or any personwho may have served at its request or by its election as a director orofficer of another society or association, or his heirs, executors andadministrators, against expenses (including attorney fees, judgments,fines and amounts paid in settlement) actually and necessarily incurredby them in connection with the defense or settlement of any action,92 AHNS 2013 Annual Meeting

Bylawssuit or proceeding in which they, or any of them, are made partiesor a party, by reason of being or having been directors or a director,officer, employee or agent of the Society or of such other Society orassociation, except in relation to matters as to which any such action,suit or proceeding to be liable for willful misconduct in the performanceof duty and to such matters as shall be settled by agreement predicatedon the existence of such liability. The termination of any action, suit,or proceeding by judgment, order, settlement, conviction, or upona plea of nolo contendere or its equivalent shall not, of itself, createa presumption that the person is engaged in willful misconduct orin conduct in any way opposed to the best interests of the Society.The provisions of this section are severable, and therefore, if any ofits provisions shall contravene or be invalidated under the laws of aparticular state, country or jurisdiction, such contravention or invalidityshall not invalidate the entire section, but it shall be construed as if notcontaining the particular provision or provisions held to be invalid in theparticular state, country, or jurisdiction and the remaining provisionsshall be construed and enforced accordingly. The foregoing right ofindemnification shall be in addition to and not exclusive of other rightsto which such director, officer, employee or agent may be entitled.ARTICLE XIVMerger ProvisionsTo facilitate the merger of the Society with The Society of Head andNeck Surgeons, an Illinois nonprofit corporation (“SHNS”), pursuantto an agreement calling for the SHNS to be dissolved and its assetstransferred to the Society and the Society recast as The American Headand Neck Society, Inc. (“AHNS”) to serve as a successor of both entities,notwithstanding any other provision of the Constitution or these By-Laws to the contrary:1. The Council shall be expanded as necessary to include the officersand directors of the SHNS, who shall serve on the Council with theirvoting status as provided by the SHNS bylaws until their term ofoffice within the SHNS shall expire. The Council shall return to its sizeand with its composition provided in Article IX hereof through thepassage of time.2. The President-Elect of the SHNS shall become as President-Elect ofthe AHNS following the completion of his term as President-Elect ofthe SHNS. The President-Elect of the Society shall become Presidentof the AHNS to serve a term of six months (i.e., from May 15, 1998through November 14, 1998), whereupon the said President-Elect ofthe SHNS shall serve as President of the AHNS to serve a term ofsix months (i.e., from November 15, 1998 through the membershipmeeting in May of 1999 or until his successor shall assume office).During the combined one-year term of office, the two said individualsshall regularly consult and cooperate with each other on allmeaningful and significant decisions to be made during the year sothat it may appear that they are serving as co-presidents for the fullyear, provided, however, that the AHNS shall have only one Presidentin office at one time. At the conclusion of this one-year term, thePresident-Elect next in line shall succeed to the Presidency.April 10 - 11, 2013 · www.ahns.info 93

Bylaws3. The members of the SHNS shall be admitted to the Society recastas the AHNS in the membership category that correspond to thatwhich they hold in the SHNS. More specifically, Active Members ofthe SHNS shall become Active Fellows of the AHNS; Senior Memberof the SHNS shall become Senior Fellows of the AHNS. ConsultingMembers of the SHNS shall become Associate Fellows of the AHNS.International Corresponding Members of the SHNS shall becomeCorresponding Members of the AHNS. Honorary Members of theSHNS shall become Honorary Fellows of the AHNS. CandidateMembers of the SHNS shall become Candidate Members of theAHNS.4. The Council shall act to preserve the unique heritage and history ofthe SHNS and the ASHNS.94 AHNS 2013 Annual Meeting

NotesApril 10 - 11, 2013 · www.ahns.info 95

Notes96 AHNS 2013 Annual Meeting


Notes98 AHNS 2013 Annual Meeting


AHNS 2013annual meetingDuring the Combined Otolaryngology Spring MeetingsThank You to Our Corporate Supporters!The American Head & Neck Society gratefully acknowledgesgenerous unrestricted educational grants in support of the2013 Annual Meeting by the following companies:PLATINUM LEVELCelSci CorporationOmni Guide, Inc.PfizerGOLD LEVELDePuy Synthes CMFStrykerSILVER LEVELMedtronic Surgical TechnologiesBRONZE LEVELCook Medical IncorporatedKarl Storz Endoscopy-America Inc.PENTAX MedicalADDITIONAL SUPPORTOlympus Corporation of the AmericasApril 10 - 11, 2013JW Marriott Grande LakesOrlando, FloridaFINAL PROGRAM

AHNS 2013 Annual Meeting - American Head and Neck Society

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?